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"We trained very hard, but it seemed that 
every time we were beginning to form in to 
teams we would be re-organised. I  was to 
learn later in life that we tend to meet any 
new situation by re-organising, and a 
wonderful method it can be for creating 
the illusion of progress, while producing 
confusion, inefficiency, and 
demoralisation. "
Gaius Petronius a.d, 66
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SUMMARY
'I
The evidence of a familial component in the development of
hypertension has been discussed in its socio-economical, genetical and 
hormonal aspects. Of the endocrine influences, the activity of the adrenal
V
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cortex and the way in which both mineralocorticoids and glucocorticoids
interact with their target tissues has been evaluated. It has been suggested
that this interaction may vary in a genetically determined manner. Recent
studies suggested that tlie restriction fragment length polymorphism .
(RFLP) of the glucocorticoid receptor (GR) is associated with differences 
.of blood pressure. Subjects from the Ladywell district of Edinburgh who 
were homozygous for one GR genotype had higher blood pressure than 
those homozygous for the other. The hypothesis that the receptor 
genotype might be associated with phenotypic differences in 
glucocorticoid responsiveness, which in turn could contribute to the 
development of hypertension, was drawn. This hypothesis has been 
investigated in sti ains of rat prone to develop hypertension and in a group 
of normotensive male subjects characterised for GR RFLP genotype.
The investigation first required the adaptation, validation 
and use of a number of biochemical and cell biology techniques. A new 
method of measuring glucocorticoid potency has been developed, based 
on the ability of glucocorticoids to inhibit the translation of the lysozyme 
gene. The lysozyme release from various types of white cells and the 
specificity of the inhibitory response to glucocorticoids and other steroid 
hormones has been examined. The results showed that the inhibition of 
lysozyme release from human mononuclear cells is a convenient and 
specific method of measuring glucocorticoid responsiveness in human 
tissues.
Glucocorticoid receptor binding characteristics were investigated 
in rat models of genetic hypertension. Preliminary results showed that 
white blood cells of spontaneously hypertensive rats (SHR) incubated at 
24® bind dexamethasone with greater affinity than those from Wistar-
white blood cells of spontaneously hypertensive rats (SHR) incubated at 
24® bind dexamethasone with greater affinity than those from Wistar- 
Kyoto (WKY) rat. This suggested that increased glucocorticoid activity 
might be a genetic component of blood pressure control. To confirm and 
extend these data, a method of studying glucocorticoid receptor binding, 
theiTnolability and thermostability was developed using rat liver cytosol. 
GR affinities and binding capacities were identical in SHR and WKY rats 
when tested in homologous competition studies of ^H-dexamethasone 
after 16 h at 5®. However, further experiments at 37® showed a time- 
dependent decrease in affinity in both SHR and WKY rats but the affinity 
in SHR was always higher compai'ed to WKY rats. This suggested that an 
altered GR-heat shock protein function may be important in the 
development of hypertension.
The Milan hypertensive strain (MHS) of rat, an established model 
of human essential hypertension, was investigated. These rats appear to 
have excess mineralocorticoid activity (raised plasma volume, 
exchangeable sodium and plasma atrial natriuretic peptide and suppressed 
plasma renin) and have been shown to have higher plasma corticosterone 
concentration than the normotensive genetic control strain (MNS). The 
hypothesis of an impaired GR which leads to raised plasma corticosterone 
was investigated. Corticosterone, by acting via mineralocorticoid rather 
than glucocorticoid receptor, may cause antinatriuresis. The results 
showed a weaker binding affinity of endogenous steroid to GR in MHS 
which is in favour of the hypothesis.
In a group of normotensive male volunteers, links between 
polymoiphism of the gene for GR and differences in GR characteristics 
and glucocorticoid responsiveness were tested. GR genotype was 
characterised by RFLP analysis. Blood pressure, plasma and urinary 
steroid concentrations, GR binding characteristics, responsiveness to 
glucocorticoids (in vivo and in vitro) and other routine biochemical 
vai’iables have been compai'ed. In a group of 64 volunteers (age range 18-
VI
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biochemical variables were observed between groups. AA subjects
VII
showed higher levels of plasma and urinary cortisol, lower apparent GR 
affinity for dexamethasone in white cells and higher IC50 values for the 
in vitro effects of dexamethasone on lysozyme activity compared to aa 
subjects, although the differences were not statistically significant. In vivo 
glucocorticoid responsiveness, measured as skin vasoconstriction test, 
showed that AA subjects were more sensitive to budesonide than those 
with aa (p=0.02). This greater sensitivity to topical steroid in subjects 
homozygous for the A allele may be a phenotypical expression of the 
glucocorticoid receptor function. However, given that other 
glucocorticoid indices were not different, it could be that human GR 
polymorphism is a marker of another cardiovascular variable which may 
not be directly related to receptor binding of steroid hormone.
In addition to this study, a large body of information on variables 
concerned with electrolyte homeostasis and the control of intermediary 
metabolism were collected. Many of the variables correlated 
independently of the receptor polymorphism. The results suggested a 
complex interaction of mineralocorticoid and glucocorticoid functions in 
the pathogenesis of hypertension.
In conclusion, studies in rats with genetic hypertension and in 
patients strongly indicate that glucocorticoid sensitivity may be a 
contributory factor in essential hypertension. If this is the case, then 
hypertension - or predisposition to hypertension - should be associated 
with a constellation of glucocorticoid sensitivity-related changes. If 
sensitivity is impaired, mineralocorticoid-Hke changes may result. If 
sensitivity is increased, glucocorticoid-dependant variables should 
change. Although neither hypothesis has been absolutely established by 
the experiments described in this thesis, they have provided some
I
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valuable guidelines for future studies.
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Chapter 1 INTRODUCTION
1.1 ESSENTIAL HYPERTENSION
Elevated arterial blood pressure is probably the most common 
public health problem in developed countries. Its prevalence depends on 
the composition of the population studied and the criteria used to define 
the condition. For example, it has been shown that the US black 
population has approximately twice the prevalence of hypertension 
compared with US whites (Cornoni-Huntley et al., 1989). Indeed, the 
prevalence of hypertension is influenced by population characteristics 
such as age, race, gender and socioeconomic status (Whelton et al., 1994). 
However, it is commonly reported that hypertension affects 
approximately 10% of the population. In only 5% of these hypertensive 
individuals can an underlying cause of high blood pressure (secondary 
hypertension) be identified and, if appropriate, specially treated before 
antihypeitensive treatment is considered. Secondaiy hypertension can be 
due to a variety of causes and these are summarized in table I. For those 
people in whom a cause cannot be identified, the hypertension is 
designated essential or primary. Despite intensive research, there is 
considerable uncertainty about the pathophysiology of early essential 
hypertension. It is likely that mechanisms which initiate the increase in 
blood pressure are quite different from those which perpetuate it. There 
is general agreement that heredity plays an important role in the genesis 
of essential hypertension, but its expression appears to be influenced by 
environmental, dietary and other cultural factors.
This literature review deals firstly with genetic and environmental 
factors and their interaction in the pathogenesis of essential hypertension, 
and secondly with the significance of abnormalities in corticosteroid 
metabolism as conditio sine qua non for high blood pressure.
Table I: Disorders causing secondary hypertension.
Congenital or hereditary problems
• Coartation of the aorta (with other cardiac defects)
• Congenital renal artery disease
• Polycystic disease (usually presents in later life)
Drug induced problems
• Oral contraceptives (5% of women)
• Carbenoxolone (mimics primary aldosteronism)
• Liquorice (mimics primary aldosteronism)
• Oral corticosteroids (systemic or topical)
Endocrine disease
• Phaeochromocytoma (may be associated with 
neurofibromatosis)
Primary aldosteronism 
Cushing's syndrome 
Acromegaly 
Hyperparathyroidism
Some inherited steroid hydroxylation and oxidation- 
reduction defects
Renal disease
Renin secreting tumours
Glomerulonephritis (particularly IgA nephropathy) 
Pyelonephritis (unilateral or bilateral)
Diabetic nephrosclerosis 
Polycystic disease (Mendelian dominant)
Renal artery stenosis (fibromuscular hyperplasia in young 
or atheroma in old patients)
Renal transplantation 
Radiation nephritis
Vasculitis
• Progressive systemic sclerosis
• Polyarteritis nodosa
• Systemic lupus erythematosus
• Pulseless disease
1.1.1 Definition and epidemiology of high blood pressure
Blood pressure is a continuously distributed variable with no 
dividing line between normal, high and low. For this reason, an 
epidemiological definition of hypertension must be arbitrary. Evans and 
Rose (1971) defined hypertension as that level of blood pressure where 
investigation and treatment do more good than harm. Thus, high blood 
pressure is not a disease in the usual sense of this term. It is a quantitative 
deviation of blood pressure from normal, which is not associated with 
symptoms but which predicts risk for future morbidity and mortality. The 
main problem in defining hypertension is the difficulty of precise 
measurement of blood pressure. The conventional methods can be 
umeliable because of technical inaccuracies, inherent variability of blood 
pressure (circadian variations of blood pressure) and tendency for blood 
pressure to increase in the presence of a physician (white-coat 
hypertension) (Pickering, 1994). Nevertheless, the Joint National 
Committee for Detection, Evaluation and Treatment of High Blood 
Pressure, 1993 (JNC V) defined cut-off points in order to facilitate the 
diagnosis of hypertension. It is recommended that blood pressure 
measurements be made by a mercury sphygmomanometer, using the 
Korotkoff technique and that the values are based on an average of two 
or more readings on two or more occasions in individuals not taking 
antihypertensive medications and not acutely ill. When the average 
systolic and diastolic blood pressure is above an arbitrary cut off point 
(table II), the patient is classified as hypertensive.
Results from longitudinal studies have shown that elevated blood 
pressure is associated with a high incidence of cardiovascular disease, 
stroke and heart failure (Smith, 1977; MacMahon et al., 1990; Stamler et 
al., 1993). Approximately 65% of deaths in hypertensive patients are due 
to cardiovascular disease (Kannel et al., 1985; Beaglehole, 1990). The 
Framingham study focused attention on systolic blood pressure elevation 
which carries a risk of cardiovascular disease similar’ to or greater than the
a  g  s
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risk associated with raised diastolic blood pressure (Kannel et al., 1981). 
Although over the past two decades diastolic blood pressure has helped 
to determine the level of blood pressure above which treatment reduces 
the risk of complications, isolated systolic hypertension is of particular 
importance and has special significance for the elderly population (VA 
Cooperative Study, 1970; Mann, 1992; Bennet, 1994). However, the total 
risk for hypertensive patients also comprises the effects of other factors. 
At any level of blood pressure, risk of death or of a cardiovascular event 
increases with high blood lipid levels, cigaiette smoking, obesity, diabetes 
and left ventricular hypertrophy (as result of prolonged high blood 
pressure). The association of hypertension and cardiovascular mortality 
and morbidity is likely to be causative. Concordant data from different 
disciplines support the idea of a cause and effect relationship.
It was first believed that a single cause could explain the aetiology 
of essential hypertension. This idea derived from Goldblatt's 
demonstration that partial renal clamping could induce hypertension. 
Moreover, single causes such as primary aldosteronism, Cushing's 
syndrome, phaeochromocytoma and coarctation of the aorta are well 
known and now classified in the field of secondaiy hypertension (see 
above). Only in the eaify 1970s did epidemiological studies confirm that 
there was probably not a single cause of hypertension but that both 
genetic and environmental factors interact to cause the disproportionate 
rise of blood pressure with age which constitutes essential hypertension. 
However, there is no clear evidence that genetic differences can explain 
genetic variations in blood pressure. Migration studies helped to separate 
racial or genetic characteristics from environmental factors in the 
aetiology of hypertension (Beaglehole et al., 1978; Elford et al., 1990; 
S almond et al.,1989; Ward et al., 1980). For example, the Japan- 
Honolulu-San Francisco study (Robertson et al., 1977) of Japanese men 
residing in Japan, Hawaii and California suggested that westernization 
may be responsible for weight and cholesterol differences among
Japanese but did not relate to level of blood pressure. There is evidence 
that the relevant factor in the high prevalence of hypertension in Japan is 
salt consumption. By contrast, the heland-Boston diet Heart Study (Kushi 
et ah, 1985) showed higher blood pressure levels among Irishmen in 
Boston compared with their brothers who had stayed in Ireland, The 
Boston subjects were also heavier and had higher cholesterol levels. Rise 
in blood pressure with age seems to relate to communities with a high 
standar d of living; such communities also tend to be obese, to have a high 
salt intake and to be relatively sedentary.
1.1.2 Genetic factors in hypertension
The study of the genetics of hypertension includes many research 
goals which have in common the aim of relating phenotypic information 
to a variety of genetic and environmental markers, of separ ating inherited 
from environmental influences, and of determining whether genetic 
effects are monogenic or polygenic.
Evidence in support of heredity as an aetiological factor in 
hypertension is derived from studies of familial aggregation of blood 
pressure in natural and adopted children and from animal experiments. 
Aggregation of a phenotypic trait among people who share genes is a 
strong indicator that it is genetically controlled, provided that a shared 
environmental influence can be excluded (Mongeau et al,, 1986; Ward, 
1990). Studies suggest a stronger correlation between the blood pressures 
of monozygotic twins than between dizygotic twins (Mather et al,, 1961; 
Miall, 1971), Stamler et al, (1979) reported that the prevalence of 
hypertension among offspring of hypertensive patients is twice that 
observed in offspring of normotensive parents, Bianchi et al. (1979) 
estimated that children with two normotensive parents have a 3% 
probability of developing hypertension compared with a 45% probability 
if both parents are hypertensive. Further evidence for an important genetic 
component comes from the finding that the correlation between parents
Î
and adopted children is smaller than that between natural parents and 
children (Annest et ah, 1979a, b). In this type of study, environmental 
influences are better controlled. Table III summarizes the familial 
correlations of blood pressure between spouses, blood relatives, and 
parents with adopted children. Hunt et al. (1986) reported that the 
predictive strength of family history as a risk factor seems to vary with the 
degree of familial hypertension that is present (e.g., the risk doubles with 
one hypertensive first degree relative and increases nearly fourfold with 
two such relatives).
The explanation that is generally felt to fit the data best is that the 
ability to respond to environmental differences by developing 
hypertension is inherited polygenically and that the development of raised 
blood pressure is a function of the number of relevant genes inherited.
This has been termed genetic heterogeneity (Dal Palu' & Pessina, 1985).
While the genetic contribution to hypertension remains unclear and 
by no means proven, the overwhelming evidence from epidemiological 
studies for an environmental factor or factors is demonstrated by the 
relationship of blood pressure levels with social class, relative weight, 
physical activity, alcohol intake, salt intake and geographic location. It is 
interesting to note that epidemiological studies have strongly implicated 
intrauterine environmental factors in the risk of hypertension in later life 
(Law et al., 1993). Low birthweight and large placental weight are potent 
predictors of hypertension at all age (Barker et al., 1990). Several 
environmental factors could be responsible for this such as maternal 
smoking (Spira et al., 1975), hypoxia (Kroger & Arias-Stella, 1970;
Godfrey et al., 1991) and maternal malnutrition (Barker et al., 1990).
Edwards et al. (1993) suggested that prenatal exposure of the fetus to 
glucocorticoid may not only retard intrauterine growth but could also 
affect the development of the fetal vasculature and its responses to pressor 
agents. Wliatever the factor/s involved during intrauterine development,
a
Table III: Familial blood pressure correlations.
Comparison of pairs
Correlation coefficient Number 
Systolic Diastolic
Spouses 1433 0.08 0.06
Pai’ent-adoptee 379 0.03 0.09
Parent-offspring 831 0.18 0.16
Sibling-sibling 2618 0.18 0.14
Dizygotic twins 264 0.25 0.27
Monozytic twins 248 0.55 0.58
Reproduced from Williams et al. (1988)
it appeal's that hypertension develops and persists after the removal of the 
primary cause, possibly because of irreversible changes in vascular 
structure (Lever & Harrap, 1992).
There are many potential physiological vehicles for translating 
genetic and environmental factors into rises in blood pressure. Among 
these are: intracellular ion transport, dietai-y salt intake, intravascular 
volume and kidney function, cai'diovascular moiphology and physiology 
and cardiovascular reactivity.
Several studies focused on the relationship between salt 
sensitivity and severity of hypertension (Pai'frey et al., 1981; Intersalt, 
1988) and it has frequently been suggested that a significant relationship 
exists between salt sensitivity of blood pressure and familial disposition 
to hypertension (Pietinen et al., 1979; Murakami et al., 1992). Tobian and 
Binion (1952) were the first to postulate raised intracellulai' sodium as a 
feature of essential hypertension. Since then, many other studies have 
confirmed this finding and shifted the research goals to studies of the 
pathways by which sodium may enter the cell. These include sodium- 
proton exchange, sodium-sodium exchange and sodium-potassium- 
chloride cotransport. Defects on ouabain-sensitive sodium pump (Na7K^ 
ATPase), sodium-potassium cotransport and sodium-lithium 
countertransport (another form of sodium-proton exchange) have been 
reported in the normotensive relatives of subjects with essential 
hypertension and in patients suffering from essential hypertension 
(Goldsmith et ah, 1991; Wehling et ah, 1991b). However, it has been 
variously reported that the rate of red blood cell Na-K cotransport is 
elevated (Adragna et al., 1982; Smith et al., 1984), depressed (Garay et ah, 
1982; Lijnen et ah, 1984) or similar (Cooper et al., 1983) in normotensive 
subjects with family history of hypertension compared with subjects 
without family histoiy. It has been suggested that the above mentioned 
sodium transport abnormalities are markers of the hypertensive process. 
They may cause hypertension or they may represent a compensatory
mechanism resulting from a blood pressure increase. This effect may be 
defective in some people.
By contrast, contradictoiy data are reported on dietary salt intake 
and blood pressure. One explanation of this inconsistent relationship is 
that subjects vary in their genetic susceptibility to dietary sodium (Watt 
& Foy, 1982). There is some evidence (Watt et ah, 1985) although 
incomplete, that the offspring of subjects with a family histoiy of high 
blood pressure show a greater rise in blood pressure in response to sodium 
than those without such a family history. It is likely that the finding of an 
abnormality of sodium transport in essential hypertensive patients 
(Blaunstein, 1984) may reflect an inherited difficulty in the ability of the 
kidney to excrete sodium (MacGregor, 1985; Blanchi et al., 1983) and 
that the abnormality of salt sensitivity and cell ion transport may be 
related.
Studies of patients with mild or borderline hypertension have 
reported an abnormal pressure response to various pressor stimuli (e.g., 
cold pressor or mental stress test) (Julius & Conway, 1968; Anderson et 
al., 1987; Borghi et al., 1988). It has also been reported that in subjects 
whose blood pressure overreacts to stress, there is a higher than expected 
prevalence of family history of hypertension (Light & Obrist, 1980). In a 
population analysis of 340 hypertensive subjects in the Utah study, Smith 
et al. (1987) estimated that the degree of increase in blood pressure during 
mental arithmetic was approximately 50% heritable after adjusting for 
age, height, weight, number of total and correct subtractions, and baseline 
blood pressure.
Although the importance of genetic factors in the pathogenesis of 
essential hypertension is clear, information so far available has not yet 
clarified its pattern of inheritance. Two approaches of study have been 
suggested (Camussi, 1988). The first aims to identify intermediate 
phenotypes that display some form of Mendelian inheritance and seem 
relevant in explaining some pathophysiological finding in hypertension.
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This is followed by the identification of candidate genes, their number, 
the frequency of particular* alleles and their mode of action, in the control 
of variation in the intermediate phenotypes. The second approach studies 
the genetic or molecular difference of the genes or primary gene products 
(eg., mRNA, proteins) and attempts to see whether their eventual 
polymorphism among hypertensives and normotensives is relevant in the 
pathogenesis of hypertension (eg., all gene coding the known vasoactive 
substances that play some role in hypertension have been studied with 
molecular biology techniques, see below).
Strains of rat provide a valuable animal model of genetic 
hypertension which permit easy control of experimental conditions, show 
an early development of high blood pressure, ease of breeding, and 
genetic homogeneity. A number of strains of rat with inherited 
hypertension are available of which the spontaneously hypertensive rat 
(SHR) has been the most intensively studied. Dahl et al. (1962) 
selectively bred another type of rat for their blood pressure response to a 
high salt diet. Two strains were established, one sensitive and the other 
resistant to the hypertensive effects of a high salt diet. Another well 
established animal model for essential hypertension suitable for both 
genetic and.physiological studies is the Milan hypertensive strain (MHS) 
of rat (Bianchi et al., 1974). This strain has an inbred normotensive 
control and hypertension develops in a well-defined fashion: pre­
hypertensive phase, followed by the development of high blood pressure 
and established hypertension (more details on these genetic model of rat 
hypertension will be given below). The study of these rat models of 
genetic hypertension has allowed the identification of DNA markers for 
some biochemical variables in hypertension. This provided evidence, 
sometimes contradictory, for the existence of gene polymorphisms which 
relate to hypertension. The next section attempts to summarize the 
abundant data obtained by molecular biology techniques in the 
identification of candidate genes for the study of essential hypertension.
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1.1.3 Candidate genes in hypertension
Over the past decades, molecular genetic techniques have become 
available for identifying gene differences even without knowledge of the 
primary gene product or the biochemical mechanism of the disease. This 
approach - genetic linkage - combines the identification of families in 
which the phenotype of interest follows a clear* pattern of inheritance with 
the use of molecular biology techniques to search for a DNA-based 
genetic marker that is so close to the aberrant gene that it has a high 
probability of being inherited with the disease (Keating, 1992; 
Lindpaintner, 1992). The genetic marker can be any variation, or 
polymorphism, in the DNA which can be revealed using restriction
these DNA fragments occur because of the presence of polymorphisms 
and are called restriction fragment length polymorphisms (RPLP). A 
polymorphism can be used as a genetic marker regardless of whether it is 
causally related to the disease phenotype (Watkins, 1988).
Genetic linkage analysis has also been applied in hypertension 
research, even though blood pressure levels in families rarely follows 
single gene inheritance patterns and is likely to be influenced by several 
definable single gene contributions, i.e. polygenic blending. These effects 
are modified by shared family environment and other environmental 
effects (Lifton & Jeunemaitre, 1993) (see earlier). Although this reduces 
the likelihood of a tight linkage, statistically significant linkage provides 
valuable guidance to aetiology.
Although the genetic linkage study has been the most extensively 
applied approach to the study of the heritability of hypertension, other 
techniques have also been used such as: a) association studies, where a 
difference in the distribution of alleles at a marker locus in case controls 
is sought, b) direct search for mutations in candidate genes by the
12
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endonucleases. These enzymes cleave DNA at precise sites to produce a 
pattern of fragments of characteristic lengths. Variation in the length of
polymerase chain reaction, and c) test of gene effects in vivo in animal 
models by transgenic techniques (Dzau et ah, 1989; Bader et al., 1992; 
Kreutz et al, 1992).
Obvious candidate genes in essential hypertension are those 
involved in physiological systems that are known to affect the tonic 
regulation of blood pressure (Williams, 1989). Over the past few years, 
RFLP analysis has been a useful tool to explore genes encoding renin, 
haptoglobin, myosin, neuropeptide Y, the Na-H antiporter, atrial 
natriuretic peptide (ANP), vasopressin and renal kallikrein.
The renin-angiotensin cascade has a legitimate and well known 
pathophysiological place in the aetiology of hypertension and genes 
encoding renin-angiotensin cascade components were an obvious choice 
(Dzau, 1988a, b; Soubrier et a l, 1988). Samani et al. (1989a) showed a 
650 base pairs deletion of a tandem repeat sequence in the first renin gene 
intron in SHR compared to WKY. Moreover, higher renin mRNA levels 
were showed in young and adult SHR when compared to WKY (Samani 
et al.', 1989b). Rapp et al. (1989) showed a significant association between 
a renin gene marker and hypertension in the Dahl rat strain of sodium- 
sensitive hypertension but similar analyses in the spontaneously 
hypertensive rat have been inconclusive (Lindpaintner et al, 1990; Kurtz 
et a l, 1990). Similarly, human population studies failed to associate a 
renin gene polymorphism with hypertension, thus deflating the initial 
enthusiasm.
Angiotensin converting enzyme (ACE) is another component of 
the renin-angiotensin cascade which may be a pathophysiological 
candidate in hypertension. Hillbert et a l (1991) using linkage analysis in 
crosses between spontaneously hypertensive stroke prone (SHR-SP) and 
Wistar-Kyoto (WKY) rats, identified two genes, BP/SPl and BP/SP2, 
that contribute significantly to blood pressure variation in the F2 
generation. Comparison of the human and rat genetic maps indicates that 
BP/SPl could reside on human chromosome 17q in a region that also
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contains the ACE gene. However, results of studies on human essential 
hypertension gave conflicting results. Jeunemaitre et al. (1992a) found no 
linkage between an ACE polymorphism and hypertension, while Zee et 
al. (1992) reported a significant association between these factors. 
Although the link between ACE gene and hypertension is not established, 
Cambien et al. (1992) and Tiret et al. (1993) showed a direct association 
between an insertion (I)/deletion (D) polymorphism in intron 16 of the 
human ACE gene and the risk of myocardial infarction, a cardiovascular 
event for which hypertension is one of many risk factors.
By contrast, Jeunemaitre et al. (1992b) have established a direct 
involvement of the locus of the angiotensinogen gene in human 
hypertension and the same group have reported that a molecular variant 
of angiotensinogen may be associated with pre-eclampsia (Ward et al.,
1993). Moreover, a significant linkage and association of the 
angiotensinogen gene locus to essential hypertension has recently been 
reported in a study which considered 63 white European families with 
two or more members suffering from hypertension (Caulfield et ai.,
1994).
West et al. (1992) looking for candidate genes in hypertension, 
chose two genes coding proteins with vasoconstrictive action (renin and 
neuropeptide Y) and two genes associated with familial hypertrophic 
cardiomyopathy (p heavy chain of cardiac myosin and haptoglobin) but 
none was associated with hypertension.
Lifton et al. (1991) in a genetic linkage study of the human gene 
encoding Na-H antiporter also excluded mutations at this locus as a 
contributing factor in the pathogenesis of hypertension.
Since the phosphoinositide signalling system mediated by the 
activation of phospholipase C (PLC) regulates cellular calcium levels and 
the activities of protein kinases, the role of PLC in the genesis of 
hypertension has become a focus of attention (related to muscle tone and 
responsiveness) (Aqel et al., 1987; Koutouzov et al., 1987; Turla &
14
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Webb, 1987). Thus, Yagisawa et al. (1991) identified eight RFLPs (six in 
the PLC-p, one in the PLC-ô and one in the PLC-tll locus) between SHR 
and WKY genomes but no conclusion concerning the relationship 
between these RFLPs and hypertension has been drawn.
Watt et al. (1992) using the "four comer" approach, suggested that 
young people with higher than average pressure, whose parents have a 
high pressure, are more likely to possess a particular RFLP for the 
glucocorticoid receptor gene (but not for the ANP gene) than young 
people with lower than average pressure. Barley et al. (1991) tested 
whether any relationship existed between allelic polymorphisms at the 
gene loci for either renin or ANP and blood pressure. They showed 
significant ethnic RFLP differences at both loci and provided evidence for 
a possible link between variations within or close to the renin gene and 
elevated blood pressure in Afro-Caribbeans.
The environment may affect the expression of genes that are not 
directly involved in blood pressure regulation. For example, some rats and 
mice have an increased susceptibility to high environmental temperature 
and respond with greater than normal rises in blood pressure. In cross­
breeding studies, of F2 generation of such mice, the abnormal 
thermosensitivity appeared to be determined by a specific locus 
cosegregating with blood pressure (Tms) (Malo et a l, 1989). The best 
candidate genes for this thermosensitivity are the heat stress protein 
genes, a major representative of which is heat shock protein 70 (Hsp70) 
(see later). Hamet et al. (1992) using a Hsp70 probe, identified a RFLP of 
Hsp70 after digestion of genomic DNA with BamHI in rats. This RFLP 
cosegregates with 15 mmHg of blood pressure in recombinant inbred 
strains of Brown-Norway and spontaneously hypertensive rats. Although
the authors could not define the precise functional significance of this 
observation, they pointed out that the area of the genome in which the 
Hsp70 gene is located is of interest since it contains other genes 
potentially relevant to environmental interactions (Hamet, 1992), such as
the steroid 21-hydroxylase gene (enzyme involved in the adrenal steroid 
synthesis) and TNF alfa gene (a growth factor which is likely to be 
involved in smooth muscle cell proliferation during hypertension). 
Moreover, Hsp70 is a protein bound to the cortisol receptor (Pratt, 1993; 
Scherrer et aL, 1990) and seems to be relevant in the regulation of the 
effectiveness of cortisol. For this reason Hamet (1992) suggested that 
increased levels of Hsp70 may enhance the potency of cortisol, resulting 
in insulin resistance, which is believed to be one of the hallmarks of 
hypertension (Ferranini et al., 1990; Williams, 1994).
Over recent years, abnormalities of corticosteroid metabolism as 
possible pathogenetic mechanisms in essential hypertension have been 
identified. Corticosteroids such as aldosterone and cortisol can be both 
directly and indirectly implicated in the control of the vascular tone. The 
following sections review the metabolism and actions of corticosteroids 
and how abnormalities can be the cause of secondary and essential
hypertension.
1.2 STEROIDS AND BLOOD PRESSURE CONTROL IN HUMANS
Despite the rarity of secondary hypertension, it is logical to 
suppose that the mechanisms which raise blood pressure in this minority 
of patients might contribute to the pathophysiology of essential 
hypertension in a more subtle way. Although the classification of 
disorders causing secondary hypertension includes renal, congenital or 
hereditary, drug-induced problems, the study of endocrine disease has 
attracted particular attention. The involvement in blood pressure control 
of the renin-angiotensin system and the adrenal cortex hormones has been 
extensively studied.
.1.2.1 Corticosteroid metabolism and physiology
The adrenal glands are extraperitoneal organs at the upper poles 
of the kidneys. They are made up of cortex and medulla which have 
separate embryological origin, mesodenn and ectoderm respectively. The 
classical view of the microscopic morphology of the adrenal cortex 
identifies 3 layers of cells arranged as concentric shells. From the outer 
layer; these are the zonae glomemlosa, fasciculata and reticularis. The 
zona glomemlosa produces aldosterone and 18-hydroxycoi*ticosterone as 
its major steroids, and is present under the capsule in ill-defined form that 
constitutes about 15% of the cortex. The cells of this zone have a 
relatively small cytoplasmic volume with a small amount of lipid. The 
cortisol-producing zona fasciculata comprises about 75% of the cortex. 
Its cells contain more cholesterol and cholesterol esters, giving them a 
vacuolated or clear appearance in stained sections. Cells of the zona 
reticularis make up the inner zone and also produce cortisol, though at a 
much lower rate than the fasciculata cells. They are relatively free of 
lipids and have a gr anular, compact appearance. This zone also produces 
ACTH -regulated adrenal androgens (dehydroepiandrosterone and its 
sulfate, androstenedione and testosterone in the rat) and oestrogens
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(Hyatt, 1987; Nussdorfer, 1986).
All corticosteroids are C21 derivatives of the pregnane series
which derive from cholesterol and its esters. Cholesterol, either from
circulating lipoprotein or synthesised de novo, is stored in esterified form 'in intracellular lipid droplets. Steroid synthesis starts with the hydrolysis
of cholesterol esters and the sterol is then transferred to the inner 
mitochondrial membrane. Following hydroxylation at 22R and 20a, the 
cholesterol side chain is lost as isocaproic aldeide first and as acid 
second following oxidation. The C21 steroid which this produces, 
pregnenolone, passes from the mitochondria to the smooth endoplasmic 
reticulum. A series of enzyme reactions leads to the formation of steroids 
with two main activities, glucocorticoid and mineralocorticoid (refer to 
Fig. 1).
The major mineralocorticoid, aldosterone, is synthesised in the 
zona glomerulosa via a series of hydroxylations of progesterone. These 
hydroxylations are catalysed by mixed function oxidase ("hydroxylases") 
enzymes, which contain cytocrome P450, with the formation of 11- 
deoxycorticosterone (DOC), corticosterone, and probably 18- 
hydroxycorticosterone as intermediates. The unique enzyme of the 
glomerulosa is aldosterone synthase which catalyses the foimation of 
aldosterone from DOC (Vinson et ah, 1992).
The zona fasciculata has two biosynthetic pathways: a) the 17a- 
hydroxysteroid pathway which involves the hydroxylation of 
progesterone to 17a -hydroxyprogesterone, 11-deoxycortisol and finally 
to cortisol; b) the 17-deoxy pathway where progesterone is converted to 
DOC by 21-hydroxylase, and then DOC is hydroxylated at the 11 and 18 
position to form corticosterone or 18-hydroxy DOC respectively. 11 p- 
Hydroxylation of DOC occurs in the mitochondria and is catalysed by a 
single enzyme, 11 p-hydroxylase.
Cortisol is the most important glucocorticoid in normal human 
subjects, but corticosterone at high concentration, in some adrenal
18
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Idiseases, may also exhibit glucocorticoid activity . The rat adrenal has no
17-hydroxylase acitivity and corticosterone is the most important 
glucocorticoid in this species. Approximately 95% of cortisol is bound to 
proteins such as tianscortin or corticosteroid-binding globulin (CBG) and 
albumin; the metabolic effects are mediated by the remaining unbound (or 
free) steroid (Pardridge, 1987; Tait & Tait, 1991).
Aldosterone and DOC are the principal mineralocorticoids. 
Aldosterone binds loosely to CBG and albumin so that 30-40% of the 
measured circulating aldosterone concentration is free. DOC is virtually :
totally bound to CBG with only 5-8% appearing as free DOC in the 
circulation.
Glucocorticoid effects are usually linked with the control of 
intermediary metabolism which includes stimulation of protein 
catabolism (Simmons et al., 1984) and hepatic glycogenesis and 
gluconeogenesis (Hers, 1985), with decreased glucose uptake and 
utilization in peripheral tissues. Glucocorticoids have direct effects on 
adipose tissue metabolism, enhancing the tendency for triglyceride 
accumulation by stimulating lipoprotein lipase activity in mature 
adipocytes (Pedersen et al., 1994). Glucocorticoids also inhibit growth 
(Smith et al., 1986; Schuchard et al. 1993), decrease calcium absorption 
in the gut and increase calcium loss in the urine causing a negative 
calcium balance (Singer, 1987), and modulate the humoral and cellulai* 
components of the inflammatory response (Bailey, 1991).
Mineralocorticoids are usually associated with changes in water 
and electrolyte metabolism. Aldosterone increases the reabsorption of 
sodium in the kidney and in secretory epithelia, thus reducing the sodium 
content of urine, saliva, sweat, gastric juice, and faeces. In the kidney 
tubules, an increased proportion of filtered sodium is exchanged for 
potassium or hydrogen ion which leads to antinatriuresis, kaliuresis and 
increased urine acidity with a metabolic alkalosis. After long-term 
treatment the kidney "escapes" from the sodium retaining actions of 
aldosterone but continues to stimulate the potassium secretion. This may
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relate to a compensatory mechanism activated both by extracellular fluid 
volume expansion as a result of sodium retention and changes in renal 
haemodynamics (Knox et aL, 1980; Hall et aL, 1984). Atrial natriuretic 
peptides seems to be involved; high levels are found during escape from 
the sodium retaining effects of both aldosterone and DOC (Metzler et aL, 
1987; Granger et aL, 1987).
Glucocorticoid and mineralocorticoid actions are mediated by 
intracytoplasmic proteins (corticosteroid receptors). It is necessary to 
define the actions of corticosteroids in terms of the receptors that mediate 
them. This is discussed in a later section (see below).
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Glucocorticoid secretion
The secretion of cortisol is largely controlled by 
adrenocorticotropic hormone (ACTH). This peptide hormone is 
synthesized in the corticotroph cells of the anterior pituitary, deriving 
from a large precursor, pro-opiomelanocortin. ACTH secretion is 
promoted by several factors, corticotropin releasing factor (secreted by the 
hypothalamus), arginine vasopresin and certain neurotransmitters, notably 
epinephrine (Dallman et al., 1987; Jacobsen & Sapolsky, 1991). The 
major physiological stimulus to ACTH secretion is "stress" both 
emotional and physiological. A negative feedback mechanism is present 
where glucocorticoids act on both the hypothalamus and adenohypophysis 
to inhibit CRF and ACTH secretion. Acutely, ACTH acts on the adrenal 
gland both by increasing the secretion rate of corticosteroids and by
f '
causing vascular changes which result in an increase in the rate of blood 
flow through the gland. ACTH and therefore cortisol are secreted with a 
distinct circadian rhythm with peak levels between 06.00-09.00 hours, 
falling during the day to reach a minimum in the late evening. The Fig. 2 
describes the mechanism for the regulation of glucocorticoid secretion.
ACTH regulates the adrenal steroidogenic pathways as well as 
being an adrenal growth factor. Its action is exerted through increments 
of adenylate cyclase activity, with subsequent activation of side chain 
cleavage enzyme complexes which transform cholesterol into 
pregnenolone. Although ACTH is the principal regulator of both 17- 
deoxysteroids and 17a -hydroxysteroids, there is growing indirect 
evidence that other factors such as endogenous opiates (De Souza & Van 
Loon, 1982), prostaglandins (Rolland et al., 1981) and growth hormone 
(Castro-Magana et al., 1983) may regulate the responsiveness of the 
adrenal gland to ACTH.
Bovine and human adrenal fasciculata-reticularis cells contain 
specific angiotensin H receptors, most of which are of the subtype ATI 
(Ouali et al., 1992), and in vitro angiotensin II (AH) induces a rapid
22
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stimulation of cortisol secretion. In vivo infusion of All in man has yelded 
contradictory results (Rayyis & Horton, 1979; Mason et aL, 1979; 
Calogero et aL, 1991), while in vitro AH causes a small increase in 
cortisol secretion by isolated adrenal cells and potentiates the acute 
steroidogenic effects of low ACTH concentrations (Parker et aL, 1983; 
Pham-Huu-Trung et aL, 1986). Lebrethon et al. (1994) have recently 
examined the effects of ACTH and All on cultured human adult 
fasciculata-reticularis specific function. The authors reported that both 
ACTH and AH stimulated the expression of the mRNA of cholesterol 
side-chain cleavage enzyme (P450ggJ, 17a-hydroxylase (P450;^^) and 3 p- 
hydroxysteroid dehydrogenase although the effects of ACTH were 
significantly greater than those of AIL
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Corticotrophin-releasing
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N egative feed back ACTH
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Free cortisol (10%) Cortisol bound to  CBG (90%)
Renal excretion A ctions on tissues Hepatic m etabolism
Fig. 2: The hypothaiamic-anterior pituitary-adrenal axis.
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Mineralocorticoid secretion
The most important stimulus to aldosterone secretion is the 
alteration of electrolytes and fluid status. Responses are mediated through 
a complex interaction between several factors, stimulatory and inhibitory, 
such as the renin-angiotensin system (see table IV). This system which 
has been mentioned earlier (reviewed by Quinn & Williams, 1988;
Mitchel & Romen, 1989) begins with the secretion of renin from the 
juxtaglomerular cells of the kidney in response to reduction of renal 
perfusion or sodium load, and to sympathetic stimulation. Renin cleaves 
angiotensinogen - an a 2-globulin secreted by the liver - to angiotensin 
I in the blood stream. This decapeptide is converted to the active 
hormone, the octapeptide angiotensin H by angiotensin-converting 
enzyme (ACE) in the lung and elseswhere. Angiotensin II has three main 
actions: 1) arteriolar vasoconstriction, 2) stimulation of aldosterone 
secretion, 3) reabsorption of sodium by direct action on the proximal 
tubule at the S-1 tubular segment.
Although the renin-angiotensin system is the most important 
mechanism for the control of aldosterone secretion, many other factors are 
also involved. Small increaes in plasma concentration specifically 
stimulate aldosterone synthesis by the zona glomerulosa. 
Hypophyseetomy or hypopituitarism may also affect basal aldosterone 
output. There is evidence that a pituitaiy factor is necessaiy to maintain 
the adrenal responsiveness to vaiious stimulators of aldosterone secretion, 
such as infusion of exogenous angiotensin H. It is likely that this factor is 
ACTH. Acute administration increases plasma aldosterone levels, while 
long term ACTH excess inhibits aldosterone secretion (Connell et ah,
.1987). In addition to those factors that exert physiological control, there 
are many others whose physiological relevance remains unclear. Table IV 
summarizes them in relation to whether they stimulate or inhibit 
aldosterone secretion.
Like cortisol, aldosterone is secreted with a clear circadian
"'i,
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rhythm, the mechanism of which is unclear (Katz et aL, 1975). This is 
maintained in absence of ACTH, does not correlate with plasma sodium 
and potassium, and does not fully relate to renin. Although the rhythm is 
abolished in anephric subjects, it persists during administration of 
angiotensin converting enzymes inhibitors (DeFonest et al., 1979). Since 
P-blockers abolish the circadian rhythm of aldosterone, a neural 
mechanism is suggested (Cugini et aL, 1977).
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Table IV: Factors influencing aldosterone secretion. All, ACTH and 
K are the major "regulators" of aldosterone secretion. The influence of 
Na"^ , independent of the renin-angiotensin-system, has contradictory 
results. The only negative regulator with a likely physiological role is 
ANP. ANP effects on blood pressure and volume are further enhanced by 
inhibition of both renin and aldosterone secretion
Stimulatory Inhibitory
Angiotensin II ANP
ACTH (acute) Dopamine
K+ Mg++
Na+ Somatostatin
Serotonin ACTH (chronic)
POMC
a-Y MSH
,T
iI
II
f
I
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1.2.2. Glucocorticoid-induced hypertension
High blood pressure is common in clinical cases of endogenous 
hypersecretion or exogenous administration of glucocorticoids. Thus, 
hypertension is a common feature of Cushing's syndrome, the clinical 
features of which occur as a result of prolonged abnormally high 
concentrations of glucocorticoids in the circulation. The disease is
:
relatively rare and this is therefore an uncommon cause of hypertension 
in the general population. The prevalence of hypertension in Cushing's 
syndrome varies with the cause of hypercortisolism but is undoubtedly 
high, probably between 75-85% (Ross & Linch, 1982; Walker &
Edwards, 1992). Hypercortisolism may either be ACTH-dependent 
(Cushing's disease per se, where there is ACTH hypersecretion from the 
pituitaiy gland, and ectopic ACTH syndrome where there is autonomous 
secretion of ACTH by a tumor of non-pituitaiy origin) or non-ACTH- 
dependent (autonomous secretion of cortisol from an adrenal adenoma or 
carcinoma, or from bilateral primary adrenocortical nodular dysplasia).
Routine biochemical investigations are rarely of diagnostic value 
in the diagnosis of Cushing's syndrome, although certain abnormalities 
may suggest it. Serum sodium concentration is normal in most patients 
but occasionally it is elevated. Serum potassium and bicarbonate levels 
are usually normal but hypokalemia and alkalosis are frequent with the 
ectopic ACTH syndrome or adrenal carcinoma. Serum calcium and 
phosphorus concentrations are almost invai'iably normal but 
hypercalciuria occurs in approximately 40% of the patients. Impaired 
glucose tolerance and elevations of triglyceride and cholesterol levels 
occurs in the majority of the patients. Studies of the renin-angiotensin 
system in Cushing's syndrome have reported normal (Brown et ah, 1965;
Ritchie et al., 1990), suppressed (Mantero et al., 1978) or ocasionally 
increased (Krakoff, 1973) plasma renin activity. This inconsistency seems 
to reflect the expected variability in mineralocorticoid expression in the 
different forms or Cushing's syndrome. Some of the biochemical and
I
clinical features of glucocorticoid excess may also be found in a variety
of conditions referred to as pseudo-Cushing's syndrome where the clinical
features can occasionally be present in the absence of biochemical
.evidence of hypercortisolemia (i.e. primary obesity and glucocorticoid 
.hypersensitivity) (lida et al., 1990). Excess cortisol secretion without
Cushing's syndrome is foimd in conditions of glucocorticoid resistance 
.secondary to defective glucocorticoid receptor function (Arai &
Chrousos, 1994).
In experimental studies in normal human subjects, high doses of
both ACTH and cortisol raise blood pressure within 3-5 days (Whitworth
et a l ,1983; Connell et al., 1987; Whitworth, 1992). Connell et al. (1987)
reported that this ACTH effect on blood pressuie is entirely a
consequence of cortisol excess. Administration of either cortisol or
.ACTH in subjects on normal sodium intake led to profound anti- 
natriuresis, kaliuresis, suppression of renin and aldosterone, and a distinct 
rise in blood pressure. There was also evidence of expansion of 
extracellular fluid volume (ECFV) and plasma volume - i.e.
mineralocorticoid-like effects- and alteration of both glomerular* filtration 
rate and renal vascular resistance (Connell et al., 1988). It has been 
hypothesized that changes in plasma volume and cardiac output might be 
important in the early stages of ACTH and cortisol-induced hypertension, 
and increased peripheral resistance is probably a necessary development 
in the long-term maintenance of high blood pressure (Scoggins et a l,
1984).
In sheep, the effects of ACTH on blood pressure may depend not 
only on cortisol but also on the synergistic action of other cosecreted 
steroids such as 17a-hydroxyprogesterone and 17a-hydroxy-20- 
dihydroprogesterone (Coghlan et al., 1988).
ACTH-induced hypertension can also be induced in the rat (Haack 
et al., 1978). It is adrenal-dependent (Whitworth et a l, 1990a) and seems 
to be due to ACTH-stimulated increases in corticosterone secretion.
.29
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Although blood pressure increase is a feature of high 
concentration of glucocorticoids (cortisol in man and corticosterone in 
rats) in both pathological and experimental conditions, in the rat it has 
been shown that only small doses of steroid are required to increase 
blood pressure. The infusion of small doses of the synthetic 
glucocorticoid dexamethasone (<5pg/rat per day), in male Spague 
Dawley rats, increases blood pressure within a few days without loss in 
body weight, although the extent of the increase is less than with 
mineralocorticoids (Tonolo et al., 1988). Interestingly, the dexamethasone 
low-dose infusion did not affect renin, aldosterone, plasma sodium and 
potassium concentrations but the concentrations of plasma atrial 
natriuretic peptide (ANP) decreased by 40-50%. The decrease of ANP 
contrasts with ANP increases in response to mineralocorticoid treatment 
in rats with DOC-induced hypertension (see below). Unlike 
mineralocorticoid-induced hypertension, the pressor effects of 
dexamethasone were ameliorated but not abolished by dietary sodium 
restriction and were unaffected by sodium loading.
Cardiovascular effects of glucocorticoids
The effects of glucocorticoids on the cardiovascular system can 
be summarized as follow:
1) Mineralocorticoid effects. Cortisol is a relatively weak 
mineralocorticoid but at high circulating concentration might act as 
mineralocorticoid (Wehling et al., 1992b) (see below).
2) Abnormalities of renin-angiotensin system. Glucocorticoids increase 
plasma renin substrate (angiotensinogen) synthesis (Hasegawa et al., 
1973; Krakoff et al., 1975; Whitworth, 1987; Feldmer et al., 1991). This 
might lead to increased plasma renin activity and to elevated plasma 
angiotensin II if angiotensinogen concentration is rate-limiting.
3) Direct effects of glucocorticoid. It has been shown that various 
glucocorticoids have direct pressor effect without altering sodium
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metabolism (Whitworth & Scoggins, 1990). It has been suggested that 
corticosteroids may have a pressor activity separate from either their 
glucocorticoid or mineralocorticoid activity, possibly acting via a 
"hypertensinogenic" receptor (Coghlan et al., 1976). This might be the 
vascular receptor.
4) Increased sympathetic neiwous system activity and increased vascular 
sensitivity to catecholamines. Steroid treatment in vivo and in vitro
" !■
potentiates the actions of epinephrine, norepinephrine, dopamine and 
serotonin (Kalsner, 1969; Russo et al., 1990; Saruta et al., 1986; Webb,
1982). This can be explained by reduction of extraneuronal 
catecholamine uptake and reduced metabolism by cathechol- o-methyl 
transferase, which is the distal regulator of catecholamine synthesis in 
chromaffin cells of the adrenal medulla. Moreover, in vitro studies 
showed that dexamethasone down-regulates the number of specific p2- 
receptor (Jazayeri & Meyer, 1988) and increases the number and affinity 
of specific a 1-receptors (Haigh & Jones, 1990).
5) Altered prostaglandin synthesis. Glucocorticoids suppress 
prostaglandin synthesis by inhibiting release of aracliidonic acid substrate 
from phospholipids by phospholipase A2 (Grunfeld et al., 1986; Sessa et 
al., 1990; Yasunari et al., 1988; Russo et al, 1990). It has been suggested 
that this also decreases the synthesis of vasodilators such as prostacyclins.
6) Altered interactions between vascular endothelial cells and underlying 
smooth muscle cells. Endothelial cell produce a potent, locally acting 
vasorelaxant, nitric oxide. Glucocorticoids inhibit the expression of the 
inducible nitric oxide synthase. The inhibition of the synthesis of this
Ï
relaxing factor should tend to increase blood pressure (Radomski et a l, 
1990).
Fig. 3 is an attempt to summarise the integration of pathophysiological 
changes leading to hypertension due to glucocorticoid excess.
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Fig. 3: Pathogenesis of hypertension due to glucocorticoid excess. ICV, 
ECFV, intra- and extracellular fluid (reproduced from Irony et aL, 1989).
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1.2.3 Mineralocorticoid-induced hypertension
Abnormally high levels of exogenous and endogenous
mineralocorticoids cause hypertension.
A pathological increase of aldosterone in human subjects is a
feature of a group of conditions termed primary hyperaldosteronism. This
term is often applied to all patients with hypertension, hyperaldosteronism ;
and concomitant renin suppression. Primaiy hyperaldosteronism is an
uncommon cause of hypertension, the prevalence among hypertensive
.patients of which is less than 1%. This includes primary
hyperaldosteronism due to a relatively autonomous adrenal adenoma 
(Conn's syndrome) or carcinoma and other forms of aldosterone excess 
with low plasma renin such as the bilateral zona glomerulosa hyperplasia
;and dexamethasone-suppressible hyperaldosteronism.
Aldosterone-producing adenoma (Conn's syndrome) is the 
commonest cause of primary hyperaldosteronism which accounts for 
approximately 75% of the patients. Plasma concentration of aldosterone 
has been reported to vary from high normal to several times the upper 
limit of the reference range. However, less variability has been observed 
when urinaiy aldosterone excretion rate was measured (Ferriss et al.,
1978; Weinberger et al., 1979). Untreated patients show plasma sodium 
concentration at the upper end of the reference range and hypokalemia 
associated with low plasma renin and angiotensin H and a metabolic
alkalosis. In a subset of patients, aldosterone secretion remains responsive 
to angiotensin II and the plasma renin activity is not maikedly suppressed 
(Gordon et al., 1987).
Adrenocortical carcinoma is the cause of only 1-2% of primary
hyperaldosteronism. In these patients, hypertension is usually associated
.with profound and often symptomatic hypokalemia and frequently there 
is evidence of glucocorticoid and androgen overproduction also (Arteaga 
et al., 1984; Isles et al., 1987).
In a subgroup of patients with features of primary
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hyperaldosteronism, no adrenocortical adenoma is present and the gland 
may instead show various degrees of bilateral micronodular hypei-plasia, 
or no discernible abnormality. Their biochemistry shows less markedly 
raised plasma aldosterone concentration while plasma renin and 
potassium concentrations are less fully suppressed. Similar adrenal 
pathology has been described at autopsy in patients who had been 
suffering from essential hypertension (Neville & O'Hare, 1985).
Dexamethasone-suppressible hyperaldosteronism is a rare familial 
autosomal dominant syndrome in which the biochemical features of 
primary hyperaldosteronism (hypokalemia and suppressed plasma renin 
activity) and raised blood pressure are corrected by administration of
dexamethasone. Patients frequently present as children or young adults
(Jamieson et al., 1993). This condition is fuifher characterized by lack of 
aldosterone response to angiotensin II but exagerated response to ACTH 
(Connell et al., 1986; Ganguly et a l, 1984), and abnormally elevated 
levels of 18-hydroxycortisol and 18-oxocortisol (Gomez-Sanchez et al., 
1984; Gomez-Sanchez, 1985). No pituitary abnormality has been 
demonstrated, even though the abnormal adrenal function is clearly 
pituitary-dependent. The genetic defect in this condition appears to 
involve a mutation by which the regulatory region of 11-p-hydroxylase 
with 5' ACTH-responsive regulatory sequence is fused to the coding 
sequences of aldosterone synthase on chromosome 8 (chimaeric gene) 
(Lifton et al, 1992). This permits the expression of aldosterone synthase 
in the zona fasciculata so that aldosterone together with the characteristic
18-oxygenated derivative of cortisol can then be produced under ACTH 
control. However, the normal gene is also expressed in the zona 
glomerulosa so that the suppression of the chimaeric gene by 
dexamethasone restores angiotensin Il-dependent aldosterone secretion. 
The disease can now be identified in affected kindreds by molecular 
biology techniques.
Mineralocorticoid hypertension can be observed in genetic defects 
of the enzymes involved in the adrenal steroidogenesis. Abnormal
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hydroxylase activity can result in hypertension. A defect of the 17a- 
hydroxylase, inherited as an autosomal recessive trait, results in an 
inability to manufacture cortisol which results in an increase in ACTH 
stimulation of the adrenal cortex (Biglieri et al., 1966; Fraser et al., 1987). 
This causes increased progesterone, pregnenolone, DOC and 
corticosterone synthesis. DOC is a mineralocorticoid and very high 
plasma levels found in this syndrome cause sodium retention with 
hypokalemia. A reduced activity of llp-hydroxylase, inherited as an 
autosomal recessive trait, results in defective conversion of DOC to 
corticosterone and of 11-deoxycortisol to cortisol in the adrenal cortex. 
This syndrome is also characterized by increased ACTH plasma levels 
which stimulate the adrenal to secrete a high level of DOC and 11- 
deoxycortisol (Fraser, 1983). In this case, corticosterone levels ai*e low. 
The increased DOC secretion results in sodium retention, potassium loss 
and associated hypertension. In both defects plasma aldosterone is 
suppressed as a consequence of inhibition of the renin angiotensin system 
by sodium retention. Disproportionate increases in DOC or 11- 
deoxycortisol level in relation to corticosterone and cortisol, respectively, 
are suggestive of impaired 11 p-hydroxylase activity, while altered 
progesterone: 17a-hydroxyprogesterone ratios suggests reduced 17a- 
hydroxylase activity.
Administration of mineralocorticoids to man and animals raises 
blood pressure. The hypertensive effects of DOC were first described in 
rats. The acetate was used. The blood pressure response was shown to be 
quicker and greater if rats aie unilaterally nephrectomized and given an 
high-sodium diet. This is called the DOCA-salt model of hypertension 
(Morton et al., 1990). Responsiveness vaiies between species and strains 
of rat. Long-Evans, Sabra normotensive, Wistar-Furth and Dahl salt- 
resistant strains are relatively insensitive to DOC compared with Spragiie- 
Dawiey, Sabra hypertensive, Dahl salt-sensitive and other Wistar strains 
(Ben-Ishay et al., 1972; Rapp et al., 1982; Bruner, 1992). Dogs and
I
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rabbits are relatively insensitive whereas in human subjects and pigs, 
mineralocorticoid hypertension can be evoked by DOC without reduction ■ If
in renal mass or modification in dietary sodium intake. Interestingly, 
depending on the dose of steroid and salt intake, rats can enter a 
malignant phase, whilst after a prolonged period of exposure to the 
steroid, blood pressure remains elevated even after stopping the treatment 
(Morton et al., 1990).
Mineralocorticoid effects in hypertension
Unlike glucocorticoid hypertension, mineralocorticoid
hypertension is sodium dependent (Fraser & Padfield, 1985; Robertson, 
1987). Plasma volume and total or exchangeable body sodium level and 
extracellular fluid volume are all increased above normal. The most 
frequent presenting biochemical feature is hypokalaemia together with a 
metabolic alkalosis. In the early stages of mineralocorticoid excess, 
hypertension is a function of an increased cardiac output but in chronic 
excess, cardiac output returns towards normal or low while total 
peripheral resistance is increased (Wenting et al., 1977). Altered 
sympathetic tone (Distler et al., 1979), increase sensitivity to angiotensin 
n  (Zoccaii et al., 1983; Gordon et al., 1987) and a direct action of 
corticosteroids on resistance blood vessels all lead to abnormal cation 
turnover, depolarization and vasoconstriction (Moreland et al., 1984; 
Gurwitz et al., 1982) which may account for the increased total peripheral 
resistance ( refer to Fig. 4).
An additional mechanism may be the direct central action of 
aldosterone. Intracerebroventricular infusion of aldosterone produced 
hypertension in rats which could be reversed by infusion in the same site 
of a competitive aldosterone antagonist (Gomez-Sanchez, 1986; Gomez-
Sanchez et al., 1992; Gomez-Sanchez, 1993). However, this should not 
be interpreted as evidence for a unique central site of action of 
mineralocorticoid in blood pressure control since intracerebroventricular
- ,.
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infusion of aldosterone in adrenalectomized animals fails to raise blood 
pressure.
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1.2.4 Altered steroid metabolism in essential hypertension
Although several abnormalities in adrenocortical function in 
subjects with hypertension have been reported, the importance of 
corticosteroids in the genesis of this condition is not yet clear. Excess, 
even minor increases in secretion of either mineralocorticoids and 
glucocorticoids can raise blood pressure but excessive secretion, by 
definition, excludes the diagnosis of essential hypertension.
Several investigators have tried to identify unusual steroids or 
steroid metabolites which might be increased in hypertensive subjects. 
Increased 18-hydroxysteroids, such as 18-hydroxy-l 1- 
deoxycorticosterone and 19-nor-deoxycorticosterone have been reported 
in hypertensive patients but the results have not been convincingly 
confirmed (Gomez-Sanchez et al, 1985; Griffing et al, 1985). Kisch et 
a l (1976) reported an increased aldosterone response to angiotensin II in 
essential hypertensive patients. However, this seems to appear only in a 
subgroup of patients with essential hypertension (Dluhy et a l, 1979; 
Williams et a l, 1979) and it is likely to reflect an underlying abnormal 
activity of the renin-angiotensin system (Wisgerhof & Brown, 1978).
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Bearing in mind the inherited hypertensive disorders of adrenal
steroid synthesis due to abnormal steroid hydroxylase activity, some 
investigators have studied adrenal function in essential hypertensive 
patients during stimulation with ACTH. Honda et a l (1977) and De 
Simone et al. (1985) reported a partial defect of 1113-hydroxylase activity 
in some patients with essential hypertension using a greater than normal 
response of 11-deoxysteroid levels after ACTH stimulation as , an 
indicator. However, neither study found an abnormal aldosterone 
response to ACTH. Unfortunately these studies are still inconclusive since 
other investigators (Guthrie et al., 1983) could find no differences in DOC 
response to ACTH in young people from the upper and lower deciles of 
blood pressure but who were not hypertensive.
Another approach has been to suggest that small changes in
II
corticosteroid concentrations contribute to the development of 
hypertension. Interestingly, Watt et al. (1992) showed higher levels of 
plasma cortisol, 18-hydroxycorticosterone and angiotensinogen in the 
adolescent offspring of hypertensive parents whose mean blood pressure 
was at the upper level of their group distribution when compared with 
those whose parents were normotensive and who had lower blood 
pressure.
These studies in general show that corticosteroids, both 
mineralocorticoids and glucocorticoids, are capable of causing 
hypertension and that this can result from relatively small increases in 
plasma concentrations persisting over long periods of time.
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1.3 RAT MODELS OF GENETIC HYPERTENSION AND 
ABNORMALITIES OF THE STEROID METABOLISM
A number of strains of rats with inherited hypertension are 
available and some of these have abnormalities of corticosteroid 
secretion. Of these, the spontaneously hypertensive rat (SHR) has been 
the most intensively studied . In the SHR, the adrenal cortex has been 
reported to be hypertrophied compared with the normotensive control 
Wistar-Kyoto (WKY) and adrenalectomy prevents the development of 
hypertension (Brownie et a l, 1990). The measurement of corticosteroid 
concentrations such as corticosterone, DOC and 18-hydroxy-DOC in SHR 
has been variably reported as increased, unchanged or decreased 
compared with controls. Dale et al. (1982) also reported an increase in 19- 
nor-DOC excretion which has not yet been confirmed. However, the use 
of SHR has been criticised because of the absence of a genetically 
appropriate normotensive control strain. It is known that among different 
sources of WKY, there ai'e substantial genetic heterogeneities (Kurtz & 
Morris, 1987).
The Dahl salt-sensitive and resistant strains of rat provide a better 
model of genetic hypertension. At least part of the salt-dependent increase 
in blood pressure is due to inherited altered llp-hydroxylase activity, 
producing an increased 18-hydroxy-DOC:corticosterone ratio in vivo and 
in vitro. Cross-breeding studies have shown that the preferential 
conversion of DOC to 18-hydroxy-DOC rather than corticosterone, which 
characterizes the salt-dependent rats, accounts for at least 16% of the 
increase in blood pressure (Rapp & Dahl, 1972). The salt-resistant and 
salt-sensitive rats possess different alleles of the 11 p-hydroxylase gene, 
differing by five amino acid substitutions. The salt-resistant allele, by 
coding for an enzyme which synthesises proportionately less 18-hydroxy- 
DOC, is thought to protect the rat from salt-induced hypertension 
(Matsukawa et a l, 1993).
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Three distinct genetic strains of Lyon rat are available: 
hypertensive, normotensive, and hypotensive (Brownie et al., 1990). Five 
weeks old hypertensive animals have increased excretion of DOC, 
reduced excretion of corticosterone and unchanged 18-hydroxy-DOC, 19- 
nor-DOC and aldosterone compared with normotensive and hypotensive 
controls (Vincent et al., 1989). However, at 20 weeks old, DOC has 
returned to normal but there is higher excretion of corticosterone, lower 
aldosterone and unchanged 9-nor-DOC compared with controls. Whether 
this represent altered corticosteroid secretion or metabolism is still 
uncertain.
Abnormal steroid secretion has been demonstrated in Milan 
hypertensive strain (MHS) of rat (Ferrari et a., 1985; Mantero et al., 1983; 
Fraser et al., 1994). Study of the MHS has the advantage of a 
simultaneous normotensive genetic control strain, Milan Normotensive 
(MNS). Fraser et ai. (1994) have recently reported higher secretion rates 
of corticosterone, 18-hydroxycorticosterone and aldosterone in the 
hypertensive group compared with the normotensive. These data have 
been interpreted as showing greater adrenocortical llp-hydroxylase 
activity rather than aldosterone synthase activity in MHS compared to 
MNS rats. An understanding of the abnormalities in steroid metabolism 
is important because there are pathophysiological similarities between 
MHS and human essential hypertension (Blanchi & Ferrari, 1983).
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1.4 THE STEROID RECEPTOR AND HYPERTENSION
The reseai'ch on relationships between corticosteroid and 
hypertension has for years addressed the role of increased seeretion or 
reduced clearance of steroids. In the recent years a link has been sought 
with altered steroid tissue metabolism (i.e., defect of 11 p-hydroxysteroid 
dehydrogenase) or receptor and/or post-receptor function (e.g., 
glucocorticoid resistance syndrome). There is now abundant support for 
the first hypothesis and increasing evidence of the second.
This section reviews the mechanism of action of corticosteroids 
via their specific receptors and how abnormalities in receptor function 
and/or specificity can lead to hypertension.
1.4.1 Mechanism of action of steroids
Steroid action is a multistage process which acts through a 
common mechanism of ligand-dependent transcriptional modulation. The 
steroid enters the target cells, probably by simple diffusion, and binds to 
receptors in the cytosol, which undergoe structural changes associated 
with activation. Activation facilitates the transfer of the hormone-receptor 
complex to the nucleus where it binds to DNA at specific steroid response 
elements, modulating the transcription of genes (Allan et al., 1991; 
Carson-Jurica et al., 1990). This then leads to increased or decreased 
mRNA and protein synthesis. The different steps are summarized in fig. 
5.
Over the past years, the cDNAs for all major steroid receptors 
have been cloned and sequenced (Caison-Jurica et al., 1990; Williams & 
Franklin, 1994). The amino acid sequences have then been deduced from 
the structure of the exons of the genes which code for them. In this way, 
it was discovered that, although the steroid receptors differ in length, their 
structure revealed remaikable homologies ('superfamily' of receptors) 
with each other and also with the receptors for 1,25-
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dihydrocholecalciferol, thyroid hormone, retinoic acid, ecdysteroids 
(hormones controlling moulting in insects), and a number of receptors for 
which the ligand has not yet been identified (oiphan receptors). The 
steroid receptor sequence homology shows three regions which aie highly 
conserved among all members (see fig. 6). The strongest homology 
among receptors is in the region C l, a 66 amino acid sequence, which 
comprises the DNA binding domain. This domain forms two "zinc 
fingers" analagous to the structures formed by transcription factor IHA, 
initially observed in the amphibian (Allan et al., 1991; Schule et al., 
1988). Each finger is composed of 4 cysteines which coordinate one zinc 
atom. Domain swapping experiments suggested that the domain binding 
region is the sequence which specifically recognizes the cognate steroid 
response elements located in the genomic DNA adjacent to target genes 
(O’Malley, 1990; Freedman & Luisi, 1993). It has also been suggested 
that the first finger contains primary information for sequence specificity
while the second stabilizes the receptor binding to its DNA response 
,element.
The other two highly homologous regions, C2 and C3 in the C- 
terminal portion, consist of approximately 42 and 22 amino acids, 
respectively. These regions share less homology than do the Cl regions. 
They are hydrophobic and it is unclear whether they participate directly 
in the ligand binding, protein-protein structural interactions, or 
transcriptional activation. However, mutational analyses revealed that the 
entire C-terminal domain must be intact for high affinity ligand binding.
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Fig.6; Sequence homologies of steroid receptor superfamily [human 
receptor for glucocorticoid (hGR), mineralocorticoid (hMR), progesterone 
(hPR), oestrogen (hER), oestrogen-related receptors (hERRl, bBRR2), 
retinoic acid (hRR), thyroid hormone (hTRp), vitamin D (hVDR) and the 
orphan receptor (COUP, chicken ovalbumin upstream promoter)]. 
Numbers inside the three major conserved regions indicate the percentage 
of amino acid homology with the hGR. The numbers to the right of each 
bar show the number of amino acid residues in that receptor (reproduced 
from O'Malley, 1990)
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The amino-terminal region of the receptor proteins is a 
hypervariable region having low homology between receptors. The 
epitopes of most antibodies raised against steroid receptors are located in 
this region. It has been suggested that this region may contribute to the 
diversity of receptor specificity.
1.4.2 Corticosteroid receptors
In the target tissues, corticosteroid action is mediated by two 
distinct intracellular (cytoplasmic) receptors, currently referred to as the 
Type I or mineralocorticoid receptor (MR) wliich shows aldosterone 
selectivity, and tire Type II or glucocorticoid receptor (GR) which shows 
selectivity for cortisol in human subjects and corticosterone in the rat. 
The classification of corticosteroid receptors into subtypes has been made 
possible, in part, by the synthesis of highly selective ligands. 
Dexamethasone and triamcinolone acetonide are high-affinity GR 
binders but the most recent synthetic corticosteroids, RU26988, 
RU28362, and RU38486, have higher specificity and affinity for GR. 
Steroids such as 9a-fluorocortisol and 19nor-progesterone are 
mineralocorticoid agonists, whilst spironolactone, ZK91587 and 
RU26752 are mineralocorticoid antagonists.
Mineralocorticoid receptors
Mineralocorticoid receptor sites may be characterised on the basis 
of the hierarchy of binding affinity shown for the different steroids.
Aldosterone > DOC > Corticosterone > Cortisol >Dexamethasone
Using different experimental approaches (biochemical studies, 
topography, and molecular biology), the high affinity aldosterone binding 
sites have been detected not only in classical epithelial tai'get tissues such 
as kidney tubules ( Lan et al., 1982; Grekin & Sider, 1980; Marver et al..
47
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1972) but also in non-epithelial tissues such as vascular smooth muscle 
cells (Meyer & Nichols, 1981; Kernel, 1993), septo-hippocampal region 
(Lowy, 1991; Reul et al., 1985; Reul et al,, 1990), mamraaiy gland (Quirk 
et al., 1983) and mononuclear leukocytes (Armanini et al., 1985). Binding 
affinities approximate to the physiological concentration of plasma 
aldosterone with dissociation constant (Kd) around 10'^  mol/1 (Lan et al., 
1982; Armanini et al., 1985) (for years the mineralocorticoid receptor 
was thought to have a higher Kd for glucocorticoids, see below).
The mineralocorticoid effector mechanism involves the binding 
of aldosterone to cytoplasmic receptor and the transcription of mRNA 
from which aldosterone-induced proteins (AIPs) aie translated. It has been 
reported that the AIPs might act by increasing the permeability of the 
apical membrane to sodium, so that passive entry of sodium into the cells 
is enhanced and intracellular sodium concentration rises (Bastl & 
Sebastian, 1987). This then activates and/or induces the activity of the 
basolateral membrane Na7K^ ATPase ('the sodium pump') (Garty, 1986) 
and also stimulates ATP synthesis to drive the pump (Law & Edelman, 
1978).
However, it has recently been reported that a rapid increase of 
sodium flux in response to aldosterone may reflect a non-genomic, 
possibly a membrane action of aldosterone (Wehling et ai., 1992a). 
Wehling et al. (1991a) demonstrated a high affinity binding site for 
aldosterone, but not cortisol and canrenone, in plasma membrane rich 
fractions from human mononuclear leukocytes with a calculated Kd for 
aldosterone of 0.04 nM. These data suggested a two-step model for 
mineralocorticoid action; firstly aldosterone binds to membrane receptors 
which trigger changes in membrane electrolyte transports systems within 
minutes (immediate activation of pre-existing NaVK"'" ATPase and 
sodium-proton exchanger) and secondly, binding to the cytoplasmic 
receptor initiating genomic mechanisms within hours/days (de-novo-
I
synthesis of Na^K"" ATPase molecules, etc.) (Wehling et al., 1992a).
Glucocorticoid receptors
The cloning of the human glucocorticoid receptor complementary 
DNA (cDNA) provided details of the receptor structure (Hollenberg et 
al., 1985). The GR gene is located on chromosome 5 and consists of 10 
different exons (Encio & Detera-Wadleigh, 1991). Exon 1 is an 
untranslated region, whereas exons 2-9 aie the coding regions. The cDNA 
encodes two types of proteins: 777-amino acid protein (a-glucocorticoid 
receptor) and 742-amino acid protein ( p-glucocorticoid receptor). These
I
proteins differ in their codons for the carboxy-terminal amino acids (50 
for ct and 15 for P) and 3'-untranslated regions. Figure 7 shows the 
human glucocorticoid receptor gene structure. The a form is more 
prevalent and binds steroid when expressed in vitro with the use of a- 
cDNA, whereas the p forms is less well represented, does not bind 
glucocorticoid when expressed in vitro and its function is unknown at the 
present.
Glucocorticoid receptors have been demonstrated in a multitude 
of organs in many species (e.g., kidney, thymus, adipose tissue, central 
nervous system, vascular smooth muscle cells, endothelium, etc.) 
(Feldman et al., 1978). Binding affinities fall within the normal range of 
plasma concentrations of free hormone (Kd around 30 nM) and are 5 to 
10 times higher for synthetic glucocorticoids such as deaxamethasone 
and triamcinolone acetonide. In a series of competitive binding assays, 
the sequence of potency for Type II receptor in the rat was:
Dexamethasone > Corticosterone > Cortisol = aldosterone
Numerous data on binding characteristics of steroid hormones suggest 
that steroid hormone receptors contain a single binding site for their 
respective ligands (Baxter & Funder, 1979). A more complex receptor- 
ligand interaction may also exist. Using a synthetic steroid such as 
cortivazol (11a, 21 -trihydroxy-6-16a-dimethyl-2'-phenyl-2'H-pregna- 
2,4,6-trieno [3,2-c]pyi'azol-20-one 21 acetate) two glucocorticoid binding
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sites on the human GR were identified in human leukaemic T cell line 
CEM C7 (Schlechte et al, 1985). The binding studies using [^H]-
:cortivazol showed a high (0.4 nM) and low (11 nM) affinity component 
with receptor concentration of 0.14 pM/mg protein and 0.30 pM/mg 
protein respectively and this compared to a single class of binding sites 
using [^H]-dexamethasone with Kd 1.9 nM and receptor concentration of 
0.46 pM/mg protein. Moreover competition studies of [^H]-cortivazol 
with unlabelled dexamethasone showed that dexamethasone binds only 
to the low affinity site detected by the labelled ligand. However, the 
physiological importance of this finding is still in debate.
Although the cascade of events which leads to glucocorticoid 
induction of gene expression is more or less as reported above (refer to 
section 1.4.1), detailed studies of the GR identified a system of 
considerable complexity. The ligand-free glucocorticoid receptor is 
present in the cytosol as a 9 S complex with a molecular* mass of 310 kDa 
(Muller & Renkawitz, 1991; Munck et al., 1990). The activated GR has 
a coefficient of sedimentation of 3.2 S (4 S form) with molecular mass of 
90 kDa. Thus, it appears that the receptor activation involves the 
dissociation of a large multiprotein complex. Using antibodies against the 
GR, it was concluded that the 9S form contains only one receptor 
molecule and is a heteromer composed of one hormone binding GR and 
two non-hormone-binding proteins of 90 kDa (Smith & Toft, 1993). This 
associated protein has been identified as the 90 kDa heat shock protein 
(Hsp90) (Joab et al., 1984; Sanchez et al., 1985). Detailed analysis of the 
9S complex showed that in addition to Hsp90, several other protein 
subunits are associated with the non-activated receptor such as Hsp56 
(Tai et al., 1986; Rexin et al., 1992) and Hsp70 (Pratt, 1990) as well as 
the smaller peptide p23 (Pratt, 1993). Hsp90 plays a biologically 
important role in GR activity, stabilising the complex in the cytosol. The 
loss of Hsp90 by heat activation decreases the affinity for the ligand of 
approximately 100 times compared to the heterocomplex GR-Hsp90 I■f
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(Nemoto et al., 1990a). Mutational analysis showed that deletion of amino 
acids 532-697, comprising two-thirds of the hormone binding domain, 
completely abolished the formation of 9S complex (i.e., Hsp90 binding) 
with consequent impairment of hormone binding (Pratt et al., 1988). It has 
been suggested that in the inactivated state, the GR is associated with two 
Hsp90 molecules which cover the DNA-binding domain. Dissociation 
from Hsp90 exposes the DNA-binding site on the GR (Carlstedt-Duke, 
1988). The stoichiometry of the complex is one GR, two Hsp90, one 
Hsp70 and one Hsp59 (Rexin et al., 1991; Rexin et al., 1992).
The Hps90 is an ubiquitous, highly conserved protein (Lindquist 
& Craig, 1988) that is bound to all the steroid receptors and to the dioxin 
receptor (Pratt, 1990), and it is thought to perform a general chaperone 
function in the cell (Wiech et al., 1992; Hendrick & Hard, 1993). The 
association of Hsp90 with steroid receptors is stabilized by molybdate, 
vandate and tungstate (Leach et al, 1979; Pratt, 1987; Pratt, 1990; Rexin 
et al., 1991). Hsp90 possesses ATPase activity and undergoes 
autophosphoiylation (Nadeau et al., 1993). It has been suggested that the 
receptor is normally phosphoiylated and that lack of hormone binding 
activity may be due to a dephosphorylated receptor (Munck et al., 1972; 
Munck et al., 1990). In cell-free assembly experiments, the GR 
heterocomplex formation was temperature- and ATP-dependent and 
appeared to be directed by an enzymatic process (Scherrer et al., 1990).
The glucocorticoid receptor bound to the cognate ligand, and 
dissociated from the Hsp, assembles to form a homodimer (Erikson et ai., 
1991; Wrange et al., 1989). This complex translocates into the nucleus by 
specific transport via the nucleai* pore (Picard & Yamamoto, 1987). Inside 
the nucleus, ligand-bound GR exerts its genomic effects by binding to 
specific glucocorticoid responsive elements (GREs) on the chromatin by 
the Zn-fingers exposed in the DNA-binding domain (Miesfled, 1990; 
Freedman, 1992; Freedman & Luisi, 1993) (refer to Fig. 8). The GREs are 
in the vicinity of the regulated genes and are composed of a palindromic
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sequence that consists of two hexameric half-sites sepaiated by three 
bases. A functional concensus which imparts glucocorticoid-inducible 
gene expression is: 5'-GGTACAnnnTGTTCT-3' (n can be any nucleotide)
(Beato, 1989; Carson-Jurica et al., 1990; Fuller, 1991; Williams &
Franklin, 1994). Once the homodimer is bound to its responsive element, 
it can couple with another dimer or transcription factor. Different 
arrangements and composition of binding sites for transcription factors 
and GR within a regulatory unit lead to different activities in gene 
expression: synergistic and non-synergistic, associated to induction or 
repression, respectively (Miesfeld, 1990; Muller & Renkawitz, 1991;
: V-King, 1992) (refer to Fig. 9). In table V are summarized the genes whose 
transcription is under glucocorticoid modulation.
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Table V: Genes whose ti*anscription is modulated by glucocorticoid. The 
proteins of the genes in bold might have physiopathological role in 
essential hypertension.
Glucocorticoid modulated genes
Positivelv Negatively
ACE (Mendelson et al., 1982) Insulin
ANP (Seidman et al., 1984; 
Gardner et al., 1986)
Lysozyme and other protein of the 
complement cascade (Lappin & 
Whaley, 1991)
Angiotensinogen (Ben-Ari et al., 
1989; Clauseret al., 1989; 
Feldmer et al., 1991)
Prostaglandin and prostacyclin
(Grunfeld et al., 1986)
Prorenin and renin (Morris et al., 
1984; Glorioso et al., 1989)
Glucocorticoid receptor
(Burnstein et ah, 1991)
Angiotensin II type 1 receptor
(Sato et al., 1994)
Nitric oxide (inducible) (Radomski 
et ah, 1990)
Insulin receptor (McDonald & 
Golfine, 1988)
Prolactin (Whorwood et ah, 1993)
Pepsinogen (Ichinose et al., 1990
Prepro-Neuropeptide Y receptor
(Larsen et al., 1994)
l ip  -Hydroxysteroid 
dehydrogenase
(Tannin et al., 1991; Stewart, 
1994)
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It is also noteworthy that glucocorticoids alter the stability of 
specific mRNAs, an important function which has been observed with i
Î
several genes, by an unknown mechanism (Kern et al., 1988; Boggaram 
et al., 1991). It has been suggested that the ligand-bound glucocorticoid 
receptor alters the transcription of proteins that regulate the stability of 
these mRNAs.
Because the presence and the quantity of GR in target cells 
correlates with the extent of hormonal responsiveness, this raises the 
possibility that mechanisms which regulate GR are pivotal in the control 
of hormone action. Endogenous glucocorticoid in patients suffering from 
Cushing's syndrome (Pardes et al., 1989) and administration of 
glucocorticoid to patients (eg., suffering from acute and chronic disorders) 
(Shipman et al., 1983), normal subjects (Schlechte et al., 1982) and rats 
(Antakly et al., 1990; Kalinyak et al., 1987) decreases GR activity in 
target cells and tissues while adrenalectomy increases GR mRNA and 
protein expression (Kalinyak et al., 1987; Reul et al., 1989). However, in 
the rat neither adrenalectomy nor administration of corticosterone 
significantly altered GR mRNA levels in the hypothalamus (Peiffer et al., 
1991). Lowy (1991), studying the GR binding characteristic in 
adrenalectomized rats, showed an increased binding capacity in the 
hippocampus, frontal cortex and hypothalamus, but not in thymus, spleen, 
lymphocytes and pituitary gland. These observations suggested that 
firstly, GR regulation is part of a negative feedback loop paitially 
controlled by glucocorticoid concentration and secondly, the 
autoregulation of the GR is likely to be tissue specific. Denton et al. 
(1993) comparing a glucocorticoid-sensitive (dex') human T-cell line 
6TG1.1 with a glucocorticoid-resistant (dex") activation-labile cell line 
3R7.6TG.4 and a dex  ^cell line CEM-Cl, demonstrated differential cell- 
specific autoregulation of human GR expression.
Dong et al. (1988), using hepatoma tissue cell culture and rat liver 
in vivo, showed a complex GR autoregulation which occurs at both
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transcriptional and post-translational levels. No effect of glucocorticoids 
on GR mRNA half-life in hepatoma tissue culture cells (determined to be 
4.5h both in presence and absence of 0.5ug of dexamethasone) was 
observed but GR protein half-life was reduced after steroid treatment (25h 
in absence of dexamethasone and 1 Ih in presence of hormone). It appeal's 
then that the primaiy mechanism of down-regulation of receptor protein 
is at the level of mRNA. Since a negative autoregulation of GR mRNA 
expression has been demonstrated, there may be a post-translational 
regulation too. Burstein et al. (1991) suggested that the transcriptional
response of the GR gene to glucocorticoid may occur via the interaction 
of GR with its own gene. They observed firstly that the human GR cDNA
contains multiple copies of the original GRE TGTTCT and secondly that 
human GR cDNA shifted the sedimentation position of the receptor on 
sucrose density gradient (Tully & Cidlowski, 1990).
1.4.3 Corticosteroid receptors specificity
In vitro studies showed that corticosteroids bind to some extent to 
both receptor types but usually prefer one or the other. Very few steroids
are absolutely specific in their effects: glucocorticoids such as cortisol 
may show mineralocorticoid activity and aldosterone potentially has 
glucocorticoid activity albeit at unphysiological high concentrations. A 
lack of specificity is indicated in Cushing's syndrome, where it has been 
suggested that the high plasma cortisol level can lead to hypertension via 
Type I receptors (Fraser et al., 1989). Several factors govern 
physiological tissue-response specificity:
a) Circulating levels of steroids. Aldosterone-mediated 
glucocorticoid activity is vei-y unlikely because plasma aldosterone level 
is 2 to 3 orders of magnitude lower than that of cortisol. It follows, 
however, that cortisol may compete for type I mineralocorticoid receptors.
The steroidal biological activity is held by the free rather than the protein- 
bound steroid which leaves the circulation and binds to the cellular
I
receptor. This presumably depends on the relative affinity of the different 
corticosteroids for albumin and transcortin (for review see Pardridge, 
1987). In practice, the levels of free cortisol and corticosterone 
approximate to 1% of total circulating levels. However, the hypothesis of 
mineralocorticoid specificity conferred by the cortisol binding globulin
(Funder et al., 1973; Stephenson et al., 1984) is not tenable since this 
specificity was retained in 10-days-old rats deficient in this protein 
(Sheppard & Funder, 1987a).
b) Receptor affinity (Baxter & Funder, 1979). Receptors have the 
ability to discriminate signal from noise. Therefore, they must have an 
appropriately lower affinity for potentially misleading signals (i.e., 
specificity). Hormonal receptor affinity is due to non-covalent binding, 
which involves electrostatic interactions including hydrogen binding, 
hydrophobic interactions and van de Waals forces. The formation of the 
hormone receptor complex is the rate-limiting step. The binding of
hormone (H) and receptor (R) can be simply represented:
H+R k 2
where HR is the hormone-receptor complex, and kl and k2 aie the two 
kinetic constants. The equilibrium constants, kl/k2 and k2/kl are 
designated association constant (Ka) and dissociation constant (Kd), 
respectively. Kd is, in practical terms, the concentration of free hormone 
required to give half maximal binding of hormone in any given system Iand is therefore a valuable expression of the avidity with which the 
receptor binds the hormone.
It has been shown that the ligand-binding domain region is 
conserved for a given type of ligand within the steroid receptor 
'superfamily' but not conserved between receptor types. This fits both with
the ligand being chemically unrelated and with the lack of cross-over 
binding between members of the group of steroids receptor 'superfamily'
(Fuller, 1991). It has been suggested that the presence of particular 
residues in the binding domain is an important determinant of specificity.
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Cysteine 638 and aspartate 641 in the GR lie within a relatively 
hydrophobic region which suggests that this region is a likely site of 
receptor ligand interaction (Carlstedt-Duke et ah, 1988). Mutations at 
these residues aie associated with reduced affinity for cortisol and 
decreased binding specificity (see earlier). Moreover, in vitro mutation of 
cysteine 656 of the rat GR causes an increased affinity for GR and a 
decrease in the relative affinity for cross-reacting steroids such as 
progesterone and aldosterone. Such a mutation has not been shown to 
occur in nature (Chakraborti et al., 1991). The proximity of two other 
cysteines to cysteine 638 is unique to the GR and it could be that these 
cysteine residues in GR play an important specificity-conferring role 
(Lopez et al, 1990).
Finally, although aldosterone and glucocorticoids show equivalent 
affinity for the mineralocorticoid receptor, Lombes et al. (1994) reported 
striking differences in the dissociation constants of aldosterone- and 
glucocorticoid-mineralocorticoid receptor complexes, as determined by 
direct in vitro binding assay. This would suggest that the preference of 
Type I receptor for aldosterone is an intrinsic feature of the receptor 
molecule.
c) Modulators. There is evidence that a variety of small, heat 
stable molecules may modulate receptor activity. Sumida et al. (1993) 
found that long chain polyunsaturated fatty acids decrease the affinity of 
the rat liver receptor for dexamethasone and suggest that they may act by 
strengthening the interaction between Hsp90 and the receptor protein. 
Interestingly, the binding of the glucocorticoid antagonist, RU486 is less 
affected, possibly suggesting that its interaction with the honnone binding 
domain is slightly different from glucocorticoid agonists. Two other 
modulators, characterised as amino-ether phosphoglycerides, have been 
identified which stabilise - i.e. reduce affinity for ligand - the receptor 
(Bodine & Litwack, 1988; Bodine & litwack, 1990). Their precise mode 
of interaction with the receptor protein has not yet been determined.
!-d) l ip  -hydroxy steroid dehydrogenase ( l i p  -HSD). In vivo studies 
of glucocorticoid binding in rat tissues involved with the transport of 
sodium showed that kidney, parotid and colon were "aldosterone- 
selective" and bound aldosterone in preference to corticosterone, whereas 
hippocampus and heart were "non-selective" and did not distinguish 
aldosterone and corticosterone (Sheppai'd & Funder, 1987a, b). Moreover, ■the in vitro expression of the cloned mineralocorticoid receptor showed 
identical binding affinity for aldosterone and cortisol (Arriza et al., 1987).
The matter was intriguing and an explanation came from the clinical 
observation that cortisol acts as mineralocorticoid in both congenital and 
acquired deficiency of l ip-HSD (Edwards et al., 1988; Fraser, 1990;
Stewart & Whorwood, 1992). As already mentioned, 11P-HSD catalyses
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the conversion of cortisol to its inactive metabolite cortisone in humans 
and corticosterone to 11-dehydrocorticosterone in rats. These 11-oxo- 
derivatives do not bind to the mineralocorticoid receptors, with the result 
that both cortisol and corticosterone are prevented from expressing their 
mineralocorticoid effect. This observation led to the proposal that i l p -
,.yHSD is normally responsible for protecting the type I receptor from
exposure to cortisol in aldosterone-selective tissue such as the kidney
(Edwards & Stewart, 1991; Monder, 1991). Thus, the target tissue
specificity appears to be enzyme- rather than receptor-mediated,
indicating that 11 P-HSD is necessary to protect mineralocorticoid
receptor from normally higher serum concentration of cortisol by its local
.inactivation, allowing aldosterone to regulate sodium homeostasis 
(Funder et al., 1988; Morris & Souness, 1992; Pearce, 1994). By contrast, 
aldosterone is protected from the enzyme action because of its 11-18 
hemi-acetal structure.
Two types of 11 P-HSD have been identified. The type 1 enzyme 
is mainly found in the liver, has an apparent molecular weight of 34000, 
requires NAD? as co-factor and shows both reductase and dehydrogenase 
activity. It has also been shown that the NADP:NADPH ratio in the liver
■I
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1.4.4 Can glucocorticoid receptor abnormalities cause hypertension?
favours reductase activity with conversion of cortisone to cortisol. The 
type 2 enzyme is found in kidney and placenta, has a molecular weight of 
approximately 40000, requires NAD as co-factor and converts cortisol to 
cortisone (dehydrogenase activity) exhibiting little or no reductase activity
(Stewart, 1994).
11 P-HSD is present in most tissues but its specific functions in 
the majority of these are unknown. In addition to the kidney, its actions
have been studied in testis and brain. Depletion of cortisol by 11 p-HSD 
may initiate testosterone production at puberty and affect testosterone 
production during adult life (testosterone synthesis is suppressed by 
glucocorticoids). Co-localization of 11 p-HSD and glucocorticoid 
receptors in the brain may be important in controlling the specificity of 
corticosteroid interaction with GR and MR.
Metabolic abormalities
Variation in 11 p-HSD activity, as discussed above, could 
represent a novel mechanism in the pathogenesis of essential hypertension 
(Stewart &,Edwards, 1991; Walker, 1993; Seckl & Brown, 1994). In a 
proportion of patients suffering from essential hypertension, it is possible 
that excessive activation of renal mineralocorticoid receptor occurs, since 
plasma renin activity is low in 20-30%. However, neither 
mineralocorticoid nor glucocorticoid is found in excess and it has been 
concluded that any abnormality of adrenal steroid secretion is not of 
sufficient magnitude to explain the rise in blood pressure. However, 
abnormally high sensitivity to cortisol might provide an explanation.
Support for this idea comes from two observations:
a) administration of dexamethasone produced a paradoxical fall in blood
:pressure in a subgroup of essential hypertensive patients, possibly 
implicating cortisol or another ACTH-dependent steroid in pathogenesis
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(Hamilton et a l, 1979; Whithworth er a l, 1989);
b) young adults at increased risk of hypertension have slightly but 
significantly higher levels of cortisol than controls (Watt et al., 1992);
c) subnormal activity of 11 p-HSD in the presence of liigher tissue steroid 
levels could be a possible hypertensinogenic mechanism. Data from 
several groups support the conclusion that 11 p-HSD is impaired in some 
hypertensive patients (Walker et al., 1993; Kornel & Margolis, 1992;
Soro et al., 1995).
However, the observation of defective 11 p-HSD in essential 
hypertension could be relevant only if it can be linked with a mechanism 
which explains the rise of blood pressure. Thus, it would be reasonable 
to expect to find suppression of renin and hypokalemia and prolonged .half life for [11 cc^H]-cortisol (the half life of this compound is the most 
sensitive technique available to study the 11 P-HSD activity in vivo) in 
essential hypertension as occurs in patients with congenital and acquired 
11 P-HSD deficiency. Because those abnormalities were not found,
Walker et al. (1991) proposed that the rise in blood pressure in essential 
hypertension is due to defective activity of 11 P-HSD in modulating 
corticosteroid actions on vascular tone at local sites in blood vessels. This 
hypothesis involves modulation of steroid access to the receptor rather 
than an abnormality in the receptor itself.
* -;'3
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Receptor abnormalities
There are clinical situations in which abnormal glucocorticoid 
activity due to mutations in the glucocorticoid receptor gene causes high 
blood pressure. The syndrome of glucocorticoid resistance in man and 
animals is well-documented (Brandon et al., 1991). In man, impairment 
at the glucocorticoid receptor level is compensated by increased ACTH 
drive in an attempt to raise plasma cortisol concentration to an effective 
level (Chi'ousos & Karl, 1992; Aral & Chrousos, 1994). This is obviously 
due to an impairment of the negative feed-back mechanism by
glucocorticoid on the hypothalamus and anterior pituitary gland. The 
syndrome frequently includes hypertension with ahypokalaemic alkalosis 
characteristic of excess mineralocorticoid activity which has usually been 
attributed to abnormally liigh secretion of the ACTH-dependent, minor 
mineralocorticoid, DOC (Vecsei et ah, 1989; Lamberts et ah, 1992). An 
alternative explanation is that the increased mineralocorticoid activity 
might also be due partially to high cortisol concentrations interacting with 
Type I receptors (see fig. 10). Thus, it is likely that the higher local 
cortisol concentrations overide the 11 p-HSD protective activity on Type 
I receptor (see earlier). Chrousos & Kaii (1992) have listed the various 
biochemical and molecular abnormalities which cause glucocorticoid 
resistance. These include reduced receptor concentration, usually caused 
by nucleotide sequence deletions of varying length, and reduced receptor 
affinity caused by point mutations at or near the steroid binding domain. 
Werner et ah (1992) analysed 7 cases of glucocorticoid insensitivity in 
some detail. In addition to the affinity and concentration changes already 
described, they also found instances of increased thermolability of the 
receptor associated with an abnormally high rate of glucocorticoid 
receptor gene expression. Interestingly, a thermolabile glucocorticoid 
receptor was the only biochemical alteration reported in one patient 
whose only symptom was fatigue (Bronnegard et ah, 1986). Mutations 
which alter the binding of the hormone-receptor complex to DNA have 
also been identified although in nonhuman primates rather than man 
(Brandon et ah, 1991). Here the crucial change is the spacing 
between zinc fingers. The consequences for blood pressure control 
were not discussed. Adcock et ah (1993) studying a group of 
asthmatic patients insensitive to glucocorticoid treatment, reported 
that the ability of GR to bind to GRE and with other transcription
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Fig. 10: Side effects of end-organ resistance to cortisol.
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:factors may be impaired in steroid-resistant patients. This study did not 
discuss blood pressure effects.
A stimulating observation came from the analysis of data obtained 
in the epidemiological study of Watt et al. (1992). Various genotypic and 
phenotypic variables were measured in a group of young subjects. Results 
were analysed on the basis of (i) whether or not their parents were 
hypertensive and (ii) where in their peer group range their personal blood 
pressure came. This "four corner" design revealed a tendency for 
offspring of higher blood pressure parents to have higher personal levels 
of blood pressure. Associated with this trend was the additional tendency 
of higher blood pressure in young subjects with hypertensive parents to 
have higher plasma cortisol concentrations. The difference was small but 
significant. In the same study, glucocorticoid receptor RFLP genotype 
was tested. The results strongly suggested a more frequent occurrence of 
one genotype (AA) in the higher blood pressure offspring of high blood 
pressure parents, although the size of the study precluded the result 
achieving conventional statistical significance. However, when results 
from all 4 groups were pooled, young subjects with the A A genotype had 
significantly higher blood pressure scores than those with the aa genotype 
(Kenyon et al., 1993). The results are presented In Fig. 11. The 
coexistence of increased cortisol levels and a possibly different receptor 
in the susceptible group could be interpreted in different ways. If the A A 
genotype is a marker for GR impairment then, as with primary cortisol 
resistance, hypertension results from excess mineralocoiticoid activity.
Against this interpretation is the lack of effect on plasma renin and 
potassium. If on the other hand, the AA genotype signifies increased 
affinity then increased receptor binding together with raised plasma 
cortisol should cause a glucocorticoid-type hypertension. This is in part 
supported from the finding of increased angiotensinogen. A third 
possibility is that RFLP is in close linkage dysequilibrium with a gene 
other than GR which is important in blood pressure regulation.
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In this thesis, an experimental approach to the testing of these 
alternatives will be described. The possibility that abnormalities in type 
n  corticosteroid receptor properties are contributory factors in two genetic 
models of hypertension will be discussed.
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1.5 SUMMARY AND AIM OF THE EXPERIMENTAL STUDIES
Current evidence suggests a familial component in the 
development of hypertension but the precise genetic abnormalities, 
obscured by interaction with many environmental influences, remain 
unknown. It seems likely that several rather than a single gene locus are 
involved and that among the systems affected aie renal, ion transport 
mechanisms and a variety of neuroendocrine and endocrine functions. Of 
the endocrine influences, corticosteroid hormones, as well as being 
hypertensinogenic themselves, have the propensity to potentiate other 
cardiovascular control elements. Although various mechanisms link 
corticosteroids to the cardiovascular system, it is not known which one, 
if any, is of overriding importance in blood pressure control. Both 
mineralocorticoid and glucocorticoids acting in different ways are key 
factors in blood pressure control. The activity of the adrenal cortex and 
the way in which its steroid products interact with their tai'get tissues, may 
vaiy in a genetically-determined manner. It also appears that some of the 
cardiovascular influences are expressed at concentrations of 
glucocorticoid hormones which are less than those required to produce 
symptoms of Cushing's syndrome.
Endogenous glucocorticoids, cortisol in man and corticosterone 
in rats, can bind to two types of receptors. The Type I or 
mineralocoiticoid receptor evokes effects on salt and water metabolism, 
the Type II or glucocorticoid receptor is conventionally linked to effects 
on intermediary metabolism, though they can also cause changes in 
electrolyte metabolism. Normally, access of cortisol and corticosterone to 
Type I receptors is prevented by the activity of the 11-OHSD which 
converts cortisol to cortisone and corticosterone to 11- 
dehydrocorticosterone. It is important to note that an increase in blood 
pressure may be due to enhanced glucocorticoid activity either via Type 
I or Type H receptors. Moreover, the Ladywell study suggested that 
plasma cortisol levels may be significantly higher and that the
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glucocorticoid receptor may be different in human subjects with a familial 
predisposition to hypertension.
The purpose of this thesis has been to investigate whether 
variations of Type H receptor function are associated with valuations in 
blood pressure.
Do the different GR RFLP genotypes, A A and aa, represent 
receptors with different binding efficiency and is GR activity a significant 
factor in genetic hypertension?
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Chapter 2 MATERIALS AND METHODS
2.1 MATERIALS AND GENERAL METHODS
2.1.1 Chemicals
Reagents were obtained from the following sources:
- Fisons, UK
Na^HPO ,^ NaHzPO ,^ NaCl, Na Citrate, NaOH, MgCl.
- Amersham International, Buckingham, UK
[l,2,4^H]-dexamethasone (1.35 Tbq/mmol)
- Sigma Chemical Co, Poole, Dorset, UK
Unlabelled dexamethasone, estradiol, progesterone, 
dehydroepiandrosterone (DHA), cortisol, aldosterone, human 
recombinant lysozyme. Micrococcus lysodeikticus, polyethylenimine 
(PEI), crystal violet, cynogen bromide, sodium molybdate, EDTA, 
ammonium cloride, Tris/Hcl, Triton xlOO, proteinase K.
- Flow Laboratories, Rickmansworth, Herts, UK
Ficol-Hypaque (lymphocytes separation medium, 1077 g/1), 
RPMI-1640, GF/C filter paper.
- Gibco BRL, Paisley, UK
Foetal-calf serum (FCS), glutamine, penicillin, streptomycin, 96- 
well culture plates.
- ICN Biochemicals LTD, Immuno-biologicals Division, High Wycombe, 
UK
Bovine serum albumin (BSA).
- Farmachem, Strathleven, Scotland, UK
D-glucose, NaHCOg (analytical grades).
- Diagnostic Products Corporation, Los Angeles, CA, USA
Coat-A-Count cortisol and aldosterone kits.
- Northumbria Biological Ltd., Cramlington, UK
Bel I restriction enzyme.
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- Merck Ltd, Hunter Boulevard, Magna Park, Lutterworth, Leicestershire, 
U.K.
Acetic acid, chloroform, dipotassium hydrogen orthophosphate, 
ethanol, glycerol, potassium dihydrogen orthophosphate, sodium dodecyl 
sulphate (SDS).
- Astra Pharmaceutical, Sweeden
Budesonide.
2.1.2 Equipment
- p-counter, LKB Wailac 1217, Rackbeta, LKB-Produckter, AB, 
Bromma, Sweeden.
- lEC Centra 8R Centrifuge, Damon/IEC division, Needham HTS, 
Massachussets, USA.
- Y-counter, LKB or LKB 1280, LKB-Produkter as above.
- Polytron homogenize!'. Kinematic, Lucerne, Switzerland.
- Microtitretek, Anachem, Luton, UK
- Spectrophotometer, LKB, LKB-Producter as above.
2.1.3 Buffers
- Phosphate-buffered saline (PBS): 0.85% NaCl and 6.7 mM sodium 
phosphate, pH 7.2
- Buffer A: 10 mM Tris-HCl, 2mM dithiothreitol, 1.5 mM EDTA, 0.1 M 
sodium molybdate, 10% (w/v) glycerol, pH 7.4
- Dextran-coated charcoal (DCC): 0.5% (w/v) of activated charcoal, 
0.005% (w/v) dextran 770 in buffer A
- Sodium citrate solution: 3.9% Na citrate, pH 7.2
- Red cell lysing buffer: 0.155 M NH4CI, 10 mM K^PO ,^ KHgPO  ^and 0.1 
mM EDTA, pH 7.2
- White cell counting solution: 1% acetic acid, 0.01 crystal violet.
- Lysis mix: 0.32 M sucrose, 10 mM Tris, 5 mM MgCl, 1% Triton xlOO, 
pH 7.5
- Nuclei lysis buffer: 10 mM Tris, 0.4 M NaCl, 2 M EDTA, pH 8.2
72
- T.E. buffer: 10 mM Tris/HCl, 0.5 mM EDTA, pH 7.4
- 20X SSC; 3 M NaCl, 0.3 M Na citrate, pH 7.0
2.1.4 Other materials
- Male Sprague-Dawley (SD), Spontaneously hypertensive (SHR) and 
Wistar-Kyoto (WKY) rats (200-250 g) were from Harlan Olac Ltd,
Bicester, Oxon, England, UK.
- Female Milan normotensive (MNS) and hypertensive (MHS) strains of 
rat (200-250 g) were from Prof. I.W, Henderson, Department of Zoology,
University of Sheffield, Sheffield, England.
- RU486 was a gift from Roussel Laboratories, Paris, France.
- Glucocorticoid receptor c-DNA insert (0B7) was a gift from Prof. R.
Evans, Salk Institute, La Jolla, CA, USA.
2.1.5 Protein measurement
The protein measurement was carried out by the method of Lowiy 
et al. (1951).
2.1.6 Hormonal measurements
a) Serum and urinary cortisol and aldosterone concentrations were 
measured using Coat-A-Coimt kits. The methods are based on a solid 
phase '^^I-radioimmunoassay.
b) Urinary tetrahydrocortisol (THF), alloTHF and tetrahydrocortisone 
(THE) were kindly measured by Ms M. Ingram by gas chromatography- 
mass spectrometry analysis (after steroid extraction using the method of 
Shakleton et al. (1985) on a ITS40 mass spectrometer (Finnigan MAT,
San Jose, Ca., USA) coupled to a Varian 3400 gas chi'omatograph (Vaiian 
Inc, Walnut Creek, Ca., USA).
The ratio of lip-hydroxy- to 11-dehydro-metabolites was 
calculated using the following foimula: THF + ailoTHF/THE. 'È.e) Plasma renin was kindly measured by Dr. J.J. Morton, MRC Blood
7!
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Pressure Unit, Western Infirmary, Glasgow, by direct radioimmunoassay 
of angiotensin I generated by sample incubation at 37°.
2.1.7 Routine measurements
Routine serum and urine measurements were carried out at 
Clinical Biochemistiy Department, Western Infirmary, Glasgow. The 
tests and respective methods are as described in table VI. Creatinine 
clearance was calculated from the following formula:
I
milliters of plasma cleared per minute: Ucr x V / Per 
where Ucr and Per are concentration of creatinine in urine and plasma, 
respectively, and V is volimie of urine in milliliters per minutes.
Glomerular filtration rate (GFR) was estimated using the serum 
creatinine concentration alone. If the endogenous production of creatinine 
remains constant then senim creatinine will be inversely proportional to 
GFR, therefore:
GFR (ml/min) -  1.2 [140-age (years)] x weight (kg)/serum creatinine 
(pmol/1)
Routine haematological profiles were carried out at the 
Department of Haematology, Western Infirmary, Glasgow by 
cytoflurimetric method.
i
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Table VI: Routine urine and serum measurement with respective method 
used.
Serum
Cholesterol Salkowski reaction
Triglyceride Enzymatic colorimetric method
Sodium Ion-selective electrode
Potassium Ion-selective electrode
Calcium o-Cresolphthalein complexone reaction
Creatinine Jaffe' reaction
Urine
Sodium Flame photometry
Potassium Flame photometry
Creatinine Jaffe' reaction
Calcium o-Cresolphthalein complexone reaction
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■ i2.1.8. DNA extraction
Total genomic DNA was extracted from white cells using a 
sodium dodecyl sulphate (SDS)/proteinase K and phenol extraction 
method as described by Miller et al. (1988). Ten ml of whole blood 
(anticoagulated with EDTA) were resuspended with 50 ml of lysis mix' 
and incubated for 5 min at 0 , This was followed by 10 min centrifugation 
at 700g. The pellets were resuspended in 3 ml of nuclei lysis buffer. The 
cell lysates were digested overnight at 37 with 0.2ml of 10% SDS and
0.1 ml of protease K solution (10 mg/ml in 1% SDS and 2 niM EDTA). 
When digestion was complete, 1 ml of saturated NaCl (approximately 6 
M) was added to each tube and shaken for 15 min. 5 ml of 
phenol/chloroform (1:1, v/v) were added and the tubes centrifuged for 10 
min at 700g. The precipitated protein pellet was left at the bottom of the 
tube, whilst the supernatant containing the DNA was transferred to a 
clean tube. Exactly two volumes of 95% ethanol at room temperature 
were added and the tubes inverted several times until the DNA 
precipitated. The DNA was dried at room temperature and resuspended 
in 0.5 ml of T.E. buffer. The DNA was allowed to dissolve 2 h at 37° 
before quantitating.
The amount of DNA was measured by spectrophotometry. The 
DNA was diluted 1:100 in distilled water and the optical density (OD) 
read at 260 and 280 nm. The OD 260/280 ratio was calculated to verify 
the purity of DNA samples. For an acceptable purity the ratio must be 
between 1.7 and 2.
2.1.9 Genotyping analysis for glucocorticoid receptor polymorphism
DNA (10 pg) was digested using the restriction enzyme Bel I 
which recognizes the sequence:
5'-TI G-A-T-C-A-3'
3'-A-C-T-A-G Î T-5' 
and cleaves at the positions shown by the arrows (Bingham et ah, 1978).
I
Restriction fragments were separated by electrophoresis on 0.8% 
agarose gels and transferred onto Hybond-N nylon membranes by 
Southern blotting (Southern, 1975; Wenham, 1992), and fixed by baking 
at 80° for at least 2 h. Radioactively labelled glucocorticoid receptor c- 
DNA (OB7) insert (Hollenberg et al., 1985; Murray et al., 1987) was 
hybridised to the membrane in 7% SDS/0.5 M phosphate buffer (pH 7.0) 
at 65° overnight. The non-specific binding was washed off in 2X standai'd 
saline citrate (SSC)in 0.1% SDS at 65°. The membranes were exposed to 
Hyperfilm MP, with intensifying screens, for at least 3 days at -70°.
2.1.10. Skin vasoconstriction test
The Stoughton-McKenzie vasoconstriction assay (McKenzie & 
Stoughton, 1962) as modified by Place et al. (1970) was used to 
determine the variability of the effect of the synthetic glucocorticoid, 
budesonide. Budesonide solutions were made up freshly in 95% ethanol 
at concentrations of 0.1, 3.9, 15.6, 62,250, 1000 pg/ml in coded vials and 
were used within 24 h of preparation. 5 pi volumes were applied in 
random order to 7 x 7 mm squares outlined by silicone grease on the 
flexor aspect of the forearm. After it had been allowed to dry, the test area 
was covered with polyester film for 18 h. The degree of blanching was 
assessed after removal of the occlusive dressing and scored by an 
independent observer on a scale of O=none, l=mild, 2=definite, 3=intense 
blanching.
The dose-dependent curve was plotted for each individual and the 
median effective dose (EC50) for budesonide calculated.
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2.2 METHOD DEVELOPMENTS
2.2.1 White blood cells separation
Glucocorticoid receptors are found in nearly all tissues (Feldman 
et al., 1978; McGimsey et al., 1991), including kidney, brain and 
circulating white blood cells. Leucocytes have frequently been used as a 
peripheral model to study GR regulation in clinical disease states 
associated with alterations in cortisol levels (Murakami et al., 1979;
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Schlechte et al., 1982; Fardes et al., 1989; Tanaka et al., 1991; Girardin 
et al., 1991). Leucocytes have the following advantages: a) ease of
isolation, b) do not need to be cultured, c) maintenance of integrity and 
physiological properties of plasma membranes and nuclei, d) free from 
contaminating extracellulai* proteins.
For these reasons, white blood cells were used to test the 
hypothesis that glucocorticoid receptor binding chaiacteristies are 
abnormal in hypertension.
Cell preparation
Peripheral blood obtained from fasting healthy volunteers was 
collected into citrate and platelet-rich plasma was removed by low speed 
centrifugation (600g for 5 min). The remaining cells were diluted 1:3 with 
PBS and fractionated on a Ficoll-Hypaque gradient according to the 
method of Boyum (1968). This separates mononuclear leucocytes (ML) 
at the top of the gradient from a mixture of polymorphonuclear cells 
(PMN) and red blood cells at the bottom. The layer of mononuclear cells 
was removed and washed three times with PBS at room temperature by 
centrifugation and resuspension to reduce platelet contamination. The
.7:
final ML pellet was resuspended in RPMI-1640 medium containing 10%
:■■ -fetal calf serum, penicillin, streptomycin, and glutamine (unless
differently stated). The ratio of mononuclear cells to platelets was 3:1 and
i
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the ratio of lymphocytes to monocytes was 15:1. Monocytes monolayers 
from this suspension of ML were prepared in 96-well tissue culture plates 
and maintained at 37° in a humidified atmosphere of air with 5% CO .^ A 
purified population of lymphocytes was obtained by collecting those cells 
that had not adhered to the tissue culture plates after 90-min incubation. 
Lymphocyte suspensions were washed by centrifugation (400g for 10 
min) and resuspension in medium before being transferred to 96-well 
plates.
PMN were obtained from the bottom of the Ficoll-Hypaque 
gradient; contaminating red cells were lysed as described by Murakami 
et al. (1978). The red cells were mixed with two parts of PBS. This 
suspension was then mixed with 8 volumes of chilled lysing buffer. After 
the colour of the red cell suspension had changed from bright red to dark 
red, the cell suspension was centiifuged at 450g for 10 min at 4°. The 
supernatant was discarded and PMN were recovered. The recovered cells 
were washed three times by centrifugation (400g for 10 min) and 
resuspension in PBS. Finally, the PMN pellet was resuspended in RPMI 
and maintained in culture as described for monocytes and lymphocytes.
The viability of all cell types was consistently higher than 95%, as 
evaluated by trypan blue dye exclusion. There were no changes in cell 
number or viability during any incubation procedure.
;7:
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2.2.2 Glucocorticoid receptor assay in mononuclear leucocytes 
Introduction
Research on glucocorticoid receptor binding has been hindered by
■complicated laboratory protocols. In developing this method, two features 
were sought: a) to have an assay which allows ease of processing of a 
high number of samples, b) to reduce the volume of blood required. These 
requisites were partially satisfied by the whole-cell competitive binding 
assays reported in literature. However, previously published protocols had 
in common firstly, the need for large amount of expensive disposables
Methods
a) Cell preparation
apparatus and secondly, laborious washing steps to remove the unbound 
steroids from the incubation mixture. To avoid this a microtitre assay 
system has been developed which is a modification of the whole-cell 
competitive binding assay previously described by Schlechte et al. (1982).
Human mononuclear leucocytes (HML) were prepared as
described in section 2.2.1. After the washing stages, the cells were 
resuspended in RPMI-1640 (supplemented with 700 mg glutamine), to 
obtain a final concentration of approximately 3-5x10^ cell/ml. Cells were 
diluted 1:20 with crystal violet solution and counted under an optical 
microscope using the 4 outer quadrants of a haemocytometer.
b) Whole cell GR assay
Glucocorticoid receptor binding characteristics were measured by 
homologous competition for specific [^H]-dexamethasone-binding sites 
under steady state conditions (Schletche et al., 1982).
Aliquots (100 pi) of cell suspension were added to 96-well 
microtitre plates containing 50 pi of [^H]-dexamethasone and 50 pi of 
unlabelled dexamethasone in duplicate. The final concentration of [ H]- 
dexamethasone was 2 nM and the final concentration of unlabelled
$
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dexamethasone was 2 nM and the final concentration of unlabelied 
dexamethasone ranged from 0 to 150 nM. The unlabelled steroids were 
dissolved in ethanol and the final ethanol concentration was always less 
than 0.01%. Non-specific binding was measured by incubating the cells 
with 1000-fold excess of unlabelled dexamethasone. The plates were 
incubated for 3 h at 24°. After incubation, HML were harvested on 
Whatman GF/C filter paper and washed with ice-cold PBS containing 
polyethylenimine (0.1%) (Bruns et al., 1983) using a Titertek cell 
harvester. Filters were treated with 1% Triton X-100 and the radioactivity 
from lysed cells was measured by scintillation spectrometry.
Binding constants [dissociation constant (Kd) and binding 
capacity (Bmax)] were calculated from Scatchard plots which were fitted 
using the computer program Ligand (Munson & Rodbard, 1980).
To standardize the experimental conditions, preliminary 
experiments of cell number, dose and time dependency and hormone 
specificity were performed.
,ï:
Results
a) Time course of^H-dexamethasone specific binding
To measure the optimum time for measuring binding 
characteristics, 4x10 cells/ml were incubated for between 0 and 240 
minutes at 24°. Analysis for specifc binding (SB=TB-NSB, where TB is 
the total binding, and NSB the non-specific binding) was done in 
triplicate for each time period. The results are shown in Fig. 12.
b) Cell number dependency
In the assessment of receptor number, "binding" and "cell
• «number" are of major importance for a reliable study of GR binding. For ;
this reason, cell number should be maximal without compromising the 
capacity of the cell harvester and witli minimal non-specific binding.
Optimal specific binding was achieved with approximately 3.0-5.0 x 10^  
cells. The results of incubating with vaiious concentrations of cells is 
illustrated in Fig. 13.
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Fig. 12: Time course of binding of dexamethasone to glucocorticoid 
receptor in HML. Using the analysis of variance, there is no evidence of 
further binding after 180 min. Values ai'e means ±SE of 3 replicates. *
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c) Dose dependency
^H-dexamethasone specific binding was competed for by several 
concentrations of unlabelled dexamethasone (range, 0-150 nM). A 
threshold competition occurred at 0.6 nM unlabelled steroid. Fig. 14a and 
14b show a representative binding and Scatchard plot analysis of one 
volunteer. Scatchard plots were lineai- with coefficients (r) predominantly 
between 0.68 and 0.90.
The GR binding characteristics were measured in 26 volunteers. 
Kd values ranged from 2.8-12.5 nM (mean±SEM, 6.6±0.45), and Bmax 
values ranged from 1701-6994 sites/cell (mean±SEM, 3974±567). In 18 
of these individuals, GR Kd and Bmax were measured on a subsequent 
occasion. The coefficient of variation within individuals was 6% for Kd 
and 15% for Bmax (Braunsberg & James, 1961).
d) Hormone specificity
Specificity was tested by incubating the HML for 3 h at 24° in the
presence of several different steroids. The relative capacities of the steroid
to compete with ^H-dexamethasone for binding sites was as follows:
RU486 = dexamethasone >cortisol > aldosterone > progesterone >E  ^>
.DHA. DHA did not compete (refer to Fig. 15).
s
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Fig. 13: Glucocorticoid receptor binding versus ceil number (HML). 
Values are means ±SE of 3 replicates.
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Fig. 14 a and b: Representative dose-dependent curve (a) and Scatchard 
plot (b) of dexamethasone binding to HML. The data are consistent with 
a single class of binding site.
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Fig. 15 : Comparison of the effect of dehydroepiandrosterone (DHA), 
oestradiol (E )^, aldosterone (Aldo), progesterone (Prog.), RU486, coitisol 
(F) and dexamethasone (Dex.) with untreated control (solid bar) on ^H- 
dexamethasone specific binding in HML during 3 h incubation. Final 
concentration of all steroids was 1 pM; values, expressed as a percentage 
of controls, are means ±SE of 3 different preparations of cells.
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Discussion
A  previously published, whole-cell competitive binding receptor 
assay method has been modified into a microtitre system. This reduces the 
blood requirement and laboratory expenditure considerably and enables 
the simultaneous processing of multiple samples and probes. Thus speed 
of analysis is greatly increased. Because many factors can influence 
results, e.g. cell number, cell storage, time of blood withdrawal, 
temperature of incubation medium (data not shown), it is important to 
monitor them carefully. Using this protocol, this information was easily 
acquired.
The Kds and receptor densities measured in the ML of 26 healthy 
volunteers with this system were within the range published by Schlechte 
et al. (1982) and other published data at the same incubation temperature.
In summary, the microtitre system is a simple and reliable in vitro 
method of assessing glucocorticoid receptor binding characteristics in ML 
obtained from a relatively small blood sample and yields consistent 
results. For these reasons, it has been used in subsequent studies of 
whole-cell GR binding measurement.
A:
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2.2.3 Dexamethasone lysozyme inhibition assay: in vitro
responsiveness to glucocorticoid
One of the aims of this study was to establish a sensitive assay to
88
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Introduction
1
test in vitro responsiveness to glucocorticoid. Variability in glucocorticoid 
responsiveness has been implicated in the aetiology of depressive illness 
(Schlechte & Sherman, 1985), obesity (Weaver et al., 1992), hirsutism 
(Werner et ah, 1992), cardiovascular disease (Watt et ah, 1992) and, on 
rare occasions, glucocorticoid resistance has been recognised as a primary 
disorder (Chrousos et ah, 1982). It follows, therefore, that for both 
therapeutic and diagnostic reasons, a method of determining 
glucocorticoid sensitivity is necessary.
Glucocorticoid receptor studies of white cells and fibroblasts have 
identified some individuals with defective ligand binding (Werner et ah, 
1992) and, more recently, those with reduced receptor binding to DNA 
(Adcock et al., 1993), but these studies do not reveal subsequent defects 
of translation and transcription.
Two in vitro physiological responses of white blood cells have 
been used widely to assess steroid resistance in asthmatic, leukaemic and 
elderly critical care patients (Corrigan et ah, 1991a; Bell et ah, 1983; 
Tanaka et ah, 1992; van Rijen et ah, 1993). Glucocorticoids reduce the 
rate of proliferation of lymphocytes treated with phytohaemagglutinin and 
also prevent the uptake of 3-0-methyl-D-glucose by HML. Both methods 
are open to criticism. Generally, inhibition of proliferation is only 
achieved with supraphysiological concentrations of glucocorticoid 
hormones. 3-O-methyl-D-giucose uptake, although a more sensitive 
indicator, may lack specificity.
The present pait of the project has validated a method of assessing 
glucocorticoid responsiveness based on the control of lysozyme gene 
expression. Inhibition of the expression of this gene by glucocorticoids
.I t
was first demonstrated in chicken macrophages (Steiner et al., 1987) and
.then in human monocytes (Lappin & Whaley, 1991). Using primary
culture of white blood cells, the effect of hormone and cell type on 
sensitivity and specifity of the lysozyme response to glucocorticoids has 
been investigated by means of IC50 values and GR binding chai*acteristics.
Methods
Cell preparation and GR assay were as described in sections 2.2.1 
and 2 .2 .2 .
Aliquots of cell suspension (0.5-1 x 10^  cell) were cultured in a 
96-well culture plate at 37° in 5% CO2 for a maximmii of 84 h, but 
routinely for 72 h. After centrifuging the plates, a 100-pl aliquot of 
supernatant was removed from each incubation well and stored at -70°.
Lysozyme activity in the supernatant was measured photometrically by 
the lysis of Micrococcus lysodeikticus (Strunk et al., 1980) using human 
recombinant lysozyme as a standard. Each sample was assayed in 
triplicate.
To standardise experimental conditions for lysozyme release from 
white cells, preliminary experiments of time-dependency, dexamethasone 
inhibition dose-dependency and hormone and cell specificity were 
performed. In one experiment with HML, lysozyme activity in the 
incubation medium and that in cells were measured simultaneously. After 
removing the incubation medium for assay, cells were centrifuged and 
washed with PBS. Cellular lysozyme was released by lysing the cells in 
distilled water.
Linear regression and correlation were calculated, and Student's 
t test was used for the comparison of variables.
Results
a) Time course
Mononucloax cells were cultured in the absence and presence of
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1 joM dexamethasone. Samples of incubation medium were collected at
intervals up to 84 h of incubation. As shown in Fig. 16, inhibition of
lysozyme by dexamethasone was significant (P<0.001) after 24 h and
reached a stable maximal inhibitory effect by 72 h. After a 72-h
incubation, the intracellular lysozyme activity was 245±8 compared with
479+23 pU/cell in the incubation medium. With dexamethasone
treatment, activities were 189±5 and 245±8 pU/cell, respectively. These
data indicate that dexamethasone regulates lysozyme activity by inhibiting
de novo synthesis, rather than by controlling the release of intracellular
stores. In subsequent experiments, lysozyme activity was measured in
incubation medium at 72 h.
b) Cell Specificity
Previous studies of glucocorticoid-sensitive lysozyme release were
performed with monocytes (Lappin & Whaley, 1991) rather than HML as
in the time course study (see above). Monocytes are the minority cell type
in HML and yet lysozyme release from HML (expressed per unit cell) was
similai* in cultures of HML and monocytes alone. It follows that
lymphocytes in HML must also release lysozyme under the control of
glucocorticoid hormones. However, if HML rather than purified
.lymphocytes or monocyte samples aie to be used to screen samples, it is 
important to confirm that all cell types produce enzyme and that enzyme 
activity in all types is regulated by glucocorticoids. Therefore, responses 
to dexamethasone were compared in HML, lymphocytes, monocytes, and 
PMN. Ceils were incubated with and without 1 pM dexamethasone and 
lysozyme activity was measured in medium after 72 h. PMN released
#
most lysozyme (Fig 17). However, the degree of inhibition by 
dexamethasone was similar for all cell types (HML, 50.2+1.5%;
lymphocytes, 57.2+4.4%; monocytes, 58±1.8%; PMN, 47.8±2.2%). 
Beai'ing in mind that HML are easier to prepare than other cells and that 
the yield of HML from blood is greater than that of any other cell type, 
HML were used in subsequent experiments.
90
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c) Glucocorticoid specificity
To test for glucocorticoid specificity of lysozyme inhibition, HML 
were incubated for 72 h in the presence of different steroids. At 1 pM, 
cortisol and dexamethasone were equally effective, but DHA, estradiol, 
progesterone, and even aldosterone had no significant effect (Fig. 18). 
Paradoxically, RU486, supposedly a GR antagonist, reduced lysozyme 
release. When comparing the concentration-dependent effects of 
dexamethasone and RU486, dexamethasone was 1000 times more 
effective. Dexamethasone showed threshold inhibition at 0.6 nM (Fig.
19). The antagonistic effects of RU486 were apparent in HML treated 
with various concentrations of dexamethasone. At 1 pM RU486, the IC50
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and threshold values for the inhibitory effects of dexamethasone were 
shifted from 1.2 nM to more than 1 pM and from less than 1.0 to 19 nM, 
respectively.
d) Subject variability o f GR binding characteristics and inhibition of 
lysozyme release by dexamethasone
The IC50 of dexamethasone for inhibition of lysozyme release was 
measured in 26 volunteers. Values ranged from 1.3-8.1 nM (mean±SEM,
3.8+0.3). In six of these individuals dexamethasone sensitivity was 
measured on a subsequent occasion. The coefficient of variation was 12%
.(Braunsberg & James, 1961). The apparent glucocorticoid receptor Kd 
values measured in HML, but not Bmax, were positively correlated with 
IC50 values for the effects of dexamethasone on lysozyme activity (refer 
to Fig. 20; r=0.57; P<0.005). Neither Bmax nor Kd correlated with 
cortisol concentrations in the plasma of blood used to isolate cells.
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Fig. 16: Lysozyme activity in medium of HML cells after incubation with 
(open circle) or without (closed circle) 1 pM dexamethasone for various 
periods of time. Values are means ±SE of 4 replicates.
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after 72 h incubation with and without 1 pM dexamethasone. Values 
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Fig. 18: Comparison of the effects of dehydroepiandrosterone (DHA), 
estradiol (E^), aldosterone (aldo), progesterone (prog), RU486, cortisol (F) 
and dexamethasone (dex) with untreated controls (solid bar) on lysozyme 
released from HML during 72 h of incubation. Final concentration of all 
steroids was 1 pM; values expressed as a percentage of controls, ai'e 
means ±SE of 6 different preparations of cells. Statistical significance of 
inhibition compared with controls were determined by paired t-test and 
are indicated by * (P<0.05) and ** (P<0.01).
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Fig. 19: Concentration-dependant antagonistic effects of RU486 on 
dexamethasone-sensitive lysozyme release from HML. Values shown are 
means of triplicate incubations.
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Fig. 20: Correlation between IC50 values for the inhibitory effects of 
dexamethasone on lysozyme activity and Kd values for dexamethasone 
binding in HML from 26 volunteers (r=0,57; P < 0.005, slope = 0.41).
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Discussion
Lysozyme is a ubiquitous enzyme whose expression and release 
from macrophages are an integral part of the immune response. In 
keeping with the immunosuppressive effects of glucocorticoids, 
dexamethasone has been shown to inliibit lysozyme activity. This effect 
appears to be due to inhibition of lysozyme synthesis rather than a 
decrease in enzyme release, as dexamethasone reduced enzyme activity 
in both incubation medium and cell lysate. This confirms previous studies 
with monocytes showing glucocorticoid-dependant inliibition of 
lysozyme gene transcription (Lappin & Whaley, 1991). This study has 
also shown that all white blood cells release lysozyme and that this 
release in all types is glucocorticoid sensitive. Although the amount of 
enzyme synthesized varies among cell types, the degree of glucocorticoid 
inhibition is constant. Tliis obviates the need for rigorous cell 
purification. HML are prepared in high yield from a small sample of 
blood; 10-20 ml are sufficient for a complete dexamethasone response 
curve.
Previously, inliibition of cell proliferation has been used widely 
as an index of glucocorticoid sensitivity. This inhibitory effect, measured 
as decreased incorporation of radioactive thymidine or uridine, is best 
seen in mononuclear cells from peripheral blood after treatment with a 
mito genic stimulus such as the lectins Concavalin-A and 
phytohemoagglutinin (Neifeld et al., 1977). As with the lysozyme 
response, the proliferative response of all white blood cell types is 
inhibited. The effect of glucocorticoids appears to be as specific as that 
for the present lysozyme response; androgens, oestrogens, and 
progestogens in both assay systems are ineffective at concentrations 
below 1 pM (Neifeld et al., 1977). The use of the lysozyme assay offers 
three potential advantages over the mitogen method: increased 
convenience, sensitivity, and reproducibility. The end point for the 
lysozyme assay is a decrease in turbidity of a suspension of Micrococcus 
lysodeikticus, as described by Strunk et al. (1980). This has been readily
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adapted to microtiter assay plates, so that a large number of small samples 
can be quickly processed using a multiscanner spectrometer. In contrast 
to methods that measure the antiproliferative effects of glucocorticoids, 
cells do not require mitogen treatment to elicit inhibitoiy effects on 
lysozyme release. Although this is a minor inconvenience in proliferation 
assays, stimulation with lectins also involves induction of GR, which, in 
turn, will influence sensitivity. Under the right conditions with the right 
degree of stimulation, the ICgo for dexamethasone's antiproliferative effect 
corresponds to that expected for an event mediated by a receptor with a 
Kd for dexamethasone in the nanomolar range. More often, however, the
antiproliferation test has been applied more crudely with steroid 
concentrations greater than 100 nM (Corrigan et al., 1991b).
mitogen are tested (van Rijen et al., 1993) or the concentration of steroid
It also appears that the proliferative response to lectins varies 
between individuals, so that either more than one concentration of
%
required to inhibit proliferation bears no relation to GR characteristics.
For example, a recent study compared receptor binding characteristics and 
the antiproliferative effects of dexamethasone in steroid sensitive and 
steroid-resistant asthmatic patients. Binding affinity and inhibition of cell 
proliferation were both reduced in the resistant patients, but the two 
variables did not correlate with each other (Corrigan et al., 1991b). This 
lack of agreement may reflect the inexactitude of the proliferation test. To 
demonstrate antiproliferation in all individuals with cells obtained from 
a modest sample of blood, a wide range of steroid concentrations with 
few intermediate points was needed. This assay was, therefore, unable to 
discriminate 2- to 3-fold differences in antiproliferative activity to 
correspond with the range of values for dexamethasone binding affinity 
in steroid-resistant and -responsive patients. Given that the lysozyme 
assay has a coefficient of variation of 12%, the values in normal 
individuals fall in the nanomolar range, and the binding affinity and 
inhibitory effect of dexamethasone on lysozyme activity are correlated.
| :
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the present assay may be of greater value in the study of glucocorticoid 
receptor abnormalities than the antiproliferative method.
Recently, another in vitro method of assessing glucocorticoid 
responsiveness has been described (Tanaka et al., 1992). The uptake of a 
nonmetabolized sugai', 3-O-methylglucose, by monocytes is inhibited by 
dexamethasone. No prestimulation of cells is required for this simple 
reproducible qualitative method. An advantage of the glucose uptake 
assay over the lysozyme assay is that it is quicker. Glucose uptake is 
inhibited in a dose-dependant manner by glucocorticoids, but perhaps 
because of the shorter incubation period, the sensitivity of the response is 
slightly less than the effect on lysozyme release. In comparing glucose 
uptake and dexamethasone binding in different blood samples, only the 
effect of a maximally effective concentration of dexamethasone on 
glucose uptake was investigated. Not surprisingly, inhibition of uptake 
with 1 pM dexamethasone correlated with receptor number rather than 
affinity. The lysozyme method is perhaps a more specific indicator of 
glucocorticoid activity than the uptake method. Progesterone at a 
concentration of 1 pM had no effect on lysozyme synthesis. The lack of 
an effect of aldosterone is surprising in view of the known affinity of the 
GR for this steroid. However, contiasting effects of mineralocorticoid and 
glucocorticoids have been described previously (Kenyon et ah, 1984). 
Similarly, the pai tial agonist effects of high concentrations of RU486 on 
lysozyme activity, although unexpected, are not without precedent (Laue 
et ah, 1988; Van Voorhis et ah, 1989). It has been demonstrated that in 
the presence of dexamethasone, RU486 is a potent glucocorticoid 
antagonist at concentrations that exhibit no agonist activity when added 
to HML alone.
In summary, the lysozyme inhibition assay is a simple, robust, in 
vitro method of assessing glucocorticoid responsiveness based on the 
inhibitoiy effects of dexamethasone on lysozyme activity in cultures of 
HML obtained from a small blood sample. The specificity of the response
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for glucocorticoid hormones is at least as good as that of any other 
method; mineralocorticoid, oestrogens, androgens, and progestogens are 
inactive, whereas the glucocorticoid antagonist RU486 markedly 
inhibited the dexamethasone response. The assay is reproducible and is 
not subject to variations caused by stimulation of cell proliferation. This 
test has been applied in the present studies to investigate potential GR 
polymoiphisms. Tliis study has been recently published (Panarelli et al., 
1994, see page 228).
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7.4 Glucocorticoid receptor binding measurement from rat liver 
cytosol
Introduction
Although the mononuclear leucocyte is a convenient tissue to 
measure GR binding characteristics in man, it has serious limitations for 
studying small animals. From an individual rat, only 9-10 ml of blood can 
be withdrawn which yields an insufficient number of ML. Thus, ML from 
several rats must be pooled to achieve the required cell number for a 
reliable measurement of GR binding (see section 2.2.2).
Glucocorticoid receptors are abundant in liver cytosol preparations 
(Howell & Lefebvre, 1989: Howell et al., 1990). The rat liver is easy to 
isolate and its homogenization yields a large amount of cytosolic protein 
for the measurement of receptor binding.
The assay has been developed using the normotensive Sprague- 
Dawley (SD) rat.
Methods
a) Tissue preparation
Six SD rats were stunned, decapitated and the liver perfused in I
situ with ice-cold 0.154 M NaCl solution. Livers were removed and
minced in 3 volumes of ice-cold buffer A and the minces were 
homogenised briefly using a Polytron. The homogenate was centrifuged 
at 20,000g for 20 min. and the supernatant centrifuged at 105,000g for 1 
h. All manipulations were carried out at 5°. The final supernatant 
(cytosol) was used in binding studies.
b) Binding studies
Binding constants for dexamethasone, corticosterone, aldosterone 
and the glucocorticoid antagonist, RU486 were estimated by measuring 
homologous and heterologous competition for specific ^H- 
dexamethasone binding sites. Aliquots of liver cytosol (final
with #
3 nM ^H-dexamethasone and vaiious concentrations of unlabelled ligands
concentration of 2 mg protein/ml) were equilibrated overnight at 5° 
I'
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(after dissolution in ethanol, the desired concentrations were obtained by 
a serial of dilutions with buffer A; final ethanol concentration was always
below 0.01%). Non-specific binding was measured by incubating the 
liver cytosol with a 500-fold excess of unlabelled dexamethasone. Bound 
and free hormone fractions were separated by incubation with an equal 
volume (v/v) of charcoal suspension for 10 min and centrifuged at 450g 
for 10 min. Radioactivity was measured in aliquots of supernatant by 
liquid scintillation spectrometry.
Preliminary experiments of cytosolic concentration and time 
dependency were carried out.
Binding constants (Kd and Bmax) were calculated using the 
Ligand curve-fitting programme (Munson & Rodbard, 1980).
c) Effects o f temperature on ^H~dexamethasone specific binding
To investigate the thermostability of the bound 
dexamethasone-receptor complex, cytosol was equilibrated overnight 
with ^H-dexamethasone (±500 nM unlabelled dexamethasone) at 5° and 
then transferred to 24° and 37° water baths. Aliquots were removed at 
intervals.
The effects of incubation at 37° on receptor binding constants 
were also investigated by measuring homologous competition for 
dexamethasone after 30, 60 and 120 min equilibration.
Results
a) Receptor affinity and concentration
The cytosolic protein concentrations and time-dependency results
are shown in Fig 21 and 22. They indicate that 2 mg/ml protein is the
.lowest concentration at which high specific binding can be detected and 
that at 16 h incubation at 5°, there is complete equilibrium of tire receptor- 
ligand binding.
The binding cui-ves for the various steroid ligands and the affinity 
constants are shown in Fig 23 and 24, respectively. ^H-dexamethasone
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binding was reduced to about half the control by equimolar unlabelled 
dexamethasone. In contrast, 50% reduction of ^ H-dexamethasone binding 
was caused by a 5-fold excess of unlabelled corticosterone and 40-fold 
excess of aldosterone. The antiglucocorticoid RU486 was also less 
effective (data not shown because they obscure the corticosterone results) 
with 6-8 times lower potency when compared to dexamethasone. The 
relative ^H-dexamethasone binding site affinities for the ligands was: 
dexamethasone = RU486 > corticosterone > aldosterone.
b) Temperature sensitivity o f receptor binding
The ^ H-dexamethasone-receptor complex was incubated overnight 
at 5° before being transferred to higher temperatures. At 24°, binding was 
constant over a period of 3 h (Fig. 25). At 37°, binding declined rapidly 
to near zero values at 1 h. To test whether this decline in specific binding 
at 37° reflected a change in affinity and/or a change in receptor 
concentration, binding characteristics were measured during longer term 
incubation at this higher temperature. Both receptor affinity and receptor 
capacity decreased with time at 37° (Fig. 26).
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cytosol from SD rats (means ±SE; n=6).
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Discussion %The aim of this method development was to devise a detailed 
protocol to study GR binding chai*acteristics in several rat models of
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genetic hypertension which had previously been shown to have an adrenal 
component in the pathogenesis of their high blood pressure (see section 
3).
According to literature reports, 16 h incubation at 5° had been 
shown to be necessary for a satisfactory liver cytosol glucococorticoid 
receptor binding (Howell & Lefebvre, 1989). As the cell number is 
important for a reliable binding assay, several protein concentrations were 
tested. As shown in Fig. 22, a concentration of 2 mg/ml was optimal and 
this made possible to cairy out binding studies with multiple ligands in 
individual rats.
The cross-competition binding studies were set up to study the 
affinity of different ligands for ^H-dexamethasone specific sites and to 
identify whether these affinities might differ between strains of rat. As 
shown in Fig. 23, in the hierarchy of differences dexamethasone has the 
highest affinity. In order to avoid degradation of the receptor-ligand 
complex both at 5° and 37 ,^ the incubation buffer (buffer A) contained a 
high concentration of sodium molybdate. This stabilizes the 
glucocorticoid receptor-Hsp complex, maintaining a state of high affinity 
of the GR (Leach et al., 1979). Despite the high concentration of sodium 
molybdate, the specific ^H-dexamethasone binding after 60 min 
incubation declined rapidly at 37°, less so at 24° and hardly at all at 5°.
Reduced binding by prolonged incubation at 37° could be
attributed to protein dénaturation or transformation of the receptor from
a high to a low affinity state. As already discussed, glucocorticoid
receptor affinity depends on whether the receptor is complexed with heat
.shock proteins (Pratt, 1993) (for details see section 1.4.2). Testing 
whether the decline in specific binding observed in the thermal stability 
experiments reflected a change in GR capacity and/or affinity, the
competition studies of labelled binding after prolonged incubation at 37° 
showed a receptor affinity decline in a time-dependant fashion. Although 
this was not dramatic in the Sprague-Dawley, it should be an useful tool 
to test receptor binding where the underlying biochemical alteration may 
be receptor thermolability (Bronnegard et al., 1986; Werner et al., 1992).
In summary, a protocol to study glucocorticoid receptor in rat 
liver cytosol has been developed. The cross-competition, thermal stability 
and thermolability studies provide a comprehensive range of tests to 
identify a) any of the biochemical abnormalities which characterize an 
impaired glucocorticoid receptor (e.g.,as reported in glucocorticoid 
resistance syndrome) and b) an increased receptor affinity for steroid 
ligands. This protocol has been used in a study accepted for publication 
(Panarelli et al., 1995, see page 228).
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Chapter 3 GLUCOCORTICOID RECEPTOR BINDING 
MEASUREMENT IN RAT MODELS OF GENETIC 
HYPERTENSION
Abnormalities of steroid metabolism and secretion in rat models 
of genetic hypertension have been reviewed in the first chapter. Several 
obseiwations suggested that glucocorticoid hormones might contribute to 
the higher blood pressure in these rats:
a) rats are particularly sensitive to blood pressure raising effects 
of glucocorticoids (Tonolo et al., 1988);
b) the adrenal glomerulosa is necessary to initiate and sustain 
blood pressure in many strains of spontaneously hypertensive rat;
c) in some strains of rat, including Okamoto SHR but particularly 
the Milan rat, plasma corticosterone concentrations are elevated.
The efficacy of a hormone depends not only on its concentration 
at target tissue level but also on the efficiency and concentration of its 
receptor mechanism. Several endocrine abnormalities are characterised 
by normal or supernormal hormonal levels but with a defect in the 
receptor activity (e.g. primary cortisol, insulin and androgen resistance). 
It is similarly possible that in genetic hypertension in the rat, a receptor 
abnormality could be responsible. The following experimental section has 
investigated whether two widely used animal model of genetic 
hypertension have a defect in glucocorticoid receptor binding.
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3.1 Alteration in the binding characteristics of glucocorticoid 
receptor in mononuclear leucocytes from spontaneously hypertensive 
rats (SHR) as compared to Wistar Kyoto rats (WKY)
3.1.1 Introduction
A number of strains of rats with inherited hypertension are 
available of which the spontaneously hypertensive rat (SHR) has been the 
most intensively studied. Intact adrenal glands are crucial to the rise in 
blood pressure but the essential component of adrenocortical function has 
not been identified (Brownie et al., 1990). Measurement of plasma 
adrenal steroid hormone levels have yielded conflicting results.
This part of the study measured glucocorticoid receptor binding 
characteristics in mononuclear leucocytes from SHR compared to WKY 
in order to obtain preliminary information on glucocorticoid receptor 
activity.
3.1.2 Methods
Adult male SH and WKY rats were anaesthetized with sodium 
phenobarbitone. Blood samples (7-10 ml) were taken from the aorta and 
anticoagulated with sodium citrate. Anticoagulated blood was centrifuged 
at 600g for 10 min. Cells at the interface between red cells and plasma 
were collected and pooled with others of the same strain (samples from 
4-5 SH or WKY rats). These pooled samples were mixed with PBS. 
Mononuclear leucocyte separation and whole cell GR assay were as 
described in section 2.2.1 and 2.2.2, respectively.
3.1.3 Results
The affinity of the mononuclear leucocyte glucocorticoid receptor 
for the synthetic glucocorticoid dexamethasone and the number of binding 
sites per cell are shown in Fig. 27. The SHR cells had a significantly 
higher affinity for the glucocorticoid. Fewer sites per cell were observed
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but this was of borderline significance.
involve changes in adrenergic receptor (Russo et al., 1990; Haigh & 
Jones, 1990) and phospholipase A2 activities (Bailey, 1991). In the SHR, 
widely used as a model for essential hypertension in man, many genetic 
loci are probably implicated in the rise of blood pressure (Rapp, 1982; 
Ikeda et al., 1991; Jacob et al., 1991; Hilbert et al., 1991; Ben-Ari et al., 
1989). However, intact adrenocortical function is essential to the 
development of hypertension and glucocorticoid and mineralocorticoid 
components aie required (Ruch et al., 1984; Morris& Kenyon., 1983). 
Kenyon et al. (1993) reported that basal plasma concentration of 
corticosterone was higher in young SHR and maximal stimulation with 
ACTH achieved a much higher concentration than in control WKY rats. 
It was suggested that these differences were due to increased 
responsiveness to ACTH. Others have suggested that pituitaiy ACTH 
activity is greater in SHR.
In mononuclear leucocytes from SHR, glucocorticoid receptors 
had a higher affinity but there were fewer receptor than in cells from 
WKY rats. Similar results were described in stroke-prone SHR by Laux 
et al. (1989). If the receptor is identical in all target tissues, this implies 
that tissues, such as brain and vascular smooth muscle, which are more 
important in blood pressure control, are also altered. A possible 
explanation of this finding could be a mutation in the glucocorticoid 
receptor gene.
3.1.4 Discussion
Glucocorticoid administration at very low doses raises blood 
pressure in genetically normotensive rats in 2-4 weeks (Tonolo et al.,
1988) by a mechanism which is not completely understood but may
g
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The second important point is the observation that the number of 
receptors per cell may be lower in mononuclear cells from SHR compared 
to the control WKY. This may represent a down-regulation mechanism 
due to the higher affinity of the receptor to steroids as indicated by the 
lower Kd values. In normal human subjects, excess glucocorticoid 
hormone causes a fall in leucocyte receptor site number coupled with a 
rise in affinity, similar to that found in SHR in this study (Schlecthe et al.,
1982). The down-regulation of the receptor is due to a fall in transcription 
rate and an increase in receptor protein turnover but not that of mRNA 
(Dong et al., 1988). However, no such changes were reported during 
normal diurnal variation in human glucocorticoid levels, nor were any 
changes detected in patients with Cushing's syndrome (Junker, 1983).
In summary, this preliminary study suggested altered 
glucocorticoid receptor binding characteristics in SHR compared to 
WKY. However, the main technical limitation was the need to pool blood 
sample from several rats of the same strain in order to obtain a sufficient 
cell number to carry out the whole cell GR assay. Further study of 
receptor specificity and affinity in individual rats was desirable. As
'reported in section 2.2.4, a protocol to study different aspects of the GR 
binding characteristics has been developed using liver cytosol from 
Sprague-Dawly rats. This was applied to a more detailed study of possible 
binding abnormalities in SHR.
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3.2 Differences in temperature-sensitive receptor binding of 
glucocorticoids in spontaneously hypertensive and normotensive 
Wistar Kyoto rats
3.2.1. Introduction
In the previous section, it was shown that leucocytes from SHR 
bound the synthetic glucocorticoid dexamethasone with greater affinity 
than those from WKY rats. The next part of the study was designed to 
assess the specificity, temperature sensitivity and thermolability of GR in 
individual rats using liver cytosol from SHR and WKY. I3.2.2 Methods
Tissue preparation, binding studies and effects of temperature on 
°H-dexamethasone specific binding in SHR and WKY were as described 
in the section 2.2.4.
Statistical comparisons were made by Students^ test for paired
data.
■i
3.2.3 Results
The effect of dexamethasone, RU486, corticosterone and ■
aldosterone competition for specific ^H-dexamethasone binding sites at 
5° are shown in Fig. 28 (RU486 data are not plotted because obscure 
corticosterone results); the affinity constants for these three steroids are 
compared in Fig. 29. Dexamethasone showed the highest binding affinity 
and aldosterone the lowest. There were no differences between SHR and 
WKY prepar ations at this temperature either in affinity or concentrations 
of receptors.
Preliminary studies indicated that equilibrium was achieved 
quicker at 37° (30-60 minutes). However, binding affinity was 
significantly less at 37° than at 5° in both species. Moreover, with
'prolonged incubation at 37“, binding decreased even further despite the
i
Î
3
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presence of molybdate. This decrease was not a function of the number 
of receptors, rather the affinity for dexamethasone was reduced. When 
comparing SHR and WKY, the decrease in affinity for dexamethasone in 
WKY was greater than that in SHR. Differences in affinity between 
strains achieved significance at 30 and 60 minutes of incubation (Fig 30). 
WKY rats had a higher concentration of binding sites (457+144 fmol/mg 
protein) than SHR (326±70 fmol/mg protein) but this was not significant.
The thermostability of the dexamethasone-receptor complex was 
assessed in a further experiment. After overnight equilibration at 5°, the 
dexamethasone-receptor complex dissociated only slowly when the 
temperature was raised to 24°; approximately 80% of basal binding 
persisted at 3h. At 37°, specific binding decreased rapidly and virtually 
zeroed at 90 min. However, there were no differences in dissociation rate 
between SHR and WKY cytosol preparations (refer to Fig. 31).
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3.2.4 Discussion
Hypertension in SHR depends at least partly on the activity of the 
adrenal cortex. While glucocorticoid (i.e. corticosterone) levels have 
frequently been reported to be higher than in WKY rats, no such elevation 
of the principal mineralocorticoid, aldosterone has been found (Brownie 
et al, 1990). This is suggestive of a glucocorticoid-type hypertension. 
The previous section described a higher dexamethasone-binding affinity 
in the leucocytes of SHR compared to WKY rat cells when measured at 
24°. This confiimed a previous observation by Laux et ah, 1988 in stroke- 
prone SHR. SHR leucocytes showed fewer binding sites, possibly due to 
down-regulation by the higher corticosterone levels mentioned above. 
The resultant of high agonist concentration, higher affinity but fewer 
binding sites in terms of real glucocorticoid activity is difficult to 
compute.
With the small number of leucocytes available from individual 
rats, detailed studies of the leucocytes receptor are not possible and a 
more abundant source is necessary. Therefore, the liver cytosolic receptor 
was studied. At 5°, no differences between SHR and WKY rat 
preparations was observed. Moreover, there were no distinguishable 
differences in receptor specificity.
Clear differences could however be demonstrated at the higher, 
physiological temperature of 37°. Dexamethasone-binding affinity at 30 
min was markedly reduced in both SHR and WKY preparations 
compared with overnight incubation at 5°. At 37°, SHR cytosol had a 
higher binding affinity and a lower concentration of binding sites than 
WKY cytosol, confirming previous results in leucocytes at 24°, Affinity 
deteriorated with time in both preparations but that of the SHR cytosol 
remained higher than that of WKY cytosol. This difference was not due 
to different rates of steroid-receptor complex dissociation; both 
preparations showed identical dissociation rates at both 24° and 37°.
I
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The agonist-free glucocorticoid receptor is part of a
heterocomplex with several heat shock proteins (Hsp) and other smaller
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molecules. The Hsp are necessary for the coiTect folding of the receptor
protein and are important in determining its binding characteristics
(details discussed in section 1.4.2). Although the stabilising influence of
.molybdate was present in the incubation medium, a plausible explanation 
of these results is that at the higher temperature, the complex dissociates 
and that this occurs more slowly in the SHR. This in turn might be due to 
differences in Hsp and/or interaction with the receptor protein between 
strains and thus account for the higher residual binding affinity of the 
SHR preparation at 37°.
Other authors (Malo et al., 1989; Hamet et al,, 1992) have 
described the phenomenon of temperature sensitivity in genetically
hypertensive rats and mice and have demonstrated that this cosegregates 
with blood pressure in F2 and backcross populations. They have also 
identified a gene polymorphism for Hsp70 between SHR and WKY rats 
which might account for the observed differences in thermosensitivity of 
dexamethasone binding. However, a later detailed study of co segregation 
of the polymorphism with blood pressure in F2 SHR x WKY rat crosses 
failed to find any association between these variables (Lodwick et al.,
. ■;1993). This study has been accepted for pubblication (Panarelli et al.,
1995, see page 228).
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3.3 Evidence of impaired giucocorticoid receptor affinity in the Milan 
hypertensive rat
125
3.3.1. Introduction
Among the more recent inbred strains of rat which develop 
hypertension in a genetically-determined manner is the Milan 
hypertensive rat (MHS) and its simultaneously selected normotensive 
strain (MNS). Detailed studies (Baer & Bianchi, 1978; Bianchi et al.,
1984) have shown that hypertension in the Milan rat cosegregates with 
smaller kidneys containing smaller nephrons and that hypertension can be 
transferred to MNS by transplanting them with MHS kidneys. Also, clear 
differences in erythrocyte and proximal tubular- cell electrolyte 
metabolism have been identified between strains.
Adrenocortical structure (Mantero et al., 1983) and function is 
also different between strains. Corticosterone secretion rate and plasma 
concentration are higher in MHS than MNS (Bianchi et al., 1984; Ferrari 
et al., 1985; Mantero et al., 1983; Stewart et al., 1993) and, in older rats, 
aldosterone excretion rate is also raised. In keeping with the suggestion 
of greater mineralocorticoid activity, MHS have higher plasma volume 
and total body sodium content and suppressed renin (Fraser et ai., 1994).
The relationship between raised corticosterone secretion and 
hypertension is unclear. If, as has been suggested (Fraser et al., 1994), the 
increase is due to 11 p-hydroxylase activity, then in an otherwise normal 
system, increased glucocorticoid secretion should be compensated by 
reduced ACTH secretion. Alternatively, high corticosterone secretion rate 
is perhaps sustained because glucocorticoid receptor affinity is impaired 
in MHS. This latter hypothesis has been tested in this section. If true, one 
might expect that normal glucocorticoid activity is maintained but that the 
excess plasma corticosterone concentrations needed to satisfy impaired 
Type n  receptor might lead to inappropriate occupancy of Type I 
receptors, causing the high volume, high sodium hypertension
I  1
I
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characteristic of the MHS rat. A precedent exists in the hypertension of 
human subjects with primaiy cortisol resistance due to mutations of the 
glucocorticoid receptor gene; this is also accompanied by salt and water 
retention (Arai & Chrousos, 1994) (see also section 1.4.4). The affinity of 
the liver cytosol glucocorticoid receptor for several ligands was therefore
compared between MHS and MNS rats. Since impairment of receptor
binding may be secondary to thermal instability of the receptor complex 
(Werner et al., 1992), comparison was made of differences in binding 
over a range of temperatures.
3.3.2 Methods
Tissue preparation, binding studies and effects of temperature on 
^H-dexamethasone specific binding in MHS and MNS were as described 
in the section 2.2.4.
Means ± standard errors (SB) were calculated for each group. Data 
from individual MHS or MNS cytosol prepared and analysed on the same 
day with the same reagents and incubation conditions were compared by 
Student's t test for paired data.
3.3.3 Results
.a) Receptor affinity and concentration
The binding curves for the various steroid ligands are shown in 
Fig. 32 and the affinity constants in Fig. 33. Corticosterone and 
aldosterone compete less effectively at 5° for specific ^H-dexamethasone 
binding sites in the liver cytosol of MHS compared with MNS rats. 
RU486 was also less effective (data not shown because they obscure the 
corticosterone results). For all ligands, including dexamethasone, affinity 
was significantly lower in MHS liver than in MNS liver but there was no 
difference in glucocorticoid receptor concentration. The relative affinities 
for the ligands were similar between strains (dexamethasone > 
corticosterone = RU486 > aldosterone) but the discrepancy between the
I
126
MHS and MNS preparations was greatest for the lower affinity ligand. 
This is illustrated in Fig. 34 where the slope of the regression of MNS 
affinity on MHS affinity for the ligands was significantly less than 45°. 
Thus for dexamethasone, the highest affinity ligand, the affinity constant 
was approximately 40% higher in MHS liver than in MNS liver. For 
aldosterone with the lowest affinity, the difference was approximately 
340%. Thus, at 5° MHS rat hepatic glucocorticoid receptors have a lower 
affinity than those from MNS rats.
b) Temperature sensitivity and thermolability of receptor binding
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The ^H-dexamethasone-receptor complex was equilibrated 
overnight at 5° before being transferred to higher temperatures. At 24°, 
binding was constant over a period of 3 h (Fig. 35). At 37°, binding 
declined rapidly to near zero values at 1 h. There was no difference 
between MHS and MNS preparations. To test whether this decline in 
specific binding at 37 reflected a change in affinity and/or a change in 
receptor concentration, binding chaiacteristics were measured during long 
term incubation at this higher temperature. Both receptor affinity and
receptor capacity decreased with time at 37° but there was no significant 
difference between MHS and MNS preparations (Fig. 36).
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3.3.4 Discussion
Previous studies have shown that MHS rats have a high body 
sodium content with increased extracellular fluid volume and plasma 
AN? levels characteristic of hypermineralocorticoidism (Fraser et ah,
1994). However, concentrations of the mineralocorticoid-type steroids,
DOC and aldosterone, are not elevated in MHS during developmental 
stages although they may be raised in older rats.
Under normal circumstances, 11P-HSD analysis activity might 
be expected to protect Type I adrenocorticoid receptors from endogenous
corticosterone. Stewart et ah (1993) considered the possibility that 11- 
pHSD might also be affected in MHS. They noted that expression of 
11-PHSD activity in the liver was reduced in MHS but not in the kidney. I
I.
Moreover, these studies were carried out more than 5 years ago at a time 
when it was not appreciated that there are two types of 11P-HSD. In the 
liver, the type 1 enzyme predominates and facilitates the net conversion 
of 11-dehydrocorticosterone to corticosterone. In the kidney, the type 2 
enzyme, with different co-factor requirements, has a marked preference 
for corticosterone catalysing its conversion to 11-dehydrocorticosterone. 
The level of expression of this latter enzyme in MHS kidney has not 
been assessed. If it were reduced, as the type 1 in the liver, this could 
contribute to the mineralocorticoid activity of corticosterone in MHS.
It is theoretically possible that glucocorticoid binding could be
affected by 11-pHSD activity. Reduced activity of the MHS liver type 1
enzyme would favour the inactive 11-dehydrogenated product. However,
the hierarchy of difference in ligand binding between strains
(dexamethasone < corticosterone  ^ RU 486 < aldosterone) does not
correspond to the specificity of the enzyme. Also, binding studies were
carried out in cytosol whereas the liver enzyme is microsomal. Binding
.efficiency for dexamethasone and corticosterone in rat liver cytosol is not 
affected by carbenoxolone, an inhibitor of 11-PHSD (Kenyon et al., 
personal comunication). Since the activity of the enzyme is regulated by
133
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glucocorticoids, reduced glucocorticoid receptor binding affinity might 
explain the lower enzyme activity in the MHS liver. However, 
corticosterone secretion rate and plasma concentration have frequently 
been shown unequivocally to be raised in MHS rats throughout life. These 
data are compatible with the suggestion of glucocorticoid excess 
combined with impaired glucocorticoid receptor binding which in turn is 
responsible for the mineralococoticoid-type hypertension seen in these 
animals. More recent cosegregation studies (Kenyon et al,, 1994) are 
contradictory whilst confirming glucocorticoid impairment. Genetic 
analysis of the OR gene suggests that the MHS OR genotype is associated 
with low blood pressure. The nature of the impairment is unlike other
human examples. It is not associated with thermolability or differences in 
temperature-sensitive binding of ligands nor is there evidence of 
mutations in the hormone-binding domain (Heeley et al., personal 
comunication). A polymorphism in the N-terminal region in exon-2 of the 
GR-gene could account for the subtle differences in binding observed.
Impaired receptor binding requires raised agonist levels for normal 
activity. In human subjects with the syndrome of glucocorticoid 
resistance, high circulating cortisol levels are achieved by increased 
ACTH drive which also stimulates DOC secretion (Ai'ai & Chrousos,
1994). Thus, patients develop hypertension with a hypokalaemic 
alkalosis. High cortisol levels may also contribute by interacting directly
•'Vwith Type I (mineralocorticoid) receptors. No comparison of ACTH 
concentrations has been made in Milan rats but DOC levels are not 
different between strains. However, the level of 11 p-hydroxylase activity 
converting DOC to corticosterone appears to be higher in MHS rats 
(Fraser et ah, 1994).
This study showed that the MHS liver cytosolic receptor has a 
lower affinity for the synthetic glucocorticoid, dexamethasone, than that 
of the MNS rat liver at 5 . The difference was greater for the natural 
ligand, corticosterone. Receptor concentration was not different between
strains. Human glucocorticoid resistance has been shown to be caused by 
a variety of genetic defects in the receptor complex. These include point 
mutations at or near the steroid-binding domain. The guinea pig also 
exhibits glucocorticoid resistance due to mutations in this region 
(Keightley & Fuller, 1994) but the blood pressure implications of this are 
not known. Moreover, the obese Zucker rat, genetic model of juvenile 
onset obesity, has a decreased GR affinity in the anterior pituitary (Kd of 
obese rats was 50% greater than that in lean rats) suggesting a reduced 
feedback inhibition of corticosterone at the anterior pituitary. A similar 
trend was observed in liver cytosol (White & Martin, 1990). Although 
there was no report on blood pressure, this may suggest a possible 
relationship between glucocorticoid receptor and obesity (Weaver et ah, 
1992) and between obesity and hypertension.
Werner et al. (1992) also described human cases of increased 
receptor complex thermolability resulting in high turnover rates. In the 
current study, no evidence of differences in thermolability between MHS 
and MNS preparations has been found. This contrasts with the previous 
study of the SHR receptor where affinity was lower than that of the WKY 
rat receptor at 37® but not at 5® (section 3.2.). The detailed structure of the 
Milan rat glucocorticoid receptor gene has not yet been elucidated; 
although polymoiphic differences between the MHS and MNS gene have 
been identified (Kenyon et al., 1994), their functional significance 
remains to be tested.
In summary, the results of this study suggest that the increased 
secretion rate of corticosterone in the MHS rat compared with the MNS 
rat is due to impaired glucocorticoid receptor binding due not to structural 
differences of or interaction with heat shock proteins but more probably 
to a modified ligand binding domain. The maikedly raised corticosterone 
levels may then contribute to hypertension by interacting with Type I 
receptors to cause sodium retention. In terms of blood pressure regulation, 
GR impairment appears to have a negative effect on blood pressure
135
because o f reduced glucocorticoid activity.
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Chapter 4 GLUCOCORTICOID RECEPTOR AND
CARDIOVASCULAR VARIABLES IN NORMOTENSIVE MALE 
VOLUNTEERS
4.1 Are glucocorticoid receptor genotypes associated with differences 
in binding characteristics and/or glucocorticoid responses?
4.1.1 Introduction
Glucocorticoid hormones (i.e. cortisol in man) have widespread 
effects on cardiovascular function and they probably raise blood pressure 
directly by a Type II receptor-dependent mechanism. In the earlier 
sections, the evidence has been reviewed that excess adrenal steroid 
secretion (e.g. Cushing syndrome) can cause hypertension and accelerated 
development of arterial disease. Glucocorticoid receptors are present in 
the cells of tissues involved in cardiovascular homeostasis (e.g. brain, 
kidney, blood vessels, heart). Following binding of glucocorticoid to the 
Type n  receptor, the receptor-steroid complex binds to genetic control 
elements and alters gene expression (Miesfeld, 1990; Allan et al., 1991).
In the case of mineralocorticoid excess, there are a number of 
interrelated causes in the pathogenesis of hypertension including volume 
expansion, vascular hypertrophy, sensitisation to vasoconstrictors and 
increased contractility of vascular smooth muscle due to changes in 
membrane cation permeability. Glucocorticoid activity is less well 
understood. Using an animal model of glucocorticoid-induced 
hypertension created by low dose infusion of dexamethasone (Tonolo et 
ah, 1988), a number of possible mechanisms have been investigated: 
altered G-protein regulation, reduced synthesis of vasorelaxants such as 
prostacyclin, atrial natriuretic peptide and nitric oxide (refer to table II, 
section 1.4.2), increased vascular reactivity to catecholamine (Russo et 
ah, 1990), altered cation transport (Bastl et ah, 1991; Berk et ah, 1988; 
Freiberg et ah, 1982), and activation of the renin-angiotensin system. II
Î
I
Although all of these factor are regulated by glucocorticoids, it is not clear 
that any one mechanism is of overriding importance in blood pressure 
control. However, some of these influences are exerted at concentrations 
of glucocorticoid hormones which are less than those required to produce 
symptoms of Cushing's syndrome. This appaient increase in sensitivity to 
glucocorticoids could be due to an abnormality at the receptor level.
Support for this hypothesis derives from both in vitro studies (alteration 
of the glucocorticoid receptor binding by modification of the GR gene in
138
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the binding domain) and clinical observations (i.e. primary cortisol
■resistance syndrome). ■Watt et al. (1992) reported that polymorphisms of the
glucocorticoid receptor gene appear" to be associated with a tendency to 
develop hypertension. When genomic DNA is digested with the 
restriction enzyme Bel I, a cDNA probe to the glucocorticoid receptor ;
identifies two alleles ("a" and "A"). Young adults with a familial 
predisposition to hypertension showed a small but significant increase in 
plasma cortisol concentration and a higher frequency of the genotype 
"AA" than in controls although this only achieved a statistical probability 
of 10%. However, when subjects with the genotype A A and aa were 
compared, those with AA had significantly (p<0.05) higher blood 
pressure scores. It could be argued of course, that a raised cortisol 
concentration is a consequence of a less effective receptor subtype leaving 
total glucocorticoid activity unchanged but one of the many factors which 
respond to cortisol, renin substrate concentration, is also raised. Similarly, 
it has been reported that plasma corticosterone concentrations and renin 
substrate levels are elevated in SHR compared to WKY rats. Differences 
in affinity and number of glucocorticoid receptors in SHR leucocytes 
compared with those of WHY rats has been noted by others and in the 
initial experimental pai’t of this thesis (refer to section 3.1.).
In a separate study of the same polymorphism , Weaver et al.,
I
(1992) reported that inheritance of the A allele was associated with ■I
ihyperinsulinaemic obesity; blood pressure in this study was not reported. 
However, this condition frequently coexists with essential hypertension 
and is a risk for cardiovascular disease. Thus, both studies support the 
notion that genetic variability of the glucocorticoid receptor is associated 
with phenotypic changes implicated in the development of high blood 
pressure and atherosclerosis.
It is appropriate therefore to investigate more thoroughly the 
possible physiological and pathophysiological links between genotypic 
differences in glucocorticoid receptors, plasma glucocorticoid 
concentrations, glucocorticoid responsiveness and blood pressure 
regulation.
4.1.2 Methods
a) Subjects
Sixty-four Caucasian normotensive males aged 18-40 years were 
sampled. All subject were admitted at 08.30 h and blood samples were 
collected after the subjects had been lying at least 30 min. Family history 
of hypertension, diabetes mellitus and other cardiovascular diseases was 
collected. Blood pressure was measured (by random zero 
sphygmomanometer) twice on the same occasion in each individual, 
supine and after standing for at least 5 min. The mean of the two readings 
was used for analysis. Mean arterial blood pressure was calculated from 
the foimula MAP=DBP+l/3 (SBP-DBP), where DBP and SBP were the 
diastolic and systolic blood pressure respectively. Height and weight were 
measured to calculate body mass index (BMI) from the formula BMI= 
weight/height^. Body fat determinations were carried out by skinfold 
caliper, measuring representative sites throughout the body. These 
measurements were then put into a mathematical equation (which 
considers adjustments for age and sex of the subjects) to estimate the 
body's density and then this was converted to percent of fat. Venous blood 
was then drawn for routine biochemical and hormonal measurement.
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DNA extraction and HML separation. A 24 h urine specimen was 
obtained prior the visit to the clinic. Finally, a skin vasoconstriction test 
was carried out in each individual. If the volunteer was a smoker, he was 
requested to abstain for at least 24 h before and during the test.
b) Procedures
Hormonal and routine biochemical measurements, DNA 
extraction and glucocorticoid receptor genotypical chai'acterization were 
as described in the sections 2.1.6 - 2.1.9. HML preparation, glucocorticoid 
receptor binding measurement in mononuclear leucocytes and in vitro 
responsiveness to glucocorticoid in terms of lysozyme inhibition assay 
were as described in the sections 2.2.1, 2.2.2 and 2.2.3. The in vivo 
responsiveness to glucocorticoid as skin vasoconstriction test was as 
described in the section 2 .1.10.
c) Statistics
The means±SEM for each variable were calculated for the three 
glucocorticoid receptor genotypes and compaied by Student's t test.
140
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4.1.3 Results (for overall summary refer to tables VII,VIII, IX, X 
and XI)
a) RFLP analysis
RFLP phenotypes after Bel 1 digestion and Southern blotting are
shown in Fig. 37. The RFLP analysis of GR identified 6 subjects 
homozygous for the allele "A", 7 homozygous for "a" and 51 were 
heterozygous. This distribution is comparable to findings in other studies. 
The expectation was that the number in each of the two homozygous 
groups would be nearer 15.
b) Clinical measurements
Thirteen subjects were smokers: 1 was in the group of subjects 
homozygos for the allele "A", 2 were in the group of homozygous for "a" 
and 10 were in the group of heterozygous.
Twenty eight subjects had a family histoiy of cardiovascular
I
.3
volunteers ranged from 2-90 ng (mean±SEM 2.8±3).
The AA group showed a statistically significant higher sensitivity
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disease of which 2 were AA, 3 aa and 21 were Aa. The remaining 36 
subjects had no family histoiy for cardiovascular disease: 4 subjects were 
AA, 4 aa and 27 were heterozygous.
Systolic, diastolic and mean blood pressure, body mass index and 
fat distribution from skin-fold thickness measurements were not different '
between the three GR genotypes.
c) Whole-cell GR binding■ Steroid binding studies were carried out in suspensions of 
mononuclear cells by homologous competition for ^H-dexamethasone 
specific sites. In the overall group of 64 male volunteers, the mean±SEM 
number of receptor sites was 5537±209/cell (range 2322-8879); the 
affinity was 6.2±0.35 nmol/1 (range 3.9-14 nmol/1).
Although a lower apparent affinity for dexamethasone was 
measured in the group AA, there was no significant statistical difference 
between genotypes.
d) In vitro responsiveness to glucocorticoid: lysozyme inhibition test
Inhibition of lysozyme synthesis by dexamethasone in 
mononuclear leucocytes (section 2.2.3) was used to assess in vitro
responsiveness to glucocorticoids.
When comparing GR genotypes, IC50 values tended to be higher 
in subjects with the AA genotype compared to aa but again this was not 
statistically significant.
e) In vivo responsiveness to glucocorticoid: skin vasoconstriction test 
The skin vasoconstriction test was used to investigate 
responsiveness to glucocorticoid in vivo. Various doses of budesonide 
were applied to the skin of the flexor aspect of the forearm and the degree 
of blanching was assessed after 18 h (see Fig. 38 and section 2.1.10). For
t
r :? -'
§
.,4 ;
each volunteer, a response curve was plotted and an ED50 value for 
budesonide calculated. The EDgo values for budesonide in the 64 male
%
!
to budesonide com pared to aa (p=0.02).
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Fig. 37: Example of Southern blotting. This is an autoradiograph of a 
Southern blot probed with glucocorticoid receptor cDNA (OB7). Band 
sizes are in kilobases and 3 phenotypes are shown, 4.5:4.5 (AA), 4.5:2.3 
(Aa) and 2.3:2.3 (aa). Lane 9 and 19 show 4.5:4.5, lane 1, 10 and 13 show 
2.3:2.3.
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Fig. 38: Skin vasoconstriction test. Representative blanching response to 
various concentrations of budesonide applied topically.
144
1 in oo +1 CNœ  U ^  +i oo zgI oo M +î \oS  z Ch M 'u
Ph1 MD^  +î cqrS +î cq^  +î enc2 Z
I o \ PS  +! §  = en 2-Z  fi o  2  r—l 4-1
1 in+1 cq+i oo+i Z Z
1 z  +1 (N ^z  z Z  Z en CN ZZ  z
1 CN
z  +1
m  oo
2 9
c  ^ vq 
Z  +1
oo Ch vo“ 9
1 s  +i
Ch
S 9
Ch oq
5  Z
V-)r-' en
^  Zï lJl <N CN en ooCN
1 O CN en
WC
vq R il ai m Z Rr) U
II n T*<4% i  ï ? !
.yI:V3I
g
a
i  •3 <0WDil
ce T3 ^ OI73II
l io
i l^  aV) oP00 -q
m «
S
I<uI
gz
m
,K .|-
g'
"%
I
I
I1 Î i i ^  o osi 9 c n  CNs i 9 VO i n^ Z
l l î
( N  c q  
\ d  c n
n  z
VO <N
2  H 3  =z  Z
M C h  oS 3 i T-^ * 09  9 2  9 s i
J r . CO§?9 O v  OVo o  Z s i z o v  c q  v qM  z
x f  » n: s 9 i n  O2 9 8  ^  qr—1 '^l c S2  9
d o  
§ 1
VO
3 9
i n^  2  
( N  +1
m  c n  
o q  o  
( N  +1 3 9
M »r> +1 3o'=d' +1 CN+1 c n3 9
Li VOs l i Ov r -  o o VO VO% 9 rn  i n^  Z
Li c q  i n  a i^  z CX) T f  Oz  z v q  o v  c nz  z g ;
l è î
VO O
3 %
( N  O3 9 CN o3  Z 83 9
Li i noc n  +1 o3 9 3 9 CC|3 9
L i = 1 2 9
VO
S  9 z z
r -m  ( N
=  9 2 9
o o  
o o  CN
3 Z
m 8
z z
3l s3 9 <N" 5 m3 9 " S
i t
P d  O r a s i a  a s i
:
a
1.
Il
a iPh X
%fK
> n tJ
S os 7-4X
!
î l% X
u
k (UII
2 9
V Io  O
N  Z
si29
i>en
§;
ÇN C'' Tt"39
en VDdVO +1
wvO^ Q
Z z
ens s 39
. o i29
?
en m
3 9
-d" V) enZ z
un
S29
R9
voVO CNq  oVO +1
a"à
en
^  Z
RVO *—i29
s i
2 § 29 ç
ooenen
Z
t~- CN oq o  un +1
00I
§
o3
I
"o
%(Ui
i ! m Z n 2M +i
CN
2 9
VOOO CN
9 9
1
i f i l si ooq o O +1 o= S2 9
xj-
5 9 m Z VO im Z
inr- Ov m +1
l i r- dm Z \q Tf oiZ Z dcn Z inCN Ov9  +i
I I VO OV2  z s i o in mz  z CNs l
2<
IÎ ov Ovz  +1 q ovCN +1 Ov ov2  Z r-i q CN +1
p&(
i î
mHtf vn2  Z 3'^2  Z
(N^ Ov +1
VO CN99
i
l l
S 8
3 9
8 8
3 9
'ej*2  'êq d o +1
vq (8 8  
3 9
11 q CN 0vd+1 o vq  ^cnz  z oq -N- vdZ Z
I t 5  a d l>§ a ?1
00-4"
3
i
I
II
I
Jw
l a ­
s'I •vt -  cn +1
O  cn un unS Z
o>îî vo
en
N Z
CN un o
<N +1
s i
r - ,  O  +1
s i
oo en C-'CN O Tf enCN T—4 CTi un+1 un +1 un
S
(77S ë
enCN +i
CN
3 %
en
vd Z
? !
4.1.4 Discussion
Endogenous glucocorticoids (i.e., cortisol in man and 
corticosterone in rats) can bind to two types of receptor. The Type I or 
mineralocorticoid receptor evokes effects on salt and water metabolism, 
the Type H or glucocorticoid receptor is conventionally linked to effects 
on intermediaiy metabolism (for details refer to section 1.2.1). However, 
Type n  receptor responses can involve changes in electrolyte metabolism 
too (Berk et al., 1988; Bastl et al., 1991; Freiberg et al, 1982). Normally 
the access of cortisol and corticosterone to Type I receptors in the kidney 
and other tissues is prevented by the activity of the 11 p-hydroxysteroid 
dehydrogenase converting cortisol to cortisone and corticosterone to 11- 
dehydrocorticosterone (Edwards et a l, 1988).
In the literature review sections, it was emphasized that 
glucocorticoids, either via Type I or Type II receptors, can cause an 
increase in blood pressure. Moreover, two separate studies associated a 
particular RFLP for GR with hypertension (Watt et al, 1992) and 
hyperinsulinaemic obesity (Weaver et al, 1992). Because no abnormality 
of GR function had been identified, the main purpose of the current study 
was to investigate whether genotype valuations of Type U receptor aie 
associated with altered receptor function which in turn might lead to 
variations in blood pressure.
The GR genotypes in this study were based on a RFLP after 
digestion of genomic DNA with the enzyme Bel I. The restriction site for 
this enzyme appears to be a non-coding region at the 5' end of the gene 
(Hollenberg et al, 1985). It is by no means certain that the amino acid 
sequence of the receptor is different in the three genotypes. So far there 
are no data on the effect of mutations within the flanking region of GR 
gene on receptor function. It could be that in studies where the association 
of the AA genotype with hypertension and obesity have been 
demonstrated, the polymorphism may merely have been a marker of a 
quite different genetic abnormality of metabolism/caidiovasculai" function
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(i.e. linkage disequilibrium).
The whole-cell binding assay did not show differences in GR 
binding chaiacteristics between genotypes nor was the lysozyme 
inhibition test able to distinguish differences although it is a particulai’ 
sensitive index of glucocorticoid activity (refer to section 2.2.3). In 
contrast to the in vitro tests, greater sensitivity to topical budesonide was 
observed in vivo in subjects homozygous for the larger allele, A. 
Vasoconstriction, evaluated as degree of blanching, was obtained with 
lower doses of steroid in those with the AA compared with the aa 
genotype. There are three possible reasons for the discrepancy between in 
vitro and in vivo results:
a) The number of homozygous volunteers were fewer than 
expected. Trends showing lower Kd values and greater steroid-dependent 
inhibition of lysozyme release in volunteers with the A allele might have 
been confirmed with higher numbers in each group.
b) The synthetic glucocorticoid budesonide, which was used in 
vivo, may be better than dexamethasone, which was used in vitro, in 
demonstrating phenotypic differences. A precedent for this steroid 
selectivity was showed in the Milan hypertensive strain of rats (refer to 
section 3.3) where the phenotypic difference was more apparent in 
binding studies using corticosterone and aldosterone than those using 
dexamethasone. Unfortunately, the results of that study were not available 
when the protocol for the present study in volunteers was designed.
c) The polymorphism described may mark a genetic variable 
involved in skin vasoconstriction which is influenced by, but distinct 
from, the receptor gene (see above). It should be remembered that 
glucocorticoid hormones probably cause vasoconstriction, not by a direct 
effect on vascular tone but by potentiating the action of vasoconstrictors 
and/or by inhibiting the action of vasodilators (Russo et al., 1990). It 
follows that variability of any one of a large number of genes with a more 
direct influence on vasoconstriction could explain differences in steroid
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responsiveness to steroids providing that the other candidate gene is 
closely linked to the glucocorticoid receptor locus.
In addition to characterising receptor genes, this study measured 
several other variables concerned with electrolyte homeostasis and the 
control of intermediary metabolism. These results are presented and 
discussed separately in section 4.2.
In summaiy, this study provides evidence that glucocorticoid- 
dependent vasoconstriction is affected by glucocorticoid receptor RFLP 
genotype. It also supports the previous observation that individuals 
predisposed to develop hypertension are more likely to have AA genotype 
(Watt et al., 1992).
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4.2 Relationships of glucocorticoid receptor and phenotypes with 
cardiovascular and other metabolic variables
153
4.2.1 Introduction
The inten'elationships of glucocorticoid receptor affinity and 
concentration with aspects of in vitro and in vivo phenotype and with 
RFLP genotype have been described and discussed. Cortisol also has 
predictable effects on many aspects of intermediaiy and electrolyte 
metabolism and indices of these were measured in the human population
group. It was of interest to relate the values found for these to the 
principal determinants of glucocortiocid activity, cortisol levels and 
receptor affinity and capacity. As a possible control analysis, the 
relationship of mineralocorticoid-dependent changes to aldosterone levels 
was also examined.
4.2.2 Method
The same variables described in section 4.1.2 were considered. 
Correlation analysis between vaiiables was carried out. A correlation 
coefficient r of 0.25 was critical to define a significance level of p -  0.05 
with a sample of 64 subjects.
A full list of correlations is provided in appendix A. I
4.2.3 Results (for more details see table in appendix A)
a) Cortisol
Urinary free cortisol excretion rate correlated positively with
sodium and potassium excretion rate supporting the knowledge that
glucocorticoid at physiological levels promote Na"'" and excretion.
Cortisol did not correlate with NaVK^ ratio which is usually taken as an
index of mineralocorticoid activity. However, plasma cortisol
.concentration, an inferior index of secretion rate, correlated negatively 
with Na^ excretion rate and NaVK^ index. Neither plasma concentration
I.
nor urinary excretion rate of cortisol correlated with plasma Na"'' and 
concentration. Urinary cortisol excretion rate correlated positively with 
white cell count, a known glucocorticoid-sensitive variable (Shoenfeld et 
ai., 1981) and to creatinine clearance rate which is used as an index of 
GFR, known to increase during glucocorticoid administration (Bastl & 
Sebastian, 1987). However, the estimated GFR itself did not correlate 
with cortisol levels. There was a negative correlation between urinary 
cortisol excretion rate and age. Plasma and urinaiy cortisol levels did not 
correlate with one another. I
b)Aldosterone
Urinary aldosterone excretion rate and plasma aldosterone 
concentration showed significant positive correlation; neither correlated 
with GFR. As the principal mineralocorticoid, aldosterone would be 
expected to cause Na'*' retention and loss. While urinaiy free 
aldosterone did correlate negatively with Na''" excretion rate, as did NaVK''’ 
index, there was no correlation with urinary K’*'. Plasma and urinary 
aldosterone correlated negatively. A negative correlation between plasma 
aldosterone and Na^ excretion rate and a positive correlation with 
haematocrit were as expected. Plasma renin levels are a determinant of 
aldosterone secretion and these should therefore be positively correlated.
However, renin and aldosterone did not correlate in this study, even 
though there was a negative correlation between renin and Na'^ ' excretion 
rate.
,4
■Ic) Blood pressure and metabolic indices
Obesity is frequently associated with hypertension. The two 
measurements relating to this were skinfold thickness and body mass 
index (BMI). Both coirelated positively with blood pressure, urinary Na'^ '
excretion rate and GFR. Skinfold thickness also correlated with age and
.with serum cholesterol concentration; BMI correlated with triglyceride
154
-
■' .4 ,5 5 '
levels.
strong correlations between glucocorticoid receptor affinity (Kd) and 
cholesterol and between cholesterol and systolic blood pressure measured 
in the lying position. Both systolic blood pressure and serum cholesterol
155
d) Calcium levels
Glucocorticoids are known to influence Ca^ "'" metabolism (Findling
et al., 1982). In this study, the urinary calcium excretion rate correlated 
positively with urinary cortisol excretion rate but not with plasma cortisol 
concentration, while plasma calcium concentration coivelated with neither 
plasma cortisol concentration nor urinary free cortisol excretion rate.
Urinary calcium excretion rate correlated with THE, THF and alloTHF 
but did not correlate with THF+alloTHF/THE ratio. However, none of 
these metabolites correlated with plasma calcium concentration. Urinary 
calcium excretion rate correlated positively with urinaiy Na''’ and K  ^
excretion rate and urinary NaVK^ ratio, while it correlated negatively with 
haemoglobin, haematocrit, renin and plasma aldosterone concentrations. 
Plasma calcium concentration correlated negatively only with diastolic 
blood pressure measured in supine position, while urinary calcium 
excretion rate correlated with none of the blood pressure measurements.
e) Cortisol, cholesterol and blood pressure
Although cortisol is a key controlling factor in lipid metabolism,
:there were no correlations between cortisol levels and skinfold thickness,
BMI, serum cholesterol or triglyceride in this study. However, there were
are risk factors for cardiovascular disease.
■I
cortisol concentration was always withdrawn at the same time of the day 
in each subject, this proved to be an inferior index of secretion rate. 
Indeed, in this study there was no correlation between plasma and urinaiy
the resultant increase in GFR, it has been speculated that it is by this 
mechanism that glucocorticoids enhance GFR. In this study, there was 
only a positive correlation between urinary cortisol secretion rate and 
creatinine clearance, a commonly used index of GFR. However, neither 
plasma nor urinary cortisol correlated with the calculated GFR. As
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4.2.4 Discussion
Urinary free cortisol excretion was a better index of cortisol g
.activity than plasma level as is shown by its correlations with g
glucocorticoid-related vaiiables. Although a blood sample for plasma
cortisol. As expected, urinary cortisol excretion rate correlated positively U
with urinary sodium and potassium excretion rate, white blood and y
polymorphonuclear cells count, and creatinine cleaiance. Although ;gglucocorticoids usually do not change Na^ excretion, in large amounts 
they may cause natriuresis. In fact glucocorticoids, by increasing GFR, g|
enhance the amount of filtered Na^ with consequent increase of salt and 
water excretion (Bastl & Sebastian, 1987). Glucocorticoids at physiologic 
doses markedly increase excretion by both increasing urine flow 
through increases in GFR and, possibly, by increasing protein catabolism
Î
with release of intracellular (Stanton et al., 1985).
As already mentioned, glucocorticoids increase GFR. In whole- 
kidney experiments, glucocorticoids decrease renal vascular resistance |
mediated by large decreases in afferent arteriolar resistance and smaller 
decreases in efferent resistance (Baylis & Brenner, 1978). It appears then 
that glucocorticoids are renal vasodilators, probably attenuating the effect
of vasoconstrictors such as epinephrine, norepinephrine, angiotensin II
'1:and ADH in a dose dependent manner. It has been suggested that ANP 
production is regulated by glucocorticoid (Gardner et al., 1986). Since
''•itANP appears to produce its physiological effect by renal vasodilation and |
'"3,5I
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reported in the method section (refer to section 2.1.7), individual GFRs 
were estimated using a formula which depend on serum creatinine 
concentration alone. This calculation is based on the assumption that 
under normal circumstances, serum creatinine remains fairly constant 
unless renal function, i.e. GFR, changes. If endogenous production of 
creatinine remains constant then serum creatinine will be inversely 
proportional to GFR. However, one of the estimation problems is that the 
precision of serum creatinine determinations increases as the creatinine 
concentration rises. Since all the serum creatinine concentrations were 
within the reference range it is likely that the measurements were subject 
to variations. Indeed, the calculation of the creatinine clearance, by 
applying Fick's principle, gives better results in the estimation of GFR in 
healthy subjects.
Glucocorticoid administration to human subjects causes a 
circulating lymphocytopenia, monocytopenia and eosinopenia but 
increases the blood polymorphonuclear leucocyte concentration 
(Shoenfeld et al., 1981). Glucocorticoids accelerate the release of 
neutrophils from the bone marrow, increase the half-life of circulating 
neutrophils and neutrophils egress from the blood. In this study, only a 
positive correlation between urinary cortisol excretion rate and white 
blood cells and polymoiphonucleate leucocytes (which largely influence 
the total white blood cells count) was observed, while neither plasma nor 
urinary cortisol correlated with lymphocytes and monocytes.
Urinaiy aldosterone excretion rate was a better index of 
aldosterone secretion rate than plasma aldosterone concentration. In this 
instance the effect of posture is important in plasma aldosterone 
measurement. However, the samples were withdrawn in each subject after 
at least 30 min of recumbent position. Contraiy to what was expected, 
there was no correlation between urinary excretion and either plasma 
or urinary aldosterone. However, both plasma and urinaiy aldosterone 
correlated negatively with Na"'" excretion rate and urinary NaVIU  ^ ratio
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where the first indicates the sodium retentive property of 
mineralocorticoids and the second is an index of mineralocorticoid 
activity. A limitation of this study in the evaluation of mineralocorticoid 
effects is that the subjects took an unrestricted salt diet. This may have 
affected correlations between plasma and urinary aldosterone and some 
of the mineralocortiocid-dependent variables and between renin and 
aldosterone in this study.
Findling et al. (1982) reported that although urinary calcium 
excretion was directly correlated to urinary free cortisol in Cushing's 
syndrome, there was no corTelation during eucortisolemia. In this study 
a positive conelation between urinary calcium excretion rate and urinary 
free cortisol excretion rate was observed, even though all the subjects had 
urinary cortisol levels within the reference range. Interestingly, this 
correlation was also present when the excretion rate of urinary 
metabolites of cortisol (THE, THF and alio THF) was used as an index 
of adrenal activity. Glucocorticoid hormones are known to regulate bone 
and mineral homeostasis, excess leading to osteopenia by an imbalance 
in bone remodelling (Reid, 1993). They act on osteoblasts to decrease 
collagen synthesis and diminish conversion of precursor cells to 
functioning osteoblasts.lt has also been proposed that glucocorticoids 
reduce intestinal calcium absorption and tubular reabsorption of 
phosphate which leads to increased urinary phosphate and calcium 
excretion and decreased serum calcium concentrations. However, in this 
study there was no relationship between either plasma or urinary 
glucocorticoid on serum calcium concentrations. Moreover, a positive 
correlation between urinary calcium excretion rate and urinaiy Na’*' and 
excretion rate and urinaiy Na’^ '/K''" ratio was observed. This may indicate 
an expected relation between urinaiy calcium excretion and 
mineralocorticoids. Indeed it has been repoited that inhibitory effects of I
NaCl-induced volume expansion and mineralocorticoid excess on calcium 
reabsorption by the collecting ducts results in increased urinary calcium
1”
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excretion (Marx & Bourdeau, 1987). However, in this study urinaiy 
calcium excretion correlated negatively with plasma aldosterone 
concentrations while it did not correlate with urinary aldosterone secretion 
rate.
Despite the described influence of glucocorticoids and 
mineralocorticoids on blood pressure control and of glucocorticoids on 
lipid metabolism, this study showed no correlation between these 
variables. In glucocorticoid excess, there is an increase in VLDL, LDL 
and HDL with consequent elevations of total triglyceride and cholesterol 
levels. In this study, there was no correlation between cortisol and 
cholesterol or triglyceride, even though there was a positive correlatation 
between glucocorticoid receptor affinity and total cholesterol 
concentrations. Although glucocorticoids are reported to inhibit the 
synthesis of cholesterol, at present the significance of the positive 
conelation between cholesterol and glucocorticoid receptor affinity needs 
further assessment.
In summary, in this study plasma total cholesterol concentrations 
conelated with systolic blood pressure and Kd values for dexamethasone 
binding. The same glucocorticoid variables also interacted with plasma 
and urinary electrolyte concentrations (sodium, potassium and calcium). 
These results, from a group of normal volunteers, may suggest a complex 
interaction of all these variables in the pathogenesis of hypertension.
s
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Chapter 5 GENERAL CONCLUSIONS
,;,S
The aetiology of essential hypertension has been discussed in 
relation to corticosteroid hormone in general and glucocorticoids in 
particular (Chapter 1). A series of experiments designed to investigate the 
importance of genetically-determined variations in the glucocorticoid 
receptor mechanism in the inheritance of hypertension in man and in 
hypertension-prone strains of rat has been carried out (Chapter 3). These 
investigations required the adaptation, validation and use of a number of 
biochemical and cell biology techniques and the development of a new 
method of measuring glucocorticoid potency (refer to section 2.3). My 
principal aims have been to measure glucocorticoid receptor activity 
accurately and specifically, to study this activity in man and well- 
established relevant rat models of genetic hypertension and to attempt to 
relate activity to receptor genotype and to cell and whole organism 
physiology.
Preliminaiy results obtained measuring the GR binding in 
mononuclear leucocytes from SHR (refer to section 3.1) lead to the 
development of a protocol to study in details the receptor binding 
characteristics in rat liver cytosol preparations. This considered not only 
sensitivity and specificity of ligand binding but also thermolability and 
thermostability of the GR-ligand complex.
In SHR liver cytosol, the difference in binding affinity observed 
using mononuclear leucocytes were not initially confirmed. One possible 
explanation of this discrepancy was the difference in the method of 
incubation. The binding in ML was carried out at 24° for 3 h whereas the 
liver cytosol was incubated overnight at 5°. A temperature factor seemed 
likely. The review of the mechanism of action of the glucocorticoid 
receptor helped to inteipret the results. The affinity of GR is influenced by 
the association with the Hsp; the GR-Hsp complex has liigh affinity for the 
ligands and can be dissociated not only by the binding with the ligand
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itself but also by high temperatures and sodium concentrations (Nemoto 
et ah, 1990a). When GR is not associated with Hsp, the binding affinity 
is reduced by approximately 100-fold. Indeed, the results of liver cytosol 
binding studies at higher temperature showed a lower affinity for 
dexamethasone for both SHR and WKY but the binding affinity in the
SHR liver cytosol preparation was consistently higher than in WKY
preparations (refer to section 3.2). A possible explanation of these results
is that the relationship of the Hsp to the receptor protein in the ligand-free
cytosolic receptor complex is different between strains. This abnormality
.may be due to either a mutation in the receptor protein or in the Hsp. 
However, both influence the stability of the GR-Hsp complex which in 
turn affects the affinity for the ligand. At present there is some evidence 
of a genetic difference in Hsp70 between SHR and WKY (Hamet et al..
§1992), even though there are contradictory data on its cosegregation with 
blood pressure (Lodwick et al., 1993). The important point highlighted 
from this set of experiments is that although differences in receptor 
binding affinities have been identified, these, at least in SHR, do not 
reside in abnormalities in the GR binding domain but in Hsp or in the 
formation of the GR-Hsp complex.
hrThe hypothesis of decreased glucocorticoid receptor activity was 
also tested. Impaired Type II receptor affinity can lead to excessively high 
plasma cortisol concentrations which although unable to bind to Type II 
receptors can bind to Type I sites, resulting in excess mineralocorticoid 
activity. A number of rare cases of primaiy cortisol resistance have been 
identified (Chi'ousos et al., 1982; Ai*ai & Chrousos, 1994). These patients 
have hypertension caused by a mutation in the Type H receptor. A number 
of phenotypic differences including raised plasma cortisosterone '
suggested that MHS rats might also have a mineralocorticoid-like 
hypertension (refer to section 4.3) due to Type II receptor impairement.
Binding studies with liver cytosol confirmed that affinities for a variety 
of ligands was lower in MHS compared with MNS. Unlike SHR,
I
differences in binding were not due to thermoinstability. Subsequent 
genetic studies have shown that the MHS GR gene has a negative effect 
on blood pressure, presumably due to reduced glucocorticoid activity. The 
suggestion that raised plasma corticosterone concentration leads to excess 
mineralocorticoid activity has been neither confirmed nor denied.
The last experimental section of this thesis investigated whether 
the polymoiphism of the glucocorticoid receptor gene identified in the 
Lady well study (Watt et al., 1992) has any physiological significance. 
This part of the project aimed to investigate links between polymoiphism 
of the gene for GR and differences in GR chai'acteristics and 
glucocorticoid responsiveness in a group of normal volunteers. Blood 
pressure, plasma and urinary steroid concentrations, GR binding 
characteristics, responsiveness to glucocorticoids (in vivo and in vitro) 
and other routine biochemical variables have been compared. The results 
did not show differences in GR binding or in vitro sensitivity to 
glucocorticoid between genotypes. As discussed the reason why no 
difference in in vitro GR properties was obseiwed may be due to the small 
numbers of homozygous individuals that were tested or that the correct 
biochemical test was not applied. In tests in SHR and MHS, abnormalities 
in ligand binding were seen when considering thermolability and ligand 
specificity respectively and not necessarily in homologous competition 
studies carried out at 24°.
To study human mononuclear leucocytes GR binding 
characteristics in the same detail, as reported for the animal studies, a veiy 
large amount of blood from each individual would be required. To 
overcome this methodological problem, two solutions can be found: use 
of i) fibroblasts in culture, which requires biopsy or ii) leucocytes 
transformed by Eptein-Barr virus (EBV). Tomita et al. (1986) reported 
that the GR in immortalized leucocytes maintains the same binding 
characteristics as in normal cells. Only the number of GR sites per cells 
varies since there is an enhanced expression of receptor induced by EBV.
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This cell model may provide a valid alternative for GR binding studies in 
cells from subjects of known receptor genotype using a small amount of 
blood.
Another factor to consider is which population to sample since 
ethnic origin is important. Bailey et al (1992) investigated the relationship 
between blood pressure and GR RFLP in a group of hypertensive patients. 
They detected no significant difference in RFLP frequency in the 
hypertensive and control group but a difference in GR allele frequency 
between Afro-Caiibbean and white populations. Therefore it is necessary 
to take particular care in selecting ethnic groups in studies of hypertension 
and its association with gene markers. However, this was not the case in 
the present thesis because the sample selected was all Caucasian.
The Bel I restriction site is not known. This could be either in the 
non-coding region, possibly at the 5' end of the GR gene, or intronic. 
Because there are no data on the effect of mutations within flanking 
regions of the GR gene on receptor function, to study the binding 
characteristics is only a preliminaiy approach. Indeed, if the mutation 
affects the coding region this may not affect the binding domain but might 
affect DNA or modulatory regions. As reported in asthmatic patients 
resistant to glucocorticoid therapy, the phenotypical abnormality could 
reside in the binding of the GR-ligand complex to the chromatin (Adcok 
et al., 1993). Unfortunately Adcok et al. (1993) did not caixy out RFLP 
analysis for GR in those subjects. In this study, the absence of a 
significant statistical difference in GR affinity between genotypes 
combined with differences in vasoconstriction may support the idea of a 
defective binding of the GR-ligand complex to the chromatin which could 
be studied by gel-shift assay (Nemoto et al., 1990b). However, this 
hypothesis was not supported from the results obtained by inhibition of 
lysozyme synthesis by dexamethasone in mononuclear leucocyte since 
differences in IC50 for dexamethasone would be expected. Since receptor 
polymorphism did not significantly influence in vitro sensitivity of HML
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to dexamethasone, the discrepancy between in vivo and in vitro tests of 
responsiveness might also be explained by tissue specificity for the effects 
of glucocorticoids, by differences in sensitivity to budesonide and 
dexamethasone (refer to section 4.1) or by close linkage disequilibrium 
with a second non-receptor blood pressure sensitive gene.
From the correlation studies between variables measured in the 
group of normal volunteers, glucocorticoid activity did not appear to be 
a major determinant of blood pressure or body fat distribution. However, 
the data confirm a complex inteirelationship between body fat and blood 
pressure control (refer to section 4.2).
In conclusion, it is reasonable to state that glucocorticoid 
sensitivity may be a contributory factor in essential hypertension. If this 
is indeed the case, then hypertension - or predisposition to hypertension - 
should be associated with a constellation of glucocorticoid sensitivity- 
related changes. If sensitivity is impaired, mineralocorticoid-like changes 
may result. If sensitivity is increased, glucocorticoid-dependent variables 
should be apparent. Although neither hypothesis has been proven in the 
human population, this thesis has provided important rationale for future 
studies. i
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Appendix A: Correlation table of variables measured in a group of 
normal volunteers (refer to section 4,2)
AGE BMI %FAT CLISBP CLIDBP ORTSBP ORTDBP
AGE 1.000
BMI 0.187 1.000
%FAT 0.275 0.840 1.000
CLISBP 0.273 0.202 0.266 1.000
CLIDBP 0.065 0.267 0.282 0.493 1.000
ORTSBP 0.081 0.450 0.391 0.631 0.430 1.000
ORTDBP -0.032 0.309 0.236 0.513 0.590 0.728 1.000
MAPCLI 0.154 0.278 0.315 0.756 0.943 0.566 0.641
MAPORT 0.010 0.389 0.322 0.595 0.586 0.878 0.961
CHOL 0.511 0.281 0.276 0.346 0.131 0.125 0.122
TRIG 0.146 0.300 0.182 0.033 -0.017 0.035 0.074
PLASMA Na 0.189 0.007 0.065 -0.076 -0.152 -0.063 -0.191
PLASMA K 0.118 0.092 0.083 0.079 0.013 0.095 0.120
PLASMA Ca -0.037 -0.225 -0.281 -0.136 -0.260 -0.152 -0.091
URIN. Na -0.198 0.182 0.251 0.073 0.118 0.065 0.002
URIN.K -0.034 0.216 0.176 -0.053 -0.044 0.037 0.001
URIN.Ca 0.005 0.037 0.002 -0,030 -0.023 0.004 -0.122
UNa/UK -0.181 0.066 0.144 0,080 0.144 0.024 -0.037
UNa/CREAT. -0.117 0.157 0.322 0.155 0.163 0.061 0.026
UK/CREAT. 0.131 0.145 0.213 -0.014 0.045 0.052 0.090
UCa/CREAT. 0.104 -0.017 0.007 -0.017 0.026 -0.035 -0.104
URIN.VOL. 0.004 0.186 0.032 0.033 0.007 0.031 0.023
SERUM.CREAT. 0.098 0.105 -0.001 -0.011 -0.184 0.333 0.073
URIN.CREAT. -0.199 0.100 -0.032 -0.099 -0.103 -0.017 -0.112
GREAT. CLEAR. -0.200 0.138 O.IOI -0.092 0.057 -0.186 -0.146
GFR -0.240 0.361 0.329 0.047 0.298 -0.047 0.137
WBC -0.146 0.335 0.236 0.069 0.122 0.116 0,200
Heb -0.241 0.149 0.069 -0.048 0.056 0.044 0.186
HCT -0.155 0.180 0.068 0.036 0.074 0.097 0.217
NEUTROPH. -0.163 0.334 0.212 0.053 0.070 0.132 0.115
LYMPH. 0.018 0.272 0.171 0.002 0.036 0.125 0.144
MONOS. 0.037 0.120 0.024 0.192 0.062 0.325 0.448
PLT 0.071 0.087 0.105 0.174 0.062 0.034 0.032
PLASMA F 0.013 -0.140 -0.110 -0.050 -0.048 0,050 0.159
PLASMA ALDO. -0.028 0.084 -0.037 -0.033 0.104 0.198 0.378
RENIN -0.161 0.047 0.043 -0.088 -0.208 -0.124 0.031
URIN.F •0.321 -0.009 0.033 -0.110 0.075 -0.102 A
ÜRIN.ALDO 0.190 -0.052 -0.062 -0.123 -0.146 -0.115 -0.203
UF/CREAT, -0.259 -0.082 0.037 -0.121 0.087 -0.146 -0.131
UALDO/CREAT. 0.298 -0.043 0.008 -0.094 -0.076 -0.083 -0.100
THE 0.071 -0.049 -0.042 -0.089 -0.027 -0.148 -0.222
THF -0.095 0.006 0.076 -0.133 0.025 0.021 -0.103
ALLOTHF -0.054 0.014 0.054 -0.294 -0.139 -0.070 -0.232
RATIO -0.132 0.013 0.111 -0.225 -0.104 0.052 -0.025
Kd 0.050 0.092 0.180 0.192 0.159 0.162 0.185
Bmax 0.025 -0.009 -0.064 0.028 0.099 0.196 0.147
ICSO 0.073 -0.043 -0.160 -0.052 -0.189 -0.068 0.014
SKIN 0.121 -0.049 0.103 0.009 0.007 -0.009 -0.008
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MAPCLI MAPORT CHOL TRIG PLASMA Na PLASMA K PLASMA Ca
AGE
BMI
%FAT
CLISBP
CLIDBP
ORTSBP
ORTDBP
MAPCLI 1.000
MAPORT 0.670 1.000
CHOL 0.233 0.133 1.000
TRIG -0.000 0.083 0.479 1.000
PLASMA Na -0.143 -0.153 0.069 0.028 1.000
PLASMA K 0.040 0.085 0.230 0.076 -0.175 1.000
PLASMA Ca -0.248 -0.124 0.181 0.034 0.081 -0.106 1.000
URIN. Na 0.117 0.026 -0.102 0.041 -0.171 0.046 -0.246
URIN.K -0.054 0.006 0.066 0.182 0.029 0.096 0.061
URIN.Ca -0.029 -0.076 -0.021 0.063 -0.127 -0.088 0.071
UNa/UK 0.139 -0.009 -0.165 -0.096 -0.227 -0.066 -0.277
UNa/CREAT. 0.182 0.038 -0.028 -0.005 -0.164 0.077 -0.273
UK/CREAT. 0.029 0.069 0,209 0.110 0.088 0.150 0.077
UCa/CREAT. 0.013 -0.079 0.042 0.058 -0.098 -0.088 0.101
URIN.VOL. 0.018 0.018 0,124 0.159 -0.300 0.170 0.084
SERUM.CREAT. -0.142 0.153 0.146 0.086 0.112 0.128 0.056
URIN.CREAT. -0.116 -0.077 -0.131 0.086 -0.087 -0.050 -0.010
CREAT. CLEAR. 0.008 -0.148 -0.072 0.042 -0.187 -0.077 -0.045
GFR 0.243 0.102 -0.107 0.107 -0.152 -0.142 -0.201
WBC 0.118 0.190 -0.009 0.206 -0.110 -0.104 -0.182
Heb 0.024 0.157 0.028 0.186 0.103 -0.006 0.052
HCT 0.070 0.195 0.119 0.159 0.103 0.059 0.069
NEUTROPH. ■ 0.073 0.134 -0.064 0.096 -0.031 0.020 -0.291
LYMPH. 0.028 0.155 -0.028 0.140 0.133 -0.250 -0.008
MONOS. 0.122 0.430 0.080 0.034 -0.199 0.088 0.220
PLT 0.113 0.039 0.250 -0.001 -0.083 0.232 -0.001
PLASMA F -0.055 0.130 0.154 0.076 -0.108 -0.181 0.227
PLASMA ALDO. 0.066 0.325 0.114 0.080 0.088 -0.068 0.157
RENIN -0.192 -0.034 -0.202 -0.189 0.115 0.107 -0.079
URIN.F 0.014 -0.109 -0.227 -0.091 -Q 204 -0.133 -0.061
URIN.ALDO -0.158 -0.170 0.089 0.126 0.084 -0.257 0.098
UF/CREAT. 0.019 -0.145 -0.169 -0,126 -0.170 -0.142 -0.052
UALDO/CREAT. -0.093 -0.094 0.217 0.079 0.133 -0.191 0.107
THE -0.055 -0.198 -0.041 0.069 -0.088 -0.081 0.054
THF -0.032 -0.045 -0.161 -0.030 -0.075 -0.192 -0.132
ALLOTHF -0.217 -0.186 -0.215 0.014 -0.011 -0.277 -0.121
RATIO -0.165 0.009 -0.199 -0.039 0.015 -0.141 -0.332
Kd 0.193 0.220 0.285 0.237 0.089 -0.006 -0.090
Bmax 0.086 0.182 0.069 0.099 -0.361 0.212 0.032
IC50 -0.163 -0.025 0.104 0,156 -0.064 -0.027 0.316
SKIN 0.009 -0.005 0.108 -0.121 0.049 0.140 -0.099
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URIN.Na URIN.K URIN.Ca UNaÆlK UNa/CREAT. UK/CREAT. UCa/CREAT.
AGE
BMI
%FAT
CLISBP
CLIDBP
ORTSBP
ORTDBP
MAPCLI
MAPORT
CHOL
TRIG
PLASMA Na
PLASMA K
PLASMA Ca
URIN. Na 1.000
URIN.K 0.374 1.000
URIN.Ca 0,545 0.320 1.000
UNa/UK 0.731 -0.303 0.381 1.000
UNa/CREAT. 0.859 0.226 0,313 0.715 1.000
UK/CREAT. -0.048 0.677 -0.119 -0.491 0.172 1.000
UCa/CREAT. 0.377 0.184 0.882 0.327 0.361 0.073 1.000
URIN.VOL. 0.082 0.410 0.362 -0.205 -0.068 0.190 0.236
SERUM.CREAT. -0.013 0.124 0.272 -0.114 -0.114 0.000 0.160
URIN.CREAT. 0,515 0.395 0.571 0.247 0.041 -0.383 0.156
CREAT. CLEAR. 0.445 0.281 0.272 0.266 0.147 -0.205 0.005
GFR 0.194 0.033 -0.219 0.175 0.181 -0.019 -0.273
WBC 0.099 0.245 0.064 -0.068 0.075 0.183 0.066
Hgb -0.149 0.068 -0.319 -0.211 -0.132 0.059 -0.342
HCT -0.212 0.039 -0.285 -0,260 -0.190 0.047 -0.293
NEUTROPH. ■0.336 0.274 0.161 0,138 0.216 0.043 0.073
LYMPH. -0.122 0.205 -0.001 -0.221 -0.140 0.205 -0.021
MONOS. -0.172 0.200 0.002 -0.322 -0.173 0.234 -0.003
PLT -0.018 -0.010 -0.108 0.007 -0.028 0.008 -0.111
PLASMA F -0.338 0.010 -0.248 -0.371 -0.257 0.204 -0.175
PLASMA ALDO. -0.387 0.022 -0.342 -0.455 -0.278 0.305 -0.241
BENIN -0.236 -0.049 -0.357 -0.237 -0.253 -0.052 -0.393
URIN.F 0.513 0.360 0.397 0.226 0.329 -0.004 0.271
URIN.ALDO -0.139 0.405 0.108 -0.422 -0.256 0.293 0.058
UF/CREAT. 0.335 0.221 0.224 0.150 0.366 0.182 0.287
UALDO/CREAT. -0.365 0.152 -0.170 -0.494 -0.230 0.495 -0.008
THE 0.435 0.266 0.384 0.216 0.198 -0.123 0.218
THF 0.433 0.273 0.290 0.213 0.191 -0.076 0.127
ALLOTHF 0.233 0.168 0.344 0.236 0.044 -0.161 0.184
RATIO 0.001 -0.015 -0.001 0.128 0.020 0.029 0.009
Kd 0.037 0.181 -0.013 -0.137 -0.008 0.132 -0.051
Bmax 0.070 0.137 0.033 -0.032 -0.033 0.093 -0.048
IC50 -0.243 -0.036 0.107 -0.143 -0.280 -0.018 0.164
SKIN -0.082 -0.199 -0.135 0.009 0.051 0.016 -0.067
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URIN.VOL. SERUM CREAT. URIN.CREAT. CREAT.CLEAR. I GFR WBC
AGE 1
BMI
% FAÏ
CLISBP
CLIDBP
ORTSBP
ORTDBP
MAPCLI
MAPORT
CHOL
TRIG
PLASMA Na
PLASMA K
PLASMA Ca
URIN. Na
URIN.K
URIN.Ca
UNaÆTK
UNa/CREAT.
UK/CREAT.
UCa/CREAT.
URIN.VOL. 1.000
SERUM.CREAT. 0.211 1.000
URIN.CREAT. 0,307 0.199 1.000
CREAT. CLEAR. 0.247 -0.463 0.654 1.000
GFR -0.064 -0.770 0.050 0.625 1.000
WBC 0.126 -0,103 0.032 0.121 0,295 1,000
Hfib -0.260 -0.337 -0.047 0.124 0.433 0.295
HCT -0,190 -0.311 -0.072 0.095 0,378 0.282
NEUTROPH. 0,190 -0.079 0.266 0.293 0,290 0.844
LYMPH. 0,099 0.077 -0,033 -0,010 0.133 0.632
MONOS. 0.283 0.217 -0.096 -0,213 -0.164 0.504
PLT -0.002 -0.067 -0.015 0,004 -0,063 0.304
PLASMA F 0.026 0.106 -0.227 -0.181 -0.202 0.208
PLASMA ALDO. 0.025 0.221 -0.385 -0.348 -0,119 0.163
RENIN -0.267 -0.219 -0.029 0.091 0,262 0.412
URIN.F 0.290 -0.095 0.421 0.473 0.147 0.333
URIN.ALDO 0.317 -0.030 0.172 0,271 0.005 0.130
UF/CREAT. 0.166 -0,136 0.021 0,221 0.084 0.332
UALDO/CREAT. 0.199 -0.066 -0.371 -0,063 -0.021 0.075
THE 0.179 -0.145 0.477 0.549 0.149 0.045
THF 0.067 -0.071 0.451 0.451 0.145 0,136
ALLOTHF 0,098 0.040 0,456 0.398 0.054 -0.132
RATIO -0.190 0.144 -0.000 -0.108 -0.119 0.031
Kd -0.060 -0.016 0.068 0.003 0.046 0.001
Bmax 0.154 0.109 0.123 0.094 -0.075 0.087
IC50 0.108 0.051 0.016 -0,082 -0.161 0.097
SKIN -0.140 -0.287 -0.272 0,061 0.243 -0,098
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Heb HCT NEUTROPH. LYMPH. MONS. PLT PLASMA F
AGE
BMI
%FAT
CLISBP
CLIDBP
ORTSBP
ORTDBP
MAPCLI
MAPORT
CHOL
TRIG
PLASMA Na
PLASMA K
PLASMA Ca
URIN. Na
ÜRIN.K
URIN.Ca
UNaÆJK
UNa/CREAT.
UK/CREAT.
UCa/CREAT.
URIN.VOL.
SERUM.CREAT.
URIN.CREAT.
CREAT. CLEAR.
GFR
WBC
Hab 1.000
HCT 0.947 1.000
NEUTROPH. 0.165 0.136 1.000
LYMPH. 0.286 0.245 0.274 1.000
MONOS. 0.141 0.172 0.220 0.552 1.000
PLT 0.135 0.154 0.350 0.127 0.366 1.000
PLASMA F 0.227 0.205 0.006 0.246 0.401 0.276 1.000
PLASMA ALDO. 0.269 0.281 -0.127 0.381 0.458 -0.003 0.517
RENIN 0.365 0.347 0.297 0.330 0.148 0.213 0.164
URIN.F 0.043 0.016 0.441 0.023 0 069 0.148 O.lll
URIN.ALDO 0.085 0.097 0.057 0.221 0.062 -0.050 0.292
UF/CREAT. 0.046 0,029 0.352 0.016 0.062 0.110 0.242
UALDO/CREAT. 0.019 0.045 -0.090 0.217 0.098 -0.084 0.376
THE -0.067 -0.120 0.168 0.003 -0.165 0.068 0.047
THF -0.068 -0.158 0.305 -0.044 -0.122 0.153 0.062
ALLOTHF -0.155 -0.246 -0.034 -0.015 -0.307 -0.181 -0.009
RATIO -0.127 -0.189 0.054 0.008 -0.059 -0.012 -0.018
Kd 0.230 0.184 -0.058 0.069 -0.065 0.190 -0.007
Bmax -0.132 -0.091 -0.086 0.159 0.214 0.165 0.037
IC50 -0.001 0.021 -0.030 0.221 0.140 0,323 0.206
SKIN 0.067 0.067 -0.101 -0.136 0.051 -0.085 -0.075
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PLASMA ALDO RENIN URIN.F URIN.ALDO UF/CREAT. 1 UALDO/CREAT.
AGE
BMI 1
%FAT
CLISBP
CLIDBP
ORTSBP
ORTDBP
MAPCLI
MAPORT
CHOL
TRIG
PLASMA Na
PLASMA K
PLASMA Ca
URIN. Na
URIN.K
URIN.Ca
UNa/UK
UNa/CREAT.
UK/CREAT.
UCa/CREAT.
URIN.VOL.
SERUM.CREAT.
URIN.CREAT.
CREAT. CLEAR.
GFR
WBC
Heb
HCT
NEUTROPH.
LYMPH.
MONOS.
PLT
PLASMA F
PLASMA ALDO. 1.000
RENIN 0.209 1.000
URIN.F -0.099 -0.032 1.000
URIN.ALDO 0.269 0.097 0.321 1.000
UF/CREAT. 0.072 -0.042 0.891 0.292 1.000
UALDO/CREAT. 0.504 0.067 0.037 0.798 0.239 1.000
THE -0.285 -0.067 0.610 0.430 0.410 0.107
THF -0.207 -0.113 0.691 0.366 0.499 0.068
ALLOTHF -0.315 -0.182 0.312 0.241 0.164 -0.039
RATIO -0.126 -0.142 -0.003 -O.lll 0.014 -0.131
Kd 0.060 -0.042 -0.077 0.074 -0.134 0.042
Bmax 0.167 -0.155 0.006 0.127 -0.044 0.100
IC50 0.054 0.187 -0.063 0.055 -0.077 0.018
SKIN 0.081 -0.058 -0.257 -0,105 -0.115 0.115
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THE THF ALLOTHF RATIO Kd Bmax ICSO SKIN
AGE
BMI
%FAT
CLISBP
CLIDBP
ORTSBP
ORTDBP
MAPCLI
MAPORT
CHOL
TRIG
PLASMA Na
PLASMA K
PLASMA Ca
URIN. Na
URIN.K
URIN.Ca
UNa/UK
UNa/CREAT.
UK/CREAT.
UCa/CREAT.
URIN.VOL.
SERUM.CREAT.
URIN.CREAT.
CREAT. CLEAR.
GFR
WBC
Hab
HCT
NEUTROPH.
LYMPH.
MONOS,
PLT
PLASMA F
PLASMA ALDO.
RENIN
URIN.F
URIN.ALDO
UF/CREAT.
UALDO/CREAT.
THE 1.000
THF 0.769 1.000
ALLOTHF 0.357 0.473 1.000
RATIO -0.323 0.134 0.536 1.000
Kd 0.081 0.165 -0.104 -0.076 1.000
Bmax 0.065 0.044 -0.057 -0.001 0.212 1.000
ICSO 0.029 -0.061 -0.032 -0.056 0.305 0.230 1.000
SKIN -0.104 -0.088 -0.054 -0,027 0.014 -0.006 -0.207 1.000
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Abbreviations used in Appendix A
BMI: body mass index
%Fat: percentage of body fat
'
CLIDBP and CLISBP; diastolic and systolic blood pressure 
measure in supine position
ORTDBP and ORTSBP: diastolic and systolic blood pressure 
measured in upright position 
MAP: mean arterial blood pressure 
CHOL: cholesterol 
TRIG: triglyceride
UNA/UK: urinary sodium/potassium ratio 
CREAT.: creatinine
Î
URIN.VOL.: urinary volume 
CREAT.CLEAR.: creatinine clearance 
GFR: glomerulai* filtration rate 
WBC: white blood cells 
Hgb: haemoglobin 
HCT: haematocrit 
NEUTROPH.: neutrophiles cells 
LYMPH.: lymphocytes 
MONOS.: monocytes 
PLT: platelet
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